UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM N-CSR

              CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT

                              INVESTMENT COMPANIES

Investment Company Act file number  811-10325

                            VANECK VECTORS ETF TRUST
               (Exact name of registrant as specified in charter)

                      666 Third Avenue, New York, NY 10017
              (Address of principal executive offices) (Zip code)

                         Van Eck Associates Corporation
                      666 THIRD AVENUE, NEW YORK, NY 10017
                    (Name and address of agent for service)

Registrant's telephone number, including area code: (212) 293-2000

Date of fiscal year end:  SEPTEMBER 30

Date of reporting period: SEPTEMBER 30, 2017


Item 1. Report to Shareholders

ANNUAL REPORT
September 30, 2017

 

VANECK VECTORS®

 

Biotech ETF BBH
   
Environmental Services ETF EVX®
   
Gaming ETF BJK®
   
Generic Drugs ETF GNRX
   
Pharmaceutical ETF PPH®
   
Retail ETF RTH®
   
Semiconductor ETF SMH®

 

  800.826.2333 vaneck.com

 

 

 

President’s Letter 1
Management Discussion 3
Biotech ETF 3
Environmental Services ETF 3
Gaming ETF 4
Generic Drugs ETF 4
Pharmaceutical ETF 4
Retail ETF 4
Semiconductor ETF 5
Performance Comparison  
Biotech ETF 6
Environmental Services ETF 7
Gaming ETF 8
Generic Drugs ETF 9
Pharmaceutical ETF 10
Retail ETF 11
Semiconductor ETF 12
Explanation of Expenses 14
Schedule of Investments  
Biotech ETF 15
Environmental Services ETF 17
Gaming ETF 19
Generic Drugs ETF 21
Pharmaceutical ETF 23
Retail ETF 25
Semiconductor ETF 26
Statements of Assets and Liabilities 28
Statements of Operations 30
Statements of Changes in Net Assets 32
Financial Highlights  
Biotech ETF 35
Environmental Services ETF 35
Gaming ETF 36
Generic Drugs ETF 36
Pharmaceutical ETF 37
Retail ETF 37
Semiconductor ETF 38
Notes to Financial Statements 39
Report of Independent Registered Public Accounting Firm 47
Tax Information 48
Board of Trustees and Officers 49
Approval of Investment Management Agreements 51

 

The information contained in the management discussion represents the opinions of VanEck Vectors ETFs and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETFs are as of September 30, 2017, and are subject to change.

 

VANECK VECTORS ETFs

(unaudited)

 

Dear Shareholder:

 

We are pleased to present this annual report for the seven industry exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust for the 12-month period ended September 30, 2017.

 

The VanEck Vectors Gaming ETF (NYSE Arca: BJK) was the third best performing fund in our suite of industry ETFs. Although placing after both the VanEck Vectors Semiconductor ETF (NYSE Arca: SMH) and the VanEck Vectors Environmental Services ETF (NYSE Arca: EVX), BJK returned a creditable 21.58% for the period under review. Over the 12 months, in addition to solid revenues from gaming operations in Las Vegas, companies in the BJK’s portfolio saw a significant improvement in the operating environment in Macau.

 

Until August 2016, Macau—the southern Chinese territory and the world’s biggest gaming hub—had been severely affected by both Beijing’s anti-corruption campaign and the slowdown in economic growth in the country. However, after following 26 consecutive months of year-over-year declines, revenues were 1.1% higher than in August 2015. In September 2016, they increased even further and were 7.4% higher than a year previously. Since then, over every month of the period under review, revenue figures from the “Games of Fortune” (as the Macau authorities describe them) have increased year-over-year.

 

Macau Gaming Revenue Growth – Year-Over-Year (%)

 

 

 

Source: Gaming Inspection and Coordination Bureau, Macao SAR. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.

 

With its strongly international flavor, BJK was also able to capture the positive performance of gaming companies in both Australia and Malaysia.

 

Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.

1

VANECK VECTORS ETFs

(unaudited)

 

Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the 12-month period ended September 30, 2017. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in future.

 

 

Jan F. van Eck
Trustee and President
VanEck Vectors ETF Trust

 

October 23, 2017

 

Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.

2

 

 

Management Discussion (unaudited)

 

Six of the seven VanEck Vectors Industry ETFs realized positive performance in the 12 months ended September 30, 2017. The two best performers were VanEck Vectors Semiconductor ETF (NYSE Arca: SMH), posting an impressive total return of 35.63%, and VanEck Vectors Environmental Services ETF (NYSE Arca: EVX) providing a total return of 24.31%. Both funds easily outperformed the S&P 500® Index’s18.61% gain over the same period.

 

 

Source: VanEck. Returns based on each fund’s net asset value (NAV). The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.

 

Biotech – FDA approvals and deal making help

 

Biotech stocks performed well over the 12-month period. After some significant movements both before and following the U.S. presidential election at the beginning of November 2016, biotech companies ended the calendar year down slightly from the start of the fourth quarter 2016. However, on the back of both drug approvals (as of September 29, 2017, the U.S. Food & Drug Administration had approved 34 novel drugs,1 12 more than in the whole of 20162) and deal making,3 biotech stocks rose during most the first nine months of 2017 to end the 12-month period up 16.77%. Positive contributions to the Fund’s performance came mainly from three companies: Celgene (10.1% of Fund net assets), Incyte (3.9% of Fund net assets), and Vertex Pharmaceuticals (4.4% of Fund net assets). The company that detracted most from performance was Allergan (5.8% of Fund net assets).

 

Environmental Services – continuing strong demand

 

The three hurricanes that hit the U.S. and its territories in the Caribbean were probably significant drivers behind the steep improvement in the performance of environmental services stocks in both August and September. The outcome of each weather occurrence was devastation with tons of debris that need to be both cleared away and disposed. While U.S. stocks accounted for the vast majority of the Fund’s healthy positive total return (gaining 24.31% during the period), the single Canadian stock in the Fund (Waste Connections, 9.8% of Fund net assets) was the best performing company over the 12-month period. Only two companies detracted from performance over the period, CECO Environmental (2.0% of Fund net assets) and Stericycle (3.6% of Fund net assets).

3

VANECK VECTORS ETFs

(unaudited)

 

Gaming – Macau revenues continue to improve

 

The Fund posted a rise of 21.58% for the 12-month period. The fourth quarter of 2016 was particularly tumultuous with the Fund dropping fast and far in December and ending 2016 well below the level at which it started the quarter. However, during the first three quarters of 2017, gaming stocks followed an upward trajectory and ended the 12-month period significantly higher than they started the year. In Macau, China—the world’s biggest gaming hub—following a solid first six months, the improvement in the gaming industry’s fortunes over the final six months of the period under review was particularly impressive. In each month of the 12-month period, the gross revenue from “Games of Fortune” (as the Macau authorities4 describe them) was higher than that recorded in the same month in the prior year. In September 2017, it was 16.1% higher than in September 2016.5 This marked the 14th consecutive month of year-on-year improvement. In Nevada, following two lackluster months in the fourth quarter of 2016, January was a particularly encouraging month for the gaming industry. At nearly $1.04 billion, the state’s “win revenue” for the month was the highest recorded since February 2013.6 Thereafter, between February and August, more often than not, such revenues were higher than those recorded in the same month in 2016. U.S. listed companies were the leading contributors to performance, followed by those listed in China (Hong Kong). The other major contributors were companies in Malaysia and Australia. Gaming businesses in Ireland, South Korea, and Sweden were the main detractors from the Fund’s overall positive performance.

 

Generic Drugs – challenged by supply imbalances

 

The Fund had a challenging and disappointing 12 months, ending the period down 7.58%. According to Chip Davis, CEO of the Association for Accessible Medicines, the trade group for generic and biosimilar medicines, the “root cause of recent pain” for companies has been an “imbalance in supply and demand.”7 According to CNBC, Mr. Davis also expects generic drugmakers will continue to feel pressure in the pharmaceutical market amid declining prices and nearly flat revenues.8 In addition to “tumbling” prices, the industry was not helped by “brutal” second-quarter earnings.9 The pharmaceuticals sector detracted the most from the Fund’s performance. The majority of positive performance was provided by the life sciences tools and services sector. In terms of individual companies, Teva Pharmaceutical Industries (5.6% of Fund net assets) was the single largest detractor from performance. The company was affected by a plethora of troubles, including weak sales, low profits, cut dividends, the sudden departure of its CEO, and missed estimates for both earnings per share and revenue.

 

Pharmaceutical – a difficult 12 months

 

In contrast with biotech stocks, pharmaceutical stocks had a lackluster 12 months, ending the period up 2.59%. Having ended the first six months down 3.33%, they traded sideways for the following six months to end the period only just in the black. As with the biotech and generic drug industries, pharmaceuticals were not helped by President Trump’s use of his Twitter account toward the end of 2016 to protest against the price of drugs. While companies in U.S. were the greatest positive contributors to the Fund’s overall performance, Israel, with its single company–Teva Pharmaceutical Industries (4.9% of Fund net assets)–detracted most from performance.

 

Retail – eCommerce continues to thrive

 

The Fund returned 6.25% for the 12-month period under review. Retail sales (excluding automobiles, gasoline stations, and restaurants) in the U.S. over the last three months of 2016 proved to be solid. In November and December, sales increased 4% over 2015 to reach $658.3 billion.10 This included some $122.9 billion of non-store sales, up 12.6% over 2015.11 Retail sales (excluding automobiles, gasoline stations, and restaurants) continued to hold up over the first seven months of 2017, rising (month-over-month) between 0.2% and 0.6%.12 In August, while retail sales may have been down 0.2% from July (on a seasonally adjusted basis) and, on a year-over-year basis, they “showed some strength, increasing 3.7% unadjusted.”13 However, for many small companies the going remained difficult. By the middle of June, some 300 retailers had filed for bankruptcy. Although most of the filings were for small companies there were also some high profile retail store bankruptcies in the U.S. including The Limited, Gymboree, Wet Seal, BCBG Max Azria, and Payless ShoeSource.14 While stores involved in Internet and catalog retailing, together with specialty retailers, contributed by far the most to the positive performance of the Fund, food and staples retailing companies also made useful contributions to performance. Both multi-line retailers and health care providers and services were detractors from performance.

4

 

 

Semiconductor – industry sales continue to boom

 

The Fund was the best performing ETF in the suite, returning 35.63% for the 12-month period under review. With global semiconductor sales in 2016 of $338.9 billion, the industry recorded its highest ever annual sales.15 Sales in December 2016 of $31.0 billion bettered sales in December 2015 by 12.3%.16 Thereafter semiconductor sales in the first two quarters of 2017 remained strong. Sales in the first quarter of 2017 were $92.6 billion. First half 2017 sales were up 20.8% over first half 2016 sales.17 According to John Neuffer, president and CEO of the Semiconductor Industry Association: “Worldwide semiconductor sales increased on a year-to-year basis for the 12th consecutive month in July, reflecting impressive and sustained growth for the global semiconductor market.”18 In July, global sales were up 3.1% from the previous month and 24.0% from the previous year.19 In August, for the first time ever, global sales reached $35 billion and were up 4% from the previous month and 23.9% from the previous year.20 NVIDIA (5.3% of Fund net assets) and Micron Technology (5.2% of Fund net assets), both in the U.S., were the two best performing companies. Qualcomm (4.9% of Fund net assets) detracted most from the Fund’s performance.

 

All Fund assets referenced are Total Net Assets as of September 30, 2017.
S&P 500® Index consists of 500 widely held common stocks covering the industrial, utility, financial, and transportation sectors.

 

 

 

1 U.S. Food & Drug Administration: Novel Drug Approvals for 2017, https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm, Accessed October 2, 2017d
2 U.S. Food & Drug Administration: Novel Drug Approvals for 2016, https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm
3 PitchBook: M&A in biotech & pharma to heat up after fall of ‘Trumpcare’, https://pitchbook.com/news/articles/ma-in-biotech-pharma-to-heat-up-after-fall-of-trumpcare
4 Gaming Inspection and Coordination Bureau, Macao SAR: Monthly Gross Revenue from Games of Fortune, http://www.dicj.gov.mo/web/en/information/DadosEstat_mensal/2017/index.html
5 Ibid.
6 Las Vegas Sun: Nevada gaming revenue up 12 percent in January, eclipses $1 billion, https://lasvegassun.com/news/2017/feb/28/nevada-gaming-revenue-up-12-percent-in-january-ecl/
7 CNBC: The generic drug market ‘is at risk now’ from deflation, trade group says, https://www.cnbc.com/2017/08/10/the-generic-drug-market-is-at-risk-now-from-deflation-trade-group-says.html
8 Ibid.
9 Investors Business Daily: Generic Drug Makers Face Pricing Issues That Other Pharmas Don’t, http://www.investors.com/news/technology/generic-drug-makers-face-pricing-issues-unlike-other-pharma-companies/
10 National Retail Federation: Holiday retail sales increased 4 percent in 2016, https://nrf.com/news/holiday-retail-sales-increased-4-percent-2016
11 Ibid.
12 National Retail Federation: Economy, https://nrf.com/news/retail-sales
13 National Retail Federation: RETAIL SALES DOWN SLIGHTLY IN AUGUST FROM JULY BUT UP OVER 2016, https://nrf.com/media/press-releases/retail-sales-down-slightly-august-july-over-2016
14 CNN Money: Retail bloodbath: Bankruptcy filings pile up, http://money.cnn.com/2017/06/13/news/companies/retail-bankruptcies/index.html
15 Semiconductor Industry Association: Global Semiconductor Sales Reach $339 Billion in 2016, https://www.semiconductors.org/news/2017/02/02/global_sales_report_2015/global_semiconductor_sales_reach_339_billion_in_2016/
16 Ibid.
17 Semiconductor Industry Association: Mid-Year Global Semiconductor Sales Up 21 Percent Compared to 2016, https://www.semiconductors.org/news/2017/08/04/global_sales_report_2017/mid_year_global_semiconductor_sales_up_21_percent_com pared_to_2016/
18 Semiconductor Industry Association: Global Semiconductor Sales Increase 24 Percent Year-to-Year in July, https://www.semiconductors.org/news/2017/09/05/global_sales_report_2017/global_semiconductor_sales_increase_24_percent_year_to_ year_in_july/
19 Ibid.
20 Semiconductor Industry Association: Monthly Semiconductor Sales Reach $35 Billion Globally for First Time in August, https://www.semiconductors.org/news/2017/10/02/global_sales_report_2017/monthly_semiconductor_sales_reach_35_billion_globally_for_first_time_in_august/

5

VANECK VECTORS BIOTECH ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  MVBBHTR1  Share Price  NAV  MVBBHTR1
One Year   16.77%     16.77%     16.91%     16.77%     16.77%     16.91%  
Five Year   20.13%   20.15%   20.34%   150.20%   150.41%   152.33%
Life*   26.21%   26.19%   26.40%   284.00%   283.79%   287.43%
   
* Commencement of Fund: 12/20/11; First Day of Secondary Market Trading: 12/21/11.
   
1 MVIS® US Listed Biotech 25 Index (MVBBHTR) is a rules-based, modified capitalization weighted, float adjusted index intended to give investors a means of tracking the overall performance of the largest and the most liquid common stocks and depositary receipts of U.S. exchange-listed companies that derive at least 50% of their revenues from biotechnology, which includes companies engaged primarily in research and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment (excluding pharmacies).

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

6

VANECK VECTORS ENVIRONMENTAL SERVICES ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  AXENVTR1  Share Price  NAV  AXENVTR1
One Year   24.94%     24.31%     25.01%     24.94   24.31%     25.01%  
Five Year   13.22%   12.98%   13.54%   86.01%   84.11%   88.65%
Ten Year   6.10%   6.08%   6.65%   80.70%   80.48%   90.43%
   
1 NYSE Arca Environmental Services Index (AXENVTR) is a modified equal dollar-weighted index comprised of publicly traded companies that engage in business activities that may benefit from the global increase in demand for consumer waste disposal, removal and storage of industrial by-products, and the management of associated resources.

 

    Hypothetical Growth of $10,000 (Ten Year)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

7

VANECK VECTORS GAMING ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  MVBJKTR1  Share Price  NAV  MVBJKTR1
One Year   21.25%     21.58%     22.15%     21.25%     21.58%     22.15%  
Five Year   8.22%   8.02%   8.34%   48.40%   47.10%   49.24%
Life*   3.47%   3.44%   4.15%   39.24%   38.80%   48.27%

 

* Commencement of Fund: 1/22/08; First Day of Secondary Market Trading: 1/24/08.
   
1 MVIS® Global Gaming Index (MVBJKTR) is a rules-based index intended to give investors a means of tracking the overall performance of the largest and most liquid companies in the global gaming industry that generate at least 50% of their revenues from casinos and hotels, sports betting (including internet gambling and racetracks) and lottery services as well as gaming services, gaming technology and gaming equipment.
   
  Index data prior to September 24, 2012 reflects that of the S-Network Global Gaming Index (WAGRT). From September 24, 2012, forward, the index data reflects that of the Fund’s underlying index, VanEck Vectors Global Gaming Index (MVBJKTR). Index history which includes periods prior to September 24, 2012 reflects a blend of the performance of WAGRT and MVB-JKTR and is not intended for third party use.

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

8

VANECK VECTORS GENERIC DRUGS ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  IGNRXT1  Share Price  NAV  IGNRXT1
One Year   (9.20)%     (7.58)%     (6.68)%     (9.20)%     (7.58)%     (6.68)%  
Life*   (7.13)%   (6.37)%   (5.66)%   (11.94)%   (10.70)%   (9.53)%

 

* Commencement of Fund: 1/12/16; First Day of Secondary Market Trading: 1/13/16.
   
1 Indxx Global Generics & New Pharma Index (IGNRXT) a rules-based, modified capitalization weighted index. The Index includes exchange-listed companies, on a global basis, that derive a significant proportion (as determined by Indxx, LLC) of their revenues (or that have the potential to derive a significant proportion of their revenues) from the generic drug industry, or that have a primary business focus on the generic drug industry.

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

9

VANECK VECTORS PHARMACEUTICAL ETF

PERFORMANCE COMPARISON

 September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  MVPPHTR1  Share Price  NAV  MVPPHTR1
One Year   2.57%     2.59%     2.62%     2.57%     2.59%     2.62%  
Five Year   9.86%   9.84%   9.83%   60.04%   59.90%   59.82%
Life*   11.15%   10.96%   10.93%   84.27%   82.45%   82.12%

 

* Commencement of Fund: 12/20/11; First Day of Secondary Market Trading: 12/21/11.
   
1 MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR) is a rules-based, modified capitalization weighted, float adjusted index intended to give investors a means of tracking the overall performance of the largest and the most liquid common stocks and depositary receipts of U.S. exchange-listed companies that derive at least 50% of their revenues from pharmaceuticals, which includes companies engaged primarily in research and development as well as production, marketing and sales of pharmaceuticals.

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

10

VANECK VECTORS RETAIL ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  MVRTHTR1  Share Price  NAV  MVRTHTR1
One Year   6.45%     6.25%     6.04%     6.45%     6.25%     6.04%  
Five Year   14.33%   14.31%   14.13%   95.36%   95.21%   93.61%
Life*   16.16%   15.92%   15.72%   137.70%   134.87%   132.62%

 

* Commencement of Fund: 12/20/11; First Day of Secondary Market Trading: 12/21/11.
   
1 MVISUS Listed Retail 25 Index (MVRTHTR) is a rules-based, modified capitalization weighted, float adjusted index intended to give investors a means of tracking the overall performance of the largest and the most liquid common stocks and depositary receipts of U.S. exchange-listed companies that derive at least 50% of their revenues from retail, which includes companies engaged primarily in retail distribution; wholesalers; online, direct mail and TV retailers; multi-line retailers; specialty retailers, such as apparel, automotive, computer and electronics, drug, home improvement and home furnishing retailers; and food and other staples retailers.

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

11

VANECK VECTORS SEMICONDUCTOR ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  MVSMHTR1  Share Price  NAV  MVSMHTR1
One Year   35.39%     35.63%     35.64%     35.39   35.63%     35.64%  
Five Year   26.08%   26.07%   26.00%   218.56%   218.44%   217.54%
Life*   23.30%   23.36%   23.28%   235.64%   236.62%   235.35%
   
* Commencement of Fund: 12/20/11; First Day of Secondary Market Trading: 12/21/11.
   
1 MVISUS Listed Semiconductor 25 Index (MVSMHTR) is a rules-based, modified capitalization weighted, float adjusted index intended to give investors a means of tracking the overall performance of the largest and the most liquid common stocks and depositary receipts of U.S. exchange-listed companies that derive at least 50% of their revenues from semiconductors, which includes the production of semiconductors and semiconductor equipment.

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 13 for more information.

12

VANECK VECTORS ETF TRUST

ABOUT FUND PERFORMANCE

(unaudited)

 

The price used to calculate market return (Share Price) is determined by using the closing price listed on its primary listing exchange. Since the shares of each Fund did not trade in the secondary market until after each Fund’s commencement, for the period from commencement to the first day of secondary market trading in shares of each Fund, the NAV of each Fund is used as a proxy for the secondary market trading price to calculate market returns.

 

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Performance information for each Fund reflects temporary waivers of expenses and/or fees. Had each Fund incurred all expenses, investment returns would have been reduced. These returns do not reflect the deduction of taxes that a shareholder would pay on Fund dividends and distributions or the sale of Fund shares.

 

Investment return and value of the shares of each Fund will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Fund returns reflect reinvestment of dividends and capital gains distributions. Performance current to the most recent month-end is available by calling 800.826.2333 or by visiting vaneck.com.

 

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called “creation units” and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market.

 

The net asset value (NAV) of each VanEck Vectors exchange-traded fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of each fund; it is calculated by taking the total assets of each fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAVs are not necessarily the same as each ETF’s intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell fund shares at NAV.

 

Index returns assume the reinvestment of all income and do not reflect any management fees or brokerage expenses associated with Fund returns. Certain indices may take into account withholding taxes. Investors cannot invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Past performance is no guarantee of future results.

 

The Biotech Index, Gaming Index, Pharmaceutical Index, Retail Index, and Semiconductor Index are published by MV Index Solutions GmbH (MVIS®), which is a wholly owned subsidiary of the Adviser, Van Eck Associates Corporation. The Environmental Services Index is published by ICE Data Indices, LLC (ICE Data). The Generic Drugs Index is published by Indxx, LLC.

 

MVIS, Indxx, and ICE Data are referred to herein as the “Index Providers.” The Index Providers do not sponsor, endorse, or promote the Funds and bear no liability with respect to the Funds or any security.

 

Premium/discount information regarding how often the closing trading price of the Shares of each Fund were above (i.e., at a premium) or below (i.e., at a discount) the NAV of the Fund for each of the four previous calendar quarters and the immediately preceding five years (if applicable) can be found at www.vaneck.com.

13

VANECK VECTORS ETF TRUST

EXPLANATION OF EXPENSES

(unaudited)

 

Hypothetical $1,000 investment at beginning of period

As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

 

The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, April 1, 2017 to September 30, 2017.

 

Actual Expenses

The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”

 

Hypothetical Example for Comparison Purposes

The second line in the table below provides information about hypothetical account values and hypothetical expenses based on your Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

 

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as brokerage commissions paid on purchases and sales. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

 

   Beginning  Ending  Annualized  Expenses Paid
   Account  Account  Expense  During the Period*
   Value  Value  Ratio  April 1, 2017-
   April 1, 2017  September 30, 2017  During Period  September 30, 2017
Biotech ETF                    
Actual  $1,000.00   $1,125.90    0.35%     $1.87   
Hypothetical**  $1,000.00   $1,023.31    0.35%  $1.78 
Environmental Services ETF                    
Actual  $1,000.00   $1,106.20    0.55%  $2.90 
Hypothetical**  $1,000.00   $1,022.31    0.55%  $2.79 
Gaming ETF                    
Actual  $1,000.00   $1,128.70    0.65%  $3.47 
Hypothetical**  $1,000.00   $1,021.81    0.65%  $3.29 
Generic Drugs ETF                    
Actual  $1,000.00   $1,000.40    0.56%  $2.81 
Hypothetical**  $1,000.00   $1,022.26    0.56%  $2.84 
Pharmaceutical ETF                    
Actual  $1,000.00   $1,061.20    0.36%  $1.86 
Hypothetical**  $1,000.00   $1,023.26    0.36%  $1.83 
Retail ETF                    
Actual  $1,000.00   $1,030.90    0.35%  $1.78 
Hypothetical**  $1,000.00   $1,023.31    0.35%  $1.78 
Semiconductor ETF                    
Actual  $1,000.00   $1,171.00    0.35%  $1.90 
Hypothetical**  $1,000.00   $1,023.31    0.35%  $1.78 

 

* Expenses are equal to the Fund’s annualized expense ratio (for the six months ended September 30, 2017) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period).
** Assumes annual return of 5% before expenses
14

VANECK VECTORS BIOTECH ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
         
COMMON STOCKS: 99.9%     
Ireland: 1.8%     
 259,942   Alkermes Plc (USD) *  $13,215,451 
Netherlands: 3.0%     
 687,826   QIAGEN NV (USD)   21,666,519 
Spain: 2.8%     
 917,676   Grifols SA (ADR)   20,087,928 
United States: 92.3%     
 300,244   ACADIA Pharmaceuticals, Inc. * †   11,310,191 
 224,419   Alexion Pharmaceuticals, Inc. *   31,483,742 
 202,223   Allergan Plc   41,445,604 
 155,185   Alnylam Pharmaceuticals, Inc. *   18,232,686 
 382,173   Amgen, Inc.   71,256,156 
 121,657   Biogen Idec, Inc. *   38,093,240 
 362,507   BioMarin Pharmaceutical, Inc. *   33,738,526 
 55,914   Bluebird Bio, Inc. *   7,679,788 
 496,333   Celgene Corp. *   72,375,278 
 152,978   Charles River Laboratories International, Inc. *   16,524,684 
 818,861   Gilead Sciences, Inc.   66,344,118 
 157,013   Illumina, Inc. *   31,276,990 
 239,715   Incyte Corp. *   27,984,329 
 257,705   Ionis Pharmaceuticals, Inc. *   13,065,644 
 272,372   Neurocrine Biosciences, Inc. *   16,690,956 
 338,365   Quintiles Transnational Holdings, Inc. *   32,168,361 
 72,341   Regeneron Pharmaceuticals, Inc. *   32,345,108 
 181,469   Seattle Genetics, Inc. * †   9,873,728 
 232,859   Shire Plc (ADR)   35,660,027 
 66,452   TESARO, Inc. * †   8,578,953 
 123,100   United Therapeutics Corp. *   14,426,089 
 207,332   Vertex Pharmaceuticals, Inc. *   31,522,757 
         662,076,955 
Total Common Stocks
(Cost: $712,792,104)
   717,046,853 
MONEY MARKET FUND: 0.1%
(Cost: $575,936)
     
 575,936   Dreyfus Government Cash Management Fund – Institutional Shares   575,936 
Total Investments Before Collateral for Securities Loaned: 100.0%
(Cost: $713,368,040)
   717,622,789 
Principal
Amount
      Value 
           
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 4.0%     
Repurchase Agreements: 4.0%     
$6,769,983   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc., 1.08%, due 10/2/17, proceeds $6,770,592; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $6,905,383 including accrued interest)  $6,769,983 
 6,769,983   Repurchase agreement dated 9/29/17 with Credit Agricole CIB, 1.05%, due 10/2/17, proceeds $6,770,575; (collateralized by various U.S. government and agency obligations, 0.13% to 3.50%, due 4/15/18 to 3/20/46, valued at $6,905,383 including accrued interest)   6,769,983 
 6,769,983   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $6,770,587; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $6,905,383 including accrued interest)   6,769,983 
 1,424,004   Repurchase agreement dated 9/29/17 with Deutsche Bank Securities, Inc., 1.05%, due 10/2/17, proceeds $1,424,129; (collateralized by various U.S. government and agency obligations, 0.88% to 5.25%, due 9/15/19 to 2/15/29, valued at $1,452,484 including accrued interest)   1,424,004 
 6,769,983   Repurchase agreement dated 9/29/17 with Nomura Securities International, Inc., 1.08%, due 10/2/17, proceeds $6,770,592; (collateralized by various U.S. government and agency   obligations, 0.00% to 9.00%, due 11/15/17 to 8/20/67, valued at   $6,905,383 including accrued interest)   6,769,983 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $28,503,936)
   28,503,936 
Total Investments: 104.0%
(Cost: $741,871,976)
   746,126,725 
Liabilities in excess of other assets: (4.0)%   (28,796,292)
NET ASSETS: 100.0%  $717,330,433 


 

See Notes to Financial Statements

15

VANECK VECTORS BIOTECH ETF

SCHEDULE OF INVESTMENTS

September 30, 2017 (continued)

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $28,118,551.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Biotechnology   61.7%  $442,658,522 
Health Care   28.5    204,920,138 
Life Sciences Tools & Services   9.7    69,468,193 
Money Market Fund   0.1    575,936 
           100.0%        $717,622,789 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $717,046,853   $     $   $717,046,853 
Money Market Fund   575,936              575,936 
Repurchase Agreements       28,503,936          28,503,936 
Total  $717,622,789   $28,503,936     $   $746,126,725 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

16

VANECK VECTORS ENVIRONMENTAL SERVICES ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
         
COMMON STOCKS: 100.1%     
Canada: 9.8%     
 24,010   Waste Connections, Inc. (USD)  $1,679,740 
United Kingdom: 10.0%     
 19,372   Steris Plc (USD)   1,712,485 
United States: 80.3%     
 15,419   ABM Industries, Inc.   643,126 
 24,773   Advanced Disposal Services, Inc. *   624,032 
 28,049   Calgon Carbon Corp.   600,249 
 7,010   Cantel Medical Corp.   660,132 
 18,937   Casella Waste Systems, Inc. *   356,016 
 40,112   Ceco Environmental Corp.   339,348 
 10,916   Clean Harbors, Inc. *   618,937 
 41,829   Covanta Holding Corp. †   621,161 
 33,199   Darling International, Inc. *   581,646 
 13,283   Donaldson Company, Inc.   610,221 
 16,397   Heritage-Crystal Clean, Inc. *   356,635 
 27,350   Layne Christensen Co. * †   343,242 
 62,525   Newpark Resources, Inc. *   625,250 
 25,407   Republic Services, Inc.   1,678,386 
 12,223   Schnitzer Steel Industries, Inc.   344,077 
 8,579   Stericycle, Inc. *   614,428 
 9,505   Tennant Co.   629,231 
 10,335   Tenneco, Inc.   627,024 
 13,831   Tetra Tech, Inc.   643,833 
 11,577   US Ecology, Inc.   622,843 
 21,470   Waste Management, Inc.   1,680,457 
         13,820,274 
Total Common Stocks
(Cost: $15,183,659)
   17,212,499 
Number
of Shares
      Value 
           
MONEY MARKET FUND: 0.2%
(Cost: $42,125)
     
 42,125   Dreyfus Government Cash Management Fund – Institutional Shares  $42,125 
Total Investments Before Collateral for Securities Loaned: 100.3%
(Cost: $15,225,784)
   17,254,624 
           
Principal
Amount
         
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES LOANED: 5.4%
(Cost: $936,694)
     
Repurchase Agreement: 5.4%     
 $936,694   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $936,778; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $955,428 including accrued interest)   936,694 
Total Investments: 105.7%
(Cost: $16,162,478)
   18,191,318 
Liabilities in excess of other assets: (5.7)%   (987,106)
NET ASSETS: 100.0%  $17,204,212 


 

 

Definitions:

USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $907,584.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Consumer Discretionary   3.6%  $627,024 
Consumer Staples   3.4    581,646 
Energy   3.6    625,250 
Health Care   13.8    2,372,617 
Industrials   69.9    12,061,636 
Materials   5.5    944,326 
Money Market Fund   0.2    42,125 
           100.0%        $17,254,624 

 

See Notes to Financial Statements

17

VANECK VECTORS ENVIRONMENTAL SERVICES ETF

SCHEDULE OF INVESTMENTS

September 30, 2017 (continued)

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $17,212,499   $     $   $17,212,499 
Money Market Fund   42,125              42,125 
Repurchase Agreement       936,694          936,694 
Total  $17,254,624   $936,694     $   $18,191,318 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

18

VANECK VECTORS GAMING ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
           
COMMON STOCKS: 96.5%     
Australia: 14.1%     
 81,373   Aristocrat Leisure Ltd. #  $1,344,512 
 62,526   Crown Ltd. #   556,147 
 103,424   Star Entertainment Group Ltd. #   426,421 
 103,110   TABCORP Holdings Ltd. #   345,751 
 199,943   Tatts Group Ltd. #   625,720 
         3,298,551 
Canada: 0.9%     
 10,154   Stars Group, Inc. (USD) * †   208,157 
China / Hong Kong: 26.3%     
 278,240   Galaxy Entertainment Group Ltd. #   1,967,231 
 33,045   Melco Crown Entertainment Ltd. (ADR)   797,045 
 108,000   Melco International Development Ltd. #   312,900 
 151,700   MGM China Holdings Ltd. † #   364,116 
 315,200   Sands China Ltd. #   1,648,717 
 390,000   SJM Holdings Ltd. #   358,316 
 264,000   Wynn Macau Ltd. #   714,065 
         6,162,390 
Greece: 1.6%     
 35,904   OPAP SA #   380,446 
Ireland: 4.1%     
 9,652   Paddy Power Betfair Plc #   961,961 
Japan: 4.0%     
 10,300   Heiwa Corp. † #   204,033 
 8,279   Sankyo Co. Ltd. #   264,076 
 33,800   Sega Sammy Holdings, Inc. #   472,309 
         940,418 
Malaysia: 2.8%     
 524,798   Genting Malaysia Bhd #   668,881 
Malta: 1.6%     
 32,586   Kindred Group Plc (SDR) #   374,189 
New Zealand: 1.0%     
 86,019   Sky City Entertainment Group Ltd.   233,187 
Singapore: 3.8%     
 1,026,000   Genting Singapore Plc #   886,216 
South Africa: 0.6%     
 100,947   Tsogo Sun Holdings Ltd. #   151,062 
South Korea: 2.9%     
 17,866   Kangwon Land, Inc. #   546,631 
 9,245   Paradise Co. Ltd. #   122,337 
         668,968 
Sweden: 1.9%     
 19,736   Betsson AB † #   179,653 
 33,359   NetEnt AB #   258,497 
         438,150 
Number
of Shares
      Value 
           
United Kingdom: 5.6%     
 28,929   GVC Holdings Plc #  $318,544 
 246,839   Ladbrokes Plc   404,360 
 28,229   Playtech Ltd. #   347,991 
 71,645   William Hill Plc   242,613 
         1,313,508 
United States: 25.3%     
 10,238   Boyd Gaming Corp.   266,700 
 1,790   Churchill Downs, Inc.   369,098 
 18,007   International Game Technology Plc   442,072 
 28,821   Las Vegas Sands Corp.   1,849,155 
 47,240   MGM Resorts International   1,539,552 
 10,114   Penn National Gaming, Inc. *   236,566 
 8,193   Wynn Resorts Ltd.   1,220,102 
         5,923,245 
Total Common Stocks
(Cost: $23,594,052)
   22,609,329 
REAL ESTATE INVESTMENT TRUST: 3.4%
(Cost: $791,046)
     
United States: 3.4%     
 21,602   Gaming and Leisure Properties, Inc.   796,898 
Total Investments Before Collateral for Securities Loaned: 99.9%
(Cost: $24,385,098)
   23,406,227 
           
Principal
Amount
         
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES LOANED: 1.8%
(Cost: $422,757)
     
Repurchase Agreement: 1.8%     
 $422,757   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $422,795; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $431,212 including accrued interest)   422,757 
Total Investments: 101.7%
(Cost: $24,807,855)
   23,828,984 
Liabilities in excess of other assets: (1.7)%   (393,296)
NET ASSETS: 100.0%  $23,435,688 


 

See Notes to Financial Statements

19

VANECK VECTORS GAMING ETF

SCHEDULE OF INVESTMENTS

September 30, 2017 (continued)

 

Definitions:

ADR American Depositary Receipt
SDR Swedish Depositary Receipt
USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $403,330.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $14,800,722 which represents 63.2% of net assets.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Consumer Discretionary   94.0%  $22,002,841 
Information Technology   2.6    606,488 
Real Estate   3.4    796,898 
          100.0%        $23,406,227 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks                    
Australia  $   $3,298,551     $   $3,298,551 
Canada   208,157            208,157 
China / Hong Kong   797,045    5,365,345        6,162,390 
Greece       380,446        380,446 
Ireland       961,961        961,961 
Japan       940,418        940,418 
Malaysia       668,881        668,881 
Malta       374,189        374,189 
New Zealand   233,187            233,187 
Singapore       886,216        886,216 
South Africa       151,062        151,062 
South Korea       668,968        668,968 
Sweden       438,150        438,150 
United Kingdom   646,973    666,535        1,313,508 
United States   5,923,245            5,923,245 
Real Estate Investment Trust*   796,898            796,898 
Repurchase Agreement       422,757          422,757 
Total  $8,605,505   $15,223,479     $   $23,828,984 

 

* See Schedule of Investments for geographic sector breakouts.

 

During the year ended September 30, 2017, transfers of securities from Level 1 to Level 2 were $388,946, and transfers of securities from Level 2 to Level 1 were $916,055. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.

 

See Notes to Financial Statements

20

VANECK VECTORS GENERIC DRUGS ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
           
COMMON STOCKS: 99.8%     
Belgium: 4.3%     
 2,037   UCB SA #  $145,210 
China / Hong Kong: 8.6%     
 64,000   CSPC Pharmaceutical Group Ltd. #   107,571 
 1,600   Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. #   4,187 
 5,000   Shanghai Fosun Pharmaceutical Group Co. Ltd. #   20,760 
 8,000   Shanghai Pharmaceuticals Holding Co. Ltd. #   19,603 
 78,000   Sino Biopharmaceutical Ltd. #   82,645 
 12,400   Sinopharm Group Co. Ltd. #   54,932 
         289,698 
Finland: 1.5%     
 1,091   Orion OYJ #   50,670 
Germany: 1.9%     
 653   Stada Arzneimittel AG   63,565 
Hungary: 1.5%     
 1,952   Richter Gedeon Nyrt #   48,680 
India: 18.3%     
 6,137   Aurobindo Pharma Ltd. #   65,081 
 6,285   Biocon Ltd. #   31,980 
 10,723   Cadila Healthcare Ltd. #   77,326 
 8,429   Cipla Ltd. #   75,644 
 1,737   Dr Reddy’s Laboratories Ltd. (ADR)   61,976 
 4,732   Lupin Ltd. #   73,498 
 25,131   Sun Pharmaceuticals Industries Ltd. #   193,946 
 1,773   Torrent Pharmaceuticals Ltd. #   33,428 
         612,879 
Indonesia: 1.8%     
 491,000   Kalbe Farma Tbk PT #   60,749 
Ireland: 8.1%     
 1,609   Alkermes Plc (USD) *   81,802 
 566   ICON Plc (USD) *   64,456 
 1,494   Perrigo Co. Plc (USD)   126,467 
         272,725 
Israel: 7.0%     
 424   Taro Pharmaceutical Industries Ltd. (USD) *   47,781 
 10,625   Teva Pharmaceutical Industries Ltd. (ADR)   187,000 
         234,781 
Japan: 6.5%     
 1,000   Hisamitsu Pharmaceutical Co., Inc. #   48,040 
 6,000   Kyowa Hakko Kirin Co. Ltd. #   102,197 
 900   Taisho Pharmaceutical Holdings Co. Ltd. #   68,361 
         218,598 
Number
of Shares
      Value 
           
Jordan: 1.2%     
 2,521   Hikma Pharmaceuticals Plc (GBP) #  $41,011 
South Africa: 3.2%     
 4,781   Aspen Pharmacare Holdings Ltd. #   107,548 
South Korea: 6.3%     
 1,285   Celltrion, Inc. * #   159,653 
 652   Hanmi Science Co. Ltd. * #   52,451 
         212,104 
Switzerland: 6.1%     
 780   Lonza Group AG #   205,115 
United States: 23.5%     
 1,157   Albemarle Corp.   157,711 
 499   Charles River Laboratories International, Inc. *   53,902 
 1,084   INC Research Holdings, Inc. *   56,693 
 1,041   Mallinckrodt Plc *   38,902 
 5,617   Mylan NV *   176,205 
 5,859   Opko Health, Inc. * †   40,193 
 656   PRA Health Sciences, Inc. *   49,968 
 2,268   Quintiles Transnational Holdings, Inc. *   215,619 
         789,193 
Total Common Stocks
(Cost: $3,509,871)
   3,352,526 
MONEY MARKET FUND: 0.8%
(Cost: $26,739)
     
 26,739   Dreyfus Government Cash Management Fund – Institutional Shares   26,739 
Total Investments Before Collateral for Securities Loaned: 100.6%
(Cost: $3,536,610)
   3,379,265 
           
Principal
Amount
         
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES LOANED: 1.2%
(Cost: $40,465)
     
Repurchase Agreement: 1.2%     
 $40,465   Repurchase agreement dated 9/29/17 with Deutsche Bank Securities, Inc., 1.05%, due 10/2/17, proceeds $40,469; (collateralized by various U.S. government and agency obligations, 0.88% to 5.25%, due 9/15/19 to 2/15/29, valued at $41,274 including accrued interest)   40,465 
Total Investments: 101.8%
(Cost: $3,577,075)
   3,419,730 
Liabilities in excess of other assets: (1.8)%   (58,871)
NET ASSETS: 100.0%  $3,360,859 


 

See Notes to Financial Statements

21

VANECK VECTORS GENERIC DRUGS ETF

SCHEDULE OF INVESTMENTS

September 30, 2017 (continued)

 

Definitions:

ADR American Depositary Receipt
GBP British Pound
USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $38,183.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $1,930,286 which represents 57.4% of net assets.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Biotechnology   9.3%  $313,628 
Health Care Distributors   2.2    74,535 
Life Sciences Tools & Services   19.1    645,753 
Pharmaceuticals   63.9    2,160,899 
Specialty Chemicals   4.7    157,711 
Money Market Fund   0.8    26,739 
          100.0%        $3,379,265 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks                    
Belgium  $   $145,210     $   $145,210 
China / Hong Kong       289,698        289,698 
Finland       50,670        50,670 
Germany   63,565            63,565 
Hungary       48,680        48,680 
India   61,976    550,903        612,879 
Indonesia       60,749        60,749 
Ireland   272,725            272,725 
Israel   234,781            234,781 
Japan       218,598        218,598 
Jordan       41,011        41,011 
South Africa       107,548        107,548 
South Korea       212,104        212,104 
Switzerland       205,115        205,115 
United States   789,193            789,193 
Money Market Fund   26,739            26,739 
Repurchase Agreement       40,465          40,465 
Total  $1,448,979   $1,970,751     $   $3,419,730 

 

During the year ended September 30, 2017, transfers of securities from Level 2 to Level 1 were $21,263. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements

 

See Notes to Financial Statements

22

VANECK VECTORS PHARMACEUTICAL ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
           
COMMON STOCKS: 99.8%     
Denmark: 4.8%     
 287,173   Novo-Nordisk AS (ADR) †  $13,827,380 
France: 4.9%     
 277,992   Sanofi SA (ADR)   13,841,222 
Ireland: 10.0%     
 340,991   Endo International Plc (USD) *   2,920,588 
 83,210   Jazz Pharmaceuticals Plc (USD) *   12,169,463 
 157,846   Perrigo Co. Plc (USD)   13,361,664 
         28,451,715 
Israel: 4.9%     
 796,696   Teva Pharmaceutical Industries Ltd. (ADR)   14,021,850 
Switzerland: 4.9%     
 163,831   Novartis AG (ADR)   14,064,891 
United Kingdom: 11.6%     
 452,826   AstraZeneca Plc (ADR) †   15,341,745 
 343,461   GlaxoSmithKline Plc (ADR) †   13,944,517 
 37,343   GW Pharmaceuticals Plc (ADR) *   3,789,941 
         33,076,203 
United States: 58.7%     
 178,312   AbbVie, Inc.   15,844,804 
 156,601   Akorn, Inc. *   5,197,587 
 153,184   AmerisourceBergen Corp.   12,675,976 
 229,479   Bristol-Myers Squibb Co.   14,626,991 
 156,925   Catalent, Inc. *   6,264,446 
 153,583   Eli Lilly & Co.   13,137,490 
 105,144   Johnson & Johnson   13,669,771 
 150,622   Mallinckrodt Plc *   5,628,744 
 81,302   McKesson Corp.   12,488,800 
 214,671   Merck and Co., Inc.   13,745,384 
 383,530   Mylan NV *   12,031,336 
 135,246   Patterson Cos, Inc.   5,227,258 
 404,193   Pfizer, Inc.   14,429,690 
 696,661   Valeant Pharmaceuticals International, Inc. * †   9,983,152 
 195,063   Zoetis, Inc.   12,437,217 
         167,388,646 
Total Common Stocks
(Cost: $345,027,453)
   284,671,907 
MONEY MARKET FUND: 0.1%
(Cost: $257,899)
     
 257,899   Dreyfus Government Cash Management Fund – Institutional Shares   257,899 
Total Investments Before Collateral for Securities Loaned: 99.9%
(Cost: $345,285,352)
   284,929,806 
Principal
Amount
      Value 
           
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 3.9%    
Repurchase Agreements: 3.9%     
$2,664,107   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc., 1.08%, due 10/2/17, proceeds $2,664,347; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $2,717,389 including accrued interest)  $2,664,107 
 490,419   Repurchase agreement dated 9/29/17 with Credit Agricole CIB, 1.04%, due 10/2/17, proceeds $490,462; (collateralized by various U.S. government and agency obligations, 2.13%, due 2/29/24, valued at $500,227 including accrued interest)   490,419 
 2,664,107   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $2,664,345; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $2,717,389 including accrued interest)   2,664,107 
 70,256   Repurchase agreement dated 9/29/17 with J.P. Morgan Securities LLC, 1.05%, due 10/2/17, proceeds $70,262; (collateralized by various U.S. government and agency obligations, 0.88% to 5.25%, due 5/31/18 to 8/15/44, valued at $71,661 including accrued interest)   70,256 
 2,664,107   Repurchase agreement dated 9/29/17 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.07%, due 10/2/17, proceeds $2,664,345; (collateralized by various U.S. government and agency obligations, 1.83% to 4.50%, due 1/1/26 to 7/15/52, valued at $2,717,389 including accrued interest)   2,664,107 
 2,664,107   Repurchase agreement dated 9/29/17 with Nomura Securities International, Inc., 1.08%, due 10/2/17, proceeds $2,664,347; (collateralized by various U.S. government and agency obligations, 0.00% to 9.00%, due 11/15/17 to 8/20/67, valued at $2,717,389 including accrued interest)   2,664,107 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $11,217,103)
   11,217,103 
Total Investments: 103.8%
(Cost: $356,502,455)
   296,146,909 
Liabilities in excess of other assets: (3.8)%   (10,956,933)
NET ASSETS: 100.0%  $285,189,976 


 

See Notes to Financial Statements

23

VANECK VECTORS PHARMACEUTICAL ETF

SCHEDULE OF INVESTMENTS

September 30, 2017 (continued)

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $11,050,667.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value  
Health Care   24.7%  $70,275,964 
Pharmaceuticals   75.2    214,395,943 
Money Market Fund   0.1    257,899 
          100.0%        $284,929,806 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

       Level 2   Level 3    
   Level 1   Significant   Significant    
   Quoted   Observable   Unobservable    
   Prices   Inputs   Inputs  Value 
Common Stocks*  $284,671,907   $     $   $284,671,907 
Money Market Fund   257,899              257,899 
Repurchase Agreements       11,217,103          11,217,103 
Total  $284,929,806   $11,217,103     $   $296,146,909 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

24

VANECK VECTORS RETAIL ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number        
of Shares      Value 
         
COMMON STOCKS: 100.1%
China / Hong Kong: 4.1%
 62,911   JD.com, Inc. (ADR) *  $2,403,200 
United States: 96.0%     
 9,916   Amazon.com, Inc. *   9,532,747 
 17,026   AmerisourceBergen Corp.   1,408,902 
 2,464   AutoZone, Inc. *   1,466,351 
 10,140   Bed Bath & Beyond, Inc. †   237,986 
 20,580   Best Buy Co., Inc.   1,172,237 
 24,993   Cardinal Health, Inc.   1,672,532 
 18,322   Costco Wholesale Corp.   3,010,121 
 36,438   CVS Caremark Corp.   2,963,138 
 22,974   Dollar General Corp.   1,862,043 
 27,036   Home Depot, Inc.   4,422,008 
 14,173   Kohl’s Corp. †   646,997 
 85,730   Kroger Co.   1,719,744 
 21,694   L Brands, Inc. †   902,687 
 37,572   Lowe’s Cos, Inc.   3,003,506 
 31,812   MACY’S, Inc.   694,138 
 17,224   McKesson Corp.   2,645,779 
 8,073   O’Reilly Automotive, Inc. *   1,738,682 
 34,874   Ross Stores, Inc.   2,251,814 
 49,511   Sysco Corp.   2,671,118 
 45,150   Target Corp.   2,664,302 
 26,476   The Gap, Inc.   781,836 
 35,870   TJX Cos., Inc.   2,644,695 
 35,600   Walgreens Boots Alliance, Inc.   2,749,032 
 45,389   Wal-Mart Stores, Inc.   3,546,696 
         56,409,091 
Total Common Stocks
(Cost: $66,899,379)
   58,812,291 
Principal        
Amount      Value 
           
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 3.0%     
Repurchase Agreements: 3.0%     
 $760,525   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc., 1.08%, due 10/2/17, proceeds $760,593; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $775,735 including accrued interest)  $760,525 
 1,000,000   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $1,000,089; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $1,020,000 including accrued interest)   1,000,000 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $1,760,525)
   1,760,525 
Total Investments: 103.1%
(Cost: $68,659,904)
   60,572,816 
Liabilities in excess of other assets: (3.1)%   (1,826,532)
NET ASSETS: 100.0%  $58,746,284 


 

 

Definitions:

ADR American Depositary Receipt

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $1,698,259.
   
Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Consumer Discretionary   61.9%  $36,425,229 
Consumer Staples   28.3    16,659,849 
Health Care   9.8    5,727,213 
          100.0%        $58,812,291 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

       Level 2   Level 3    
   Level 1   Significant   Significant    
   Quoted   Observable   Unobservable    
   Prices   Inputs   Inputs  Value 
Common Stocks*  $58,812,291   $     $   $58,812,291 
Repurchase Agreements       1,760,525          1,760,525 
Total  $58,812,291   $1,760,525     $   $60,572,816 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

25

VANECK VECTORS SEMICONDUCTOR ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number        
of Shares      Value 
         
COMMON STOCKS: 100.1%
Bermuda: 1.9%
 864,943   Marvell Technology Group Ltd. (USD)  $15,482,480 
Netherlands: 9.5%
 241,783   ASML Holding NV (USD) †   41,393,250 
 303,581   NXP Semiconductors NV (USD) *   34,331,975 
         75,725,225 
Taiwan: 10.2%
 2,176,860   Taiwan Semiconductor Manufacturing Co. Ltd. (ADR)   81,741,093 
United States: 78.5%
 1,629,419   Advanced Micro Devices, Inc. * †   20,775,092 
 412,671   Analog Devices, Inc.   35,559,860 
 845,856   Applied Materials, Inc.   44,060,639 
 151,611   Broadcom Ltd.   36,771,732 
 429,418   Cadence Design Systems, Inc. *   16,949,128 
 103,756   Cavium, Inc. *   6,841,671 
 1,924,275   Intel Corp.   73,276,392 
 251,451   KLA-Tencor Corp.   26,653,806 
 206,347   Lam Research Corp.   38,182,449 
 485,389   Maxim Integrated Products, Inc.   23,157,909 
 395,370   Microchip Technology, Inc. †   35,496,319 
 1,055,807   Micron Technology, Inc. *   41,524,889 
 180,024   Microsemi Corp. *   9,267,636 
 236,505   NVIDIA Corp.   42,279,999 
 695,665   ON Semiconductor Corp. *   12,848,933 
 156,037   Qorvo, Inc. *   11,028,695 
 749,911   Qualcomm, Inc.   38,875,386 
 307,568   Skyworks Solutions, Inc.   31,341,179 
 340,488   Teradyne, Inc.   12,696,797 
 460,990   Texas Instruments, Inc.   41,323,144 
 404,429   Xilinx, Inc.   28,645,706 
         627,557,361 
Total Common Stocks
(Cost: $804,594,190)
   800,506,159 
Principal        
Amount      Value 
           
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 4.9%     
Repurchase Agreements: 4.9%     
$9,365,858   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc., 1.08%, due 10/2/17, proceeds $9,366,701; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $9,553,175 including accrued interest)  $9,365,858 
 1,970,667   Repurchase agreement dated 9/29/17 with Credit Agricole CIB, 1.04%,due 10/2/17, proceeds $1,970,838; (collateralized by various U.S. government and agency obligations, 2.13%, due 2/29/24, valued at $2,010,080 including accrued interest)   1,970,667 
 9,365,858   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $9,366,693; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $9,553,175 including accrued interest)   9,365,858 
 9,365,858   Repurchase agreement dated 9/29/17 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.07%, due 10/2/17, proceeds $9,366,693; (collateralized by various U.S. government and agency obligations, 1.83% to 4.50%, due 1/1/26 to 7/15/52, valued at $9,553,175 including accrued interest)   9,365,858 
 9,365,858   Repurchase agreement dated 9/29/17 with Nomura Securities International, Inc., 1.08%, due 10/2/17, proceeds $9,366,701; (collateralized by various U.S. government and agency obligations, 0.00% to 9.00%, due 11/15/17 to 8/20/67, valued at $9,553,176 including accrued interest)   9,365,858 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $39,434,099)
   39,434,099 
Total Investments: 105.0%
(Cost: $844,028,289)
   839,940,258 
Liabilities in excess of other assets: (5.0)%   (39,887,601)
NET ASSETS: 100.0%  $800,052,657 


 

See Notes to Financial Statements

26

 

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $38,637,822.
   
Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Information Technology   14.9%  $119,734,248 
Semiconductor Equipment   20.4    162,986,941 
Semiconductors   64.7    517,784,970 
          100.0%        $800,506,159 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

       Level 2   Level 3    
   Level 1   Significant   Significant    
   Quoted   Observable   Unobservable    
   Prices   Inputs   Inputs  Value 
Common Stocks*  $800,506,159   $     $   $800,506,159 
Repurchase Agreements       39,434,099          39,434,099 
Total  $800,506,159   $39,434,099     $   $839,940,258 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

27

VANECK VECTORS ETF TRUST

STATEMENTS OF ASSETS AND LIABILITIES

September 30, 2017

 

   Biotech
ETF
  Environmental
Services
ETF
  Gaming
ETF
  Generic
Drugs
ETF
Assets:                            
Investments, at value (1) (2)    $717,622,789     $17,254,624     $23,406,227     $3,379,265 
Short-term investments held as collateral for securities loaned (3)     28,503,936      936,694      422,757      40,465 
Cash                        
Cash denominated in foreign currency, at value (4)                 284      2,716 
Receivables:                            
Investment securities sold           2,452,495             
Shares sold                        
Due from Adviser           3,621            20,657 
Dividends     8,913      22,538      97,621      3,901 
Prepaid expenses     6,235      180      324      31 
Total assets     746,141,873      20,670,152      23,927,213      3,447,035 
                             
Liabilities:                            
Payables:                            
Investment securities purchased           395,431             
Collateral for securities loaned     28,503,936      936,694      422,757      40,465 
Line of credit                        
Due to Adviser     192,362            2,716       
Due to custodian.           2,084,425      15,606       
Deferred Trustee fees     35,785      2,454      6,243      10 
Accrued expenses     79,357      46,936      44,203      45,701 
Total liabilities     28,811,440      3,465,940      491,525      86,176 
NET ASSETS    $717,330,433     $17,204,212     $23,435,688     $3,360,859 
Shares outstanding     5,346,503      200,000      550,000      150,000 
Net asset value, redemption and offering price per share    $134.17     $86.02     $42.61     $22.41 
                             
Net assets consist of:                            
Aggregate paid in capital    $723,005,348     $21,846,250     $30,523,555     $3,727,174 
Net unrealized appreciation (depreciation)     4,254,749      2,028,840      (978,796)     (157,273)
Undistributed net investment income     2,529,843      122,134      604,910      20,513 
Accumulated net realized gain (loss)     (12,459,507)     (6,793,012)     (6,713,981)     (229,555)
     $717,330,433     $17,204,212     $23,435,688     $3,360,859 
(1) Value of securities on loan    $28,118,551     $907,584     $403,330     $38,183 
(2) Cost of investments    $713,368,040     $15,225,784     $24,385,098     $3,536,610 
(3) Cost of short-term investments held as collateral for securities loaned    $28,503,936     $936,694     $422,757     $40,465 
(4) Cost of cash denominated in foreign currency    $     $     $284     $2,697 

 

See Notes to Financial Statements

28

 

 

Pharmaceutical
ETF
 Retail
ETF
 Semiconductor
ETF
       
  $284,929,806     $58,812,291     $800,506,159 
   11,217,103      1,760,525      39,434,099 
   73,719            4,139 
                
 
                
               2,339 
                
   323,580      37,817      110,712 
   2,674      735      5,206 
   296,546,882      60,611,368      840,062,654 
                   
                
   11,217,103      1,760,525      39,434,099 
               247,284 
   71,674      8,097      247,768 
         51,950       
   21,755      4,949      25,174 
   46,374      39,563      55,672 
   11,356,906      1,865,084      40,009,997 
  $285,189,976     $58,746,284     $800,052,657 
   4,938,138      721,531      8,570,937 
  $57.75     $81.42     $93.34 
                   
  $356,559,884     $68,770,501     $798,714,325 
   (60,355,546)     (8,087,088)     (4,088,031)
   1,067,099      851,261      7,500,486 
   (12,081,461)     (2,788,390)     (2,074,123)
  $285,189,976     $58,746,284     $800,052,657 
  $11,050,667     $1,698,259     $38,637,822 
  $345,285,352     $66,899,379     $804,594,190 
  $11,217,103     $1,760,525     $39,434,099 
  $     $     $ 

 

See Notes to Financial Statements

29

VANECK VECTORS ETF TRUST

STATEMENTS OF OPERATIONS

For the Year Ended September 30, 2017

 

   Biotech
ETF
  Environmental
Services
ETF
  Gaming
ETF
  Generic
Drugs
ETF
Income:                            
Dividends    $5,386,388     $261,448     $843,289     $37,769 
Securities lending income     78,361      2,941      3,272      5,413 
Foreign taxes withheld     (50,233)     (2,337)     (18,125)     (3,620)
Total income     5,414,516      262,052      828,436      39,562 
                             
Expenses:                            
Management fees     2,270,074      92,593      114,186      20,418 
Professional fees     89,700      57,120      54,481      47,178 
Insurance     6,539      215      256      31 
Trustees’ fees and expenses     13,611      402      446      51 
Reports to shareholders.     49,812      10,794      15,096      14,492 
Indicative optimized portfolio value fee     5,000            6,848      5,360 
Custodian fees.     17,937      1,350      6,015      16,282 
Registration fees     5,873      6,532      5,932      5,328 
Transfer agent fees     2,400      2,400      2,387      2,400 
Fund accounting fees     34,289      1,065      3,741      3,616 
Interest     3,859      333      1,194      829 
Other     18,491      2,199      4,247      4,096 
Total expenses     2,517,585      175,003      214,829      120,081 
Waiver of management fees     (243,683)     (72,819)     (65,192)     (20,418)
Expenses assumed by the Adviser                       (76,374)
Net expenses     2,273,902      102,184      149,637      23,289 
Net investment income     3,140,614      159,868      678,799      16,273 
                             
Net realized gain (loss) on:                            
Investments     (3,921,838)     (314,590)     (954,154)     (187,551)
In-kind redemptions     17,925,118      4,043,667      2,063,589      248,785 
Foreign currency transactions and foreign denominated assets and liabilities                 (6,252)     5,808 
Net realized gain     14,003,280      3,729,077      1,103,183      67,042 
                             
Net change in unrealized appreciation (depreciation) on:                            
Investments     84,996,662      178,828      2,504,320      (106,627)
Foreign currency transactions and foreign denominated assets and liabilities                 (2,747)     2 
Net change in unrealized appreciation (depreciation)     84,996,662      178,828      2,501,573      (106,625)
Net Increase (Decrease) in Net Assets Resulting from Operations    $102,140,556     $4,067,773     $4,283,555     $(23,310)

 

See Notes to Financial Statements

30

 

 

Pharmaceutical
ETF
  Retail
ETF
  Semiconductor
ETF
       
  $7,457,814     $1,460,119     $12,497,531 
   36,536      2,661      50,470 
   (443,586)           (545,711)
   7,050,764      1,462,780      12,002,290 
                   
   989,366      283,681      2,416,649 
   69,463      59,458      76,284 
   3,206      1,406      4,634 
   6,803      2,341      12,747 
   26,553      29,815      29,079 
   5,000      4,998      5,000 
   7,277      4,303      19,819 
   5,521      5,061      5,146 
   2,387      2,786      2,400 
   14,556      4,398      33,669 
   12,790      1,237      20,751 
   2,369      4,510      13,153 
   1,145,291      403,994      2,639,331 
   (143,130)     (119,085)     (201,986)
                
   1,002,161      284,909      2,437,345 
   6,048,603      1,177,871      9,564,945 
                   
   (5,979,474)     (990,478)     16,881 
   13,959,507      1,172,947      221,330,886 
                
   7,980,033      182,469      221,347,767 
                   
   1,765,322      2,134,169      (6,994,961)
                
   1,765,322      2,134,169      (6,994,961)
  $15,793,958     $3,494,509     $223,917,751 

 

See Notes to Financial Statements

31

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Biotech ETF  Environmental Services ETF
       
   For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
Operations:                            
Net investment income    $3,140,614     $1,702,727     $159,868     $157,460 
Net realized gain (loss)     14,003,280      8,194,712      3,729,077      1,075,833 
Net change in unrealized appreciation (depreciation)     84,996,662      (11,399,323)     178,828      1,814,655 
Net increase (decrease) in net assets resulting from operations     102,140,556      (1,501,884)     4,067,773      3,047,948 
                             
Dividends to shareholders:                            
Dividends from net investment income     (1,715,606)     (1,869,172)     (132,750)     (170,000)
                             
Share transactions:**                            
Proceeds from sale of shares     188,497,661      141,425,835      12,005,278      3,356,139 
Cost of shares redeemed     (170,506,515)     (191,118,834)     (16,156,568)     (3,406,498)
Increase (Decrease) in net assets resulting from share transactions     17,991,146      (49,692,999)     (4,151,290)     (50,359)
Total increase (decrease) in net assets     118,416,096      (53,064,055)     (216,267)     2,827,589 
Net Assets, beginning of period     598,914,337      651,978,392      17,420,479      14,592,890 
Net Assets, end of period†    $717,330,433     $598,914,337     $17,204,212     $17,420,479 
† Including undistributed net investment income    $2,529,843     $1,104,835     $122,134     $119,922 
                             
** Shares of Common Stock Issued (no par value)                            
Shares sold     1,600,000      1,250,000      150,000      50,000 
Shares redeemed     (1,450,000)     (1,750,000)     (200,000)     (50,000)
Net increase (decrease)     150,000      (500,000)     (50,000)      

* Commencement of operations

 

See Notes to Financial Statements

32

 

 

Gaming ETF  Generic Drugs ETF  Pharmaceutical ETF
For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Year
Ended
September 30,
2017
  For the Period
January 12, 2016*
through
September 30,
2016
  For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
                
  $678,799     $588,473     $16,273     $6,737     $6,048,603     $5,886,451 
   1,103,183      (3,609,513)     67,042      (41,959)     7,980,033      (8,539,825)
   2,501,573      7,968,522      (106,625)     (50,648)     1,765,322      (22,231,883)
   4,283,555      4,947,482      (23,310)     (85,870)     15,793,958      (24,885,257)
                                        
   (586,300)     (909,300)     (19,400)           (5,854,105)     (6,437,588)
                                        
   14,154,237            4,333,286      2,521,970      786,410,157      335,719,958 
   (14,296,884)     (8,016,264)     (3,365,817)           (743,098,245)     (386,756,125)
   (142,647)     (8,016,264)     967,469      2,521,970      43,311,912      (51,036,167)
   3,554,608      (3,978,082)     924,759      2,436,100      53,251,765      (82,359,012)
   19,881,080      23,859,162      2,436,100            231,938,211      314,297,223 
  $23,435,688     $19,881,080     $3,360,859     $2,436,100     $285,189,976     $231,938,211 
  $604,910     $522,377     $20,513     $6,258     $1,067,099     $872,601 
                                        
   350,000            200,000      100,000      14,500,000      5,400,000 
   (350,000)     (250,000)     (150,000)           (13,600,000)     (6,350,000)
         (250,000)     50,000      100,000      900,000      (950,000)

 

See Notes to Financial Statements

33

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

(continued)

 

   Retail ETF  Semiconductor ETF
   For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
Operations:                            
Net investment income    $1,177,871     $1,825,711     $9,564,945     $4,266,314 
Net realized gain     182,469      11,123,462      221,347,767      89,252,283 
Net increase from payment from Adviser (See Note 3)                       340,000 
Net change in unrealized appreciation (depreciation)     2,134,169      (2,141,071)     (6,994,961)     21,502,117 
Net increase in net assets resulting from operations     3,494,509      10,808,102      223,917,751      115,360,714 
                             
Dividends to shareholders:                            
Dividends from net investment income     (1,772,514)     (3,353,072)     (4,764,060)     (5,557,739)
                             
Share transactions:**                            
Proceeds from sale of shares     32,054,970      107,980,044      10,938,048,365      6,483,334,545 
Cost of shares redeemed     (93,737,069)     (200,637,218)     (10,934,279,639)     (6,206,930,426)
Increase (Decrease) in net assets resulting from share transactions     (61,682,099)     (92,657,174)     3,768,726      276,404,119 
Total increase (decrease) in net assets     (59,960,104)     (85,202,144)     222,922,417      386,207,094 
Net Assets, beginning of period     118,706,388      203,908,532      577,130,240      190,923,146 
Net Assets, end of period†    $58,746,284     $118,706,388     $800,052,657     $577,130,240 
† Including undistributed net investment income    $851,261     $1,445,904     $7,500,486     $2,986,492 
                             
** Shares of Common Stock Issued (no par value)                            
Shares sold     400,000      1,400,000      137,800,000      114,550,000 
Shares redeemed     (1,200,000)     (2,650,000)     (137,550,000)     (110,050,000)
Net increase (decrease)     (800,000)     (1,250,000)     250,000      4,500,000 

 

See Notes to Financial Statements

34

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each year:

 

   Biotech ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year      $115.25         $114.45         $105.84         $82.74         $54.07     
Income from investment operations:                                     
Net investment income (loss)     0.58(a)     0.33      0.24      (0.03)     0.01   
Net realized and unrealized gain on investments     18.67      0.81      8.37      23.13      28.85   
Total from investment operations     19.25      1.14      8.61      23.10      28.86   
Less:                                     
Dividends from net investment income     (0.33)     (0.34)           (d)     (0.02)  
Distributions from net realized capital gains                             (0.17)  
Total dividends and distributions     (0.33)     (0.34)                 (0.19)  
Net asset value, end of year    $134.17     $115.25     $114.45     $105.84     $82.74   
Total return (b)     16.77%     0.97%     8.13%     27.92%     53.55%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $717,330   $598,914   $651,978   $539,423   $434,089   
Ratio of gross expenses to average net assets     0.39%     0.40%     0.40%     0.41%     0.41%  
Ratio of net expenses to average net assets     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net expenses to average net assets excluding interest expense     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net investment income (loss) to average net assets     0.48%     0.29%     0.18%     (0.03)%     0.01%  
Portfolio turnover rate (c)     27%     41%     12%     11%     0%  
                                      
   Environmental Services ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year    $69.68     $58.37     $64.57     $62.43     $49.65   
Income from investment operations:                                     
Net investment income     0.66(a)     0.63      0.73      1.00      0.91   
Net realized and unrealized gain (loss) on investments     16.21      11.36      (5.88)     1.89      12.66   
Total from investment operations     16.87      11.99      (5.15)     2.89      13.57   
Less:                                     
Dividends from net investment income     (0.53)     (0.68)     (1.05)     (0.75)     (0.79)  
Net asset value, end of year    $86.02     $69.68     $58.37     $64.57     $62.43   
Total return (b)     24.31%     20.75%     (8.18)%     4.62%     27.67%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $17,204   $17,420   $14,593   $16,142   $18,729   
Ratio of gross expenses to average net assets     0.95%     0.93%     1.15%     0.92%     1.01%  
Ratio of net expenses to average net assets     0.55%     0.55%     0.55%     0.55%     0.55%  
Ratio of net expenses to average net assets excluding interest expense     0.55%     0.55%     0.55%     0.55%     0.55%  
Ratio of net investment income to average net assets     0.86%     1.00%     1.15%     1.32%     1.60%  
Portfolio turnover rate (c)     20%     40%     19%     13%     5%  

 

 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the year, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the year. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(d) Amount represents less than $0.005 per share

 

See Notes to Financial Statements

35

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Gaming ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year      $36.15         $29.82           $43.38           $47.49         $34.22     
Income from investment operations:                                     
Net investment income     1.13(a)     0.94(a)     1.12(a)     1.76      1.10   
Net realized and unrealized gain (loss) on investments     6.40      6.69      (12.80)     (5.35)     13.55   
Total from investment operations     7.53      7.63      (11.68)     (3.59)     14.65   
Less:                                     
Dividends from net investment income     (1.07)     (1.30)     (1.88)     (0.52)     (1.38)  
Net asset value, end of year    $42.61     $36.15     $29.82     $43.38     $47.49   
Total return (b)     21.58%     26.23%     (27.91)%     (7.76)%     44.14%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)    $23,436   $19,881   $23,859   $43,384   $56,982   
Ratio of gross expenses to average net assets     0.94%     0.93%     1.00%     0.73%     0.83%  
Ratio of net expenses to average net assets     0.65%     0.67%     0.66%     0.65%     0.65%  
Ratio of net expenses to average net assets excluding interest expense     0.65%     0.65%     0.65%     0.65%     0.65%  
Ratio of net investment income to average net assets     2.97%     2.88%     2.92%     2.73%     2.73%  
Portfolio turnover rate (c)     22%     29%     27%     35%     16%  
                                      
   Generic Drugs ETF                                
   For the Year
Ended
September 30,
2017
  For the Period
January 12,
2016 (d)
through
September 30,
2016
                               
Net asset value, beginning of period           $24.36               $25.21                                      
Income from investment operations:                                              
Net investment income     0.09(a)     0.07                                 
Net realized and unrealized loss on investments     (1.94)     (0.92)                                
Total from investment operations     (1.85)     (0.85)                                
Less:                                              
Dividends from net investment income     (0.10)                                      
Net asset value, end of period    $22.41     $24.36                                 
Total return (b)     (7.58)%     (3.37)%(e)                                
Ratios/Supplemental Data                                              
Net assets, end of period (000’s)  $ 3,361   $ 2,436                                 
Ratio of gross expenses to average net assets     2.94%     5.70%(f)                                
Ratio of net expenses to average net assets     0.57%     0.55%(f)                                
Ratio of net expenses to average net assets excluding interest expense     0.55%     0.55%(f)                                
Ratio of net investment income to average net assets     0.40%     0.39%(f)                                
Portfolio turnover rate (c)     61%     47%(e)                                

 

 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(d) Commencement of operations
(e) Not Annualized
(f) Annualized

 

See Notes to Financial Statements

36

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each year:

 

   Pharmaceutical ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year       $57.44           $63.01           $63.54           $47.89           $41.03      
Income from investment operations:                                     
Net investment income     1.18(a)     1.24(a)     1.31      1.02      1.08   
Net realized and unrealized gain (loss) on investments     0.26      (5.41)     (0.62)     15.66      7.78   
Total from investment operations     1.44      (4.17)     0.69      16.68      8.86   
Less:                                     
Dividends from net investment income     (1.13)     (1.40)     (1.22)     (1.03)     (2.00)  
Net asset value, end of year    $57.75     $57.44     $63.01     $63.54     $47.89   
Total return (b)     2.59%     (6.72)%     0.96%     35.19%     22.44%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $285,190   $231,938   $314,297   $405,888   $241,267   
Ratio of gross expenses to average net assets     0.40%     0.41%     0.41%     0.42%     0.43%  
Ratio of net expenses to average net assets     0.35%     0.35%     0.36%     0.35%     0.35%  
Ratio of net expenses to average net assets excluding interest expense     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net investment income to average net assets     2.14%     2.04%     1.78%     1.85%     2.30%  
Portfolio turnover rate (c)     40%     25%     12%     14%     3%  
                                      
   Retail ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year    $78.02     $73.57     $62.27     $55.34     $44.88   
Income from investment operations:                                     
Net investment income     1.15(a)     0.93(a)     1.12(a)     0.60      0.27   
Net realized and unrealized gain on investments     3.64      5.27      10.47      6.94      11.04   
Total from investment operations     4.79      6.20      11.59      7.54      11.31   
Less:                                     
Dividends from net investment income     (1.39)     (1.75)     (0.29)     (0.61)     (0.85)  
Net asset value, end of year    $81.42     $78.02     $73.57     $62.27     $55.34   
Total return (b)     6.25%     8.42%     18.63%     13.65%     25.69%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $58,746   $118,706   $203,909   $66,724   $42,696   
Ratio of gross expenses to average net assets     0.50%     0.43%     0.42%     0.63%     0.69%  
Ratio of net expenses to average net assets     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net expenses to average net assets excluding interest expense     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net investment income to average net assets     1.46%     1.22%     1.49%     1.23%     1.84%  
Portfolio turnover rate (c)     17%     9%     5%     3%     3%  

 

 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the year, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the year. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.

 

See Notes to Financial Statements

37

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each year:

 

   Semiconductor ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year       $69.36           $49.97           $51.10           $39.88           $31.66      
Income from investment operations:                                     
Net investment income     1.10(a)     0.82(a)     1.08(a)     0.62      0.72   
Net realized and unrealized gain (loss) on investments     23.46      19.67      (1.58)     11.26      8.20   
Payment from Adviser           0.04(d)                    
Total from investment operations     24.56      20.53      (0.50)     11.88      8.92   
Less:                                     
Dividends from net investment income     (0.58)     (1.14)     (0.63)     (0.66)     (0.70)  
Net asset value, end of year    $93.34     $69.36     $49.97     $51.10     $39.88   
Total return (b)     35.63%     41.73%     (1.09)%     30.13%     28.70%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $800,053   $577,130   $190,923   $414,959   $262,017   
Ratio of gross expenses to average net assets     0.38%     0.41%     0.41%     0.41%     0.43%  
Ratio of net expenses to average net assets     0.35%     0.36%     0.35%     0.35%     0.35%  
Ratio of net expenses to average net assets excluding interest expense     0.35%     0.35%     0.35%     0.35%     0.35%  
Ratio of net investment income to average net assets     1.38%     1.45%     2.01%     1.68%     1.81%  
Portfolio turnover rate (c)     22%     53%     18%     9%     4%  

 

 
(a) Calculated based upon average shares outstanding
(b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the year, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the year. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.
(d) For the year ended September 30, 2016, 0.06% of total return, representing $0.04 per share, consisted of a payment by the Adviser (See Note 3).

 

See Notes to Financial Statements

38

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

 

Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of September 30, 2017, offers fifty-nine investment portfolios, each of which represents a separate series of the Trust.

 

These financial statements relate only to the following investment portfolios: Biotech ETF, Environmental Services ETF, Gaming ETF, Generic Drugs ETF, Pharmaceutical ETF, Retail ETF and Semiconductor ETF (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index published by Indxx LLC, ICE Data Indices, LLC or MV Index Solutions GmbH (“MVIS”), a wholly owned subsidiary of Van Eck Associates Corporation (the “Adviser”).

 

The Funds’ commencement of operations dates and their respective indices are presented below:

 

Fund  Commencement
of Operations     
  Index
Biotech ETF  December 20, 2011  MVIS® US Listed Biotech 25 Index*
Environmental Services ETF  October 10, 2006  NYSE Arca Environmental Services Index
Gaming ETF  January 22, 2008  MVIS® Global Gaming Index*
Generic Drugs ETF  January 12, 2016  Indxx Global Generics & New Pharma Index
Pharmaceutical ETF  December 20, 2011  MVIS® US Listed Pharmaceutical 25 Index*
Retail ETF  December 20, 2011  MVIS® US Listed Retail 25 Index*
Semiconductor ETF  December 20, 2011  MVIS® US Listed Semiconductor 25 Index*
   
* Published by MV Index Solutions GmbH

 

Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.

 

The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services - Investment Companies.

 

The following is a summary of significant accounting policies followed by the Funds.

 

A. Security Valuation-The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Standard Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term debt securities with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Adviser provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the
39

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

  security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and procedures. The Pricing Committee employs various methods for calibrating the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis.
   
  Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments.
   
  The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below:
   
  Level 1 — Quoted prices in active markets for identical securities.
   
  Level 2 — Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
   
  Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
   
  A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments.
   
B. Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required.
   
C. Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund (except for dividends from net investment income on Pharmaceutical ETF, which are declared and paid quarterly). Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP.
   
D. Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations.
   
E. Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments.
40

 

 

F. Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of September 30, 2017 are reflected in the Schedules of Investments.
   
G. Use of Derivative Instruments—The Funds may invest in derivative instruments, including, but not limited to, options, futures, swaps and other derivatives relating to foreign currency transactions. A derivative is an instrument whose value is derived from underlying assets, indices, reference rates or a combination of these factors. Derivative instruments may be privately negotiated contracts (often referred to as over-the-counter (“OTC”) derivatives) or they may be listed and traded on an exchange. Derivative contracts may involve future commitments to purchase or sell financial instruments at specified terms on a specified date, or to exchange interest payment streams or currencies based on a notional or contractual amount. Derivative instruments may involve a high degree of financial risk. The use of derivative instruments also involves the risk of loss if the Adviser is incorrect in its expectation of the timing or level of fluctuations in securities prices, interest rates or currency prices. Investments in derivative instruments also include the risk of default by the counterparty, the risk that the investment may not be liquid and the risk that a small movement in the price of the underlying security or benchmark may result in a disproportionately large movement, unfavorable or favorable, in the price of the derivative instruments. The Funds held no derivative instruments during the year ended September 30, 2017.
   
H. Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at September 30, 2017 is presented in the Schedules of Investments. Refer to related disclosures in Note 2F (Repurchase Agreements) and Note 9 (Securities Lending).
   
I. Other—Security transactions are accounted for on trade date. Realized gains and losses are calculated on the identified cost basis. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date/rate. Interest income, including amortization of premiums and discounts, is accrued as earned.
   
  In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote.

 

Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2018, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding the expense limitations listed in the table below.

41

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

The current expense limitations, management fee rates and the amounts waived/assumed by the Adviser for the year ended September 30, 2017, are as follows:

 

Fund  Expense
Limitations
  Management
Fee Rates
  Waiver of
Management Fees
  Expenses Assumed
by the Adviser
Biotech ETF   0.35%   0.35%  $243,683   $ 
Environmental Services ETF   0.55    0.50    72,819     
Gaming ETF   0.65    0.50    65,192     
Generic Drugs ETF   0.55    0.50    20,418    76,374 
Pharmaceutical ETF   0.35    0.35    143,130     
Retail ETF   0.35    0.35    119,085     
Semiconductor ETF   0.35    0.35    201,986     

 

During the year ended September 30, 2016, the Adviser voluntarily reimbursed the Semiconductor ETF $340,000 for transactional losses. This reimbursement is reflected in the Statements of Changes in Net Assets as a net increase from payment from Adviser. The per share and total return impact to the Fund is reflected in the Financial Highlights.

 

In addition, Van Eck Securities Corporation (the “Distributor”), an affiliate of the Adviser, acts as the Funds’ distributor. Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.

 

Note 4—Investments—For the year ended September 30, 2017, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:

 

Fund  Cost of Investments
Purchased
  Proceeds from
Investments Sold
Biotech ETF   $176,336,280    $174,057,418 
Environmental Services ETF   3,658,218    7,805,245 
Gaming ETF   5,034,979    4,976,291 
Generic Drugs ETF   2,817,384    2,424,682 
Pharmaceutical ETF   112,913,776    112,988,742 
Retail ETF   14,049,410    15,319,770 
Semiconductor ETF   145,983,765    141,094,360 

 

Note 5—Income Taxes—As of September 30, 2017, for Federal income tax purposes, the identified cost of investments owned, net unrealized appreciation (depreciation), gross unrealized appreciation, and gross unrealized depreciation of investments were as follows:

 

Fund  Cost of Investments  Gross Unrealized
Appreciation
  Gross Unrealized
Depreciation
  Net Unrealized
Appreciation
(Depreciation)
Biotech ETF   $742,857,199    $54,983,748    $(51,714,222)   $   3,269,526 
Environmental Services ETF   16,169,156    2,136,087    (113,925)   2,022,162 
Gaming ETF   25,370,583    1,999,738    (3,541,337)   (1,541,599)
Generic Drugs ETF   3,605,888    431,392    (617,550)   (186,158)
Pharmaceutical ETF   356,504,894    5,931,994    (66,289,979)   (60,357,985)
Retail ETF   68,694,513    2,765,224    (10,886,921)   (8,121,697)
Semiconductor ETF   844,028,289    14,257,580    (18,345,611)   (4,088,031)

 

At September 30, 2017, the components of accumulated earnings (deficit) on a tax basis, for each Fund, were as follows:

 

Fund  Undistributed
Ordinary
Income
  Accumulated
Capital
Losses
  Other
Temporary
Differences
  Unrealized
Appreciation
(Depreciation)
  Total
Biotech ETF   $2,565,628    $(11,474,284)   $(35,785)   $   3,269,526    $  (5,674,915)
Environmental Services ETF   121,949    (6,783,695)   (2,454)   2,022,162    (4,642,038)
Gaming ETF   587,278    (6,129,043)   (4,578)   (1,541,524)   (7,087,867)
Generic Drugs ETF   20,523    (200,742)   (10)   (186,086)   (366,315)
Pharmaceutical ETF   1,088,854    (12,079,022)   (21,755)   (60,357,985)   (71,369,908)
Retail ETF   856,210    (2,753,781)   (4,949)   (8,121,697)   (10,024,217)
Semiconductor ETF   7,525,660    (2,074,123)   (25,174)   (4,088,031)   1,338,332 
42

 

 

The tax character of dividends paid to shareholders during the years ended September 30, 2017 and September 30, 2016 was as follows:

 

Fund  2017 Dividends
Ordinary Income
  2016 Dividends
Ordinary Income
Biotech ETF  $1,715,606   $1,869,172 
Environmental Services ETF   132,750    170,000 
Gaming ETF   586,300    909,300 
Generic Drugs ETF   19,400     
Pharmaceutical ETF   5,854,105    6,437,588 
Retail ETF   1,772,514    3,353,072 
Semiconductor ETF   4,764,060    5,557,739 

 

At September 30, 2017, the Funds had capital loss carryforwards available to offset future capital gains, as follows:

 

Fund  Short-Term
Capital Losses
with No Expiration
  Long-Term
Capital Losses
with No
Expiration
  Amount
Expiring in the
Year Ended
September 30, 2018
  Total
Biotech ETF  $   $(11,474,284)  $   $(11,474,284)
Environmental Services ETF   (539,614)   (5,764,706)   (479,375)   (6,783,695)
Gaming ETF   (2,187,113)   (3,941,930)       (6,129,043)
Generic Drugs ETF   (120,655)   (80,087)       (200,742)
Pharmaceutical ETF   (5,362,815)   (6,716,207)       (12,079,022)
Retail ETF   (1,336,686)   (1,417,095)       (2,753,781)
Semiconductor ETF   (1,648,128)   (425,995)       (2,074,123)

 

During the year ended September 30, 2017, Environmental Services ETF had $6,445,705 of its accumulated capital loss carryforwards expire.

 

During the year ended September 30, 2017, Semiconductor ETF utilized $29,112 of its accumulated capital losses available from previous years.

 

During the year ended September 30, 2017, as a result of permanent book to tax differences, primarily due to investments in Passive Foreign Investment Companies, foreign currency gains and losses, and tax treatment of in-kind redemptions, the Funds incurred differences that affected undistributed net investment income (loss), accumulated net realized gain (loss) on investments and aggregate paid in capital by the amounts in the table below. Net assets were not affected by these reclassifications.

 

Fund  Increase (Decrease)
in Undistributed Net
Investment Income (Loss)
  Increase (Decrease)
in Accumulated Net
Realized Gain (Loss)
  Increase (Decrease)
in Aggregate
Paid in Capital
Biotech ETF  $   $(17,589,331)  $17,589,331 
Environmental Services ETF   (24,906)   2,451,849    (2,426,943)
Gaming ETF   (9,966)   (1,962,244)   1,972,210 
Generic Drugs ETF   17,382    (255,117)   237,735 
Pharmaceutical ETF       (13,958,912)   13,958,912 
Retail ETF       (1,164,638)   1,164,638 
Semiconductor ETF   (286,891)   (220,802,617)   221,089,508 

 

The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, the Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.

 

The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the year ended September 30, 2017, the Funds did not incur any interest or penalties.

43

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

Note 6—Capital Share Transactions—As of September 30, 2017, there was an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.

 

The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of market circumstances, or when the securities are not available in sufficient quantity for delivery, or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.

 

Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.

 

For the year ended September 30, 2017, the Funds had in-kind contributions and redemptions as follows:

 

Fund  In-Kind Contributions  In-Kind Redemptions
Biotech ETF  $188,500,550   $170,556,678 
Environmental Services ETF   12,000,670    11,997,400 
Gaming ETF   13,022,593    13,154,273 
Generic Drugs ETF   3,094,928    2,523,974 
Pharmaceutical ETF   786,304,488    742,811,426 
Retail ETF   32,052,693    93,098,156 
Semiconductor ETF   10,937,423,778    10,933,640,643 

 

The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect gross shareholder transactions including any cash component of the transactions.

 

Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Fund’s index. Each of the Funds is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrences affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.

 

In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the European Union (“EU”) by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal and the effects such withdrawal will have on the EU and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volitality and uncertainty in European and global markets.

 

A more complete description of risks is included in each Fund’s prospectus and Statement of Additional Information.

 

Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination

44

 

 

from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.

 

The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.

 

Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto, on the securities loaned while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at September 30, 2017 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.

 

The following table presents the amount of repurchase agreements held as collateral by type of security on loan pledged as of September 30, 2017:

 

   Gross Amount of Recognized
Liabilities for Securities Loaned
in the Statements of Assets
and Liabilities*
Fund  Equity Securities
Biotech ETF  $28,503,936 
Environmental Services ETF   936,694 
Gaming ETF   422,757 
Generic Drugs ETF   40,465 
Pharmaceutical ETF   11,217,103 
Retail ETF   1,760,525 
Semiconductor ETF   39,434,099 

 

*Remaining contractual maturity of the agreements: overnight and continuous

 

Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds at the request of the shareholders and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the period ended September 30, 2017, the following Funds borrowed under this Facility:

45

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

Fund  Days
Outstanding
  Average Daily
Loan Balance
  Average
Interest Rate
  Outstanding Loan
Balance as of
September 30, 2017
Biotech ETF   95   $676,831    2.29%  $ 
Environmental Services ETF   4    1,277,626    2.24     
Gaming ETF   75    146,518    1.94     
Generic Drugs ETF   6    329,594    2.35     
Pharmaceutical ETF   225    817,658    2.28     
Retail ETF   158    121,837    2.14     
Semiconductor ETF   233    1,042,713    2.21    247,284 

 

Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the year ended September 30, 2017, there were offsets to custodian fees and these amounts are reflected in custody expense in the Statements of Operations.

 

Note 12—Subsequent Events—The Funds have evaluated events and transactions for potential recognition or disclosure through the date the financial statements were issued.

 

The following dividend from net investment income was declared and paid subsequent to September 30, 2017:

 

Fund  Ex-Date  Record Date  Payable Date  Per Share
Pharmaceutical ETF  10/2/17  10/3/17  10/6/17  $0.2210
46

VANECK VECTORS ETF TRUST

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Board of Trustees and Shareholders of VanEck Vectors ETF Trust

 

We have audited the accompanying statements of assets and liabilities, including the schedules of investments, of VanEck Vectors Biotech ETF, VanEck Vectors Environmental Services ETF, VanEck Vectors Gaming ETF, VanEck Vectors Generic Drugs ETF, VanEck Vectors Pharmaceutical ETF, VanEck Vectors Retail ETF and VanEck Vectors Semiconductor ETF (seven of the series constituting VanEck Vectors ETF Trust) (the “Funds”) as of September 30, 2017, and the related statements of operations, the statements of changes in net assets and the financial highlights for the periods indicated therein. These financial statements and financial highlights are the responsibility of the Funds’ management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement. We were not engaged to perform an audit of the Funds’ internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements and financial highlights, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our procedures included confirmation of securities owned as of September 30, 2017, by correspondence with the custodian and brokers or by other appropriate auditing procedures where replies from brokers were not received. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements and financial highlights referred to above present fairly, in all material respects, the financial position of VanEck Vectors Biotech ETF, VanEck Vectors Environmental Services ETF, VanEck Vectors Gaming ETF, VanEck Vectors Generic Drugs ETF, VanEck Vectors Pharmaceutical ETF, VanEck Vectors Retail ETF and VanEck Vectors Semiconductor ETF (seven of the series constituting VanEck Vectors ETF Trust) at September 30, 2017, and the results of their operations, the changes in their net assets and the financial highlights for the periods indicated therein, in conformity with U.S. generally accepted accounting principles.

 

 

New York, New York
November 27, 2017

47

VANECK VECTORS ETF TRUST

TAX INFORMATION

(unaudited)

 

The information set forth below relates to distributions paid during each Fund’s current fiscal year as required by federal laws. Shareholders, however, must report dividends on a calendar year basis for income tax purposes, which may include dividends for portions of two fiscal years of a Fund.

 

Accordingly, the information needed by shareholders for calendar year 2017 income tax purposes will be sent to them in early 2018. Please consult your tax advisor for proper treatment of this information.

 

The following information is provided with respect to the distributions paid during the taxable year ended September 30, 2017:

 

   Biotech
ETF
  Environmental
Services ETF
  Gaming
ETF
  Generic
Drugs ETF
  Pharmaceutical ETF  Retail ETF  Semiconductor
ETF
 
Record Date  12/21/2016  12/21/2016  12/21/2016  12/21/2016  10/05/16 &
12/30/16
  04/05/17 &
07/06/17
  12/21/2016  12/21/2016  
Ex Date  12/19/2016  12/19/2016  12/19/2016  12/19/2016  10/03/16 &
12/28/16
  04/03/17 &
07/03/17
  12/19/2016  12/19/2016  
Payable Date  12/23/2016  12/23/2016  12/23/2016  12/23/2016  10/07/16 &
01/04/17
  04/07/17 &
07/10/17
  12/23/2016  12/23/2016  
Amount Paid Per Share  $0.327000  $0.531000  $1.066000  $0.097000  $0.359700  $0.769100  $1.394000  $0.576000  
                           
Ordinary Income:                          
Qualified Dividend Income for Individuals  100.00% 100.00% 68.42%* 92.80%* 81.88% 75.74% 100.00% 42.14 %
Dividends Qualifying for the Dividends Received                          
Deduction for Corporations  100.00% 100.00% 19.81%* 6.64%* 53.09% 50.16% 100.00% 49.05 %
Foreign Source Income      69.93%* 93.87%*        
Foreign Taxes Paid Per Share      0.014412** 0.010024**        
   
* Expressed as a percentage of the cash distribution grossed up for foreign taxes.
** The foreign taxes paid represent taxes incurred by the Fund on income received by the Fund from foreign sources. Foreign taxes paid may be included in taxable income with an offsetting deduction from gross income or may be taken as a credit for taxes paid to foreign governments. You should consult your tax adviser regarding the appropriate treatment of foreign taxes paid.

 

Please retain this information for your records.

48

VANECK VECTORS ETF TRUST

BOARD OF TRUSTEES AND OFFICERS

September 30, 2017 (unaudited)

 

Name, Address1
and Year of Birth
  Position(s)
Held with
the Trust
  Term of
Office2 and
Length of
Time Served
  Principal Occupation(s)
During Past Five Years
  Portfolios
in Fund
Complex3
Overseen
  Other Directorships Held
By Trustee During Past Five Years
Independent Trustees:            
David H. Chow, 1957*†  Chairman Trustee  Since 2008 Since 2006  Founder and CEO, DanCourt Management LLC (financial/strategy consulting firm and Registered Investment Adviser), March 1999 to present.  59  Director, Forward Management LLC and Audit Committee Chairman, May 2008 to June 2015; Trustee, Berea College of Kentucky and Vice-Chairman of the Investment Committee, May 2009 to present; Member of the Governing Council of the Independent Directors Council, October 2012 to present; President, July 2013 to June 2015, and Board Member of the CFA Society of Stamford, July 2009 to present; Advisory Board member, MainStay Fund Complex4, June 2015 to December 2015; Trustee, MainStay Fund Complex4, January 2016 to present.
R. Alastair Short, 1953*†  Trustee  Since 2006  President, Apex Capital Corporation (personal investment vehicle), January 1988 to present; Vice Chairman, W.P. Stewart & Co., Inc. (asset management firm), September 2007 to September 2008; and Managing Director, The GlenRock Group, LLC (private equity investment firm), May 2004 to September 2007.  71  Chairman and Independent Director, EULAV Asset Management, January 2011 to present; Independent Director, Tremont offshore funds, June 2009 to present; Director, Kenyon Review.
Peter J. Sidebottom, 1962*†  Trustee  Since 2012  Lead Partner, North America Banking and Capital Markets Strategy, Accenture, May 2017 to present; Partner, PWC/Strategy & Financial Services Advisory, February 2015 to March 2017; Founder and Board Member, AspenWoods Risk Solutions, September 2013 to February 2016; Independent consultant, June 2013 to February 2015; Partner, Bain & Company (management consulting firm), April 2012 to December 2013; Executive Vice President and Senior Operating Committee Member, TD Ameritrade (on-line brokerage firm), February 2009 to January 2012.  59  Board Member, Special Olympics, New Jersey, November 2011 to September 2013; Director, The Charlotte Research Institute, December 2000 to 2009; Board Member, Social Capital Institute, University of North Carolina Charlotte, November 2004 to January 2012; Board Member, NJ-CAN, July 2014 to 2016.
Richard D. Stamberger,
1959*†
  Trustee  Since 2006  Director, President and CEO, SmartBrief, Inc. (media company).  71  Director, Food and Friends, Inc., 2013 to present.
Interested Trustee:            
Jan F. van Eck,
19635
  Trustee, President and Chief Executive Officer  Trustee
(Since 2006); President and Chief Executive Officer
(Since 2009)
  Director, President, Chief Executive Officer and Owner of the Adviser, Van Eck Associates Corporation; Director, President and Chief Executive Officer, VESC; Director, President and Chief Executive Officer, VEARA.  59  Director, National Committee on US-China Relations.

 

 

1 The address for each Trustee and Officer is 666 Third Avenue, 9th Floor, New York, New York 10017.
2 Each Trustee serves until resignation, death, retirement or removal. Officers are elected yearly by the Trustees.
3 The Fund Complex consists of the VanEck Funds, VanEck VIP Trust, and the Trust.
4 The MainStay Fund Complex consists of MainStay Funds Trust, MainStay Funds, MainStay VP Funds Trust, Private Advisors Alternative Strategies Master Fund, Private Advisors Alternative Strategies Fund and MainStay DefinedTerm Municipal Opportunities Fund.
5 “Interested person” of the Trust within the meaning of the 1940 Act. Mr. van Eck is an officer of the Adviser.
* Member of the Audit Committee.
Member of the Nominating and Corporate Governance Committee.
49

VANECK VECTORS ETF TRUST

BOARD OF TRUSTEES AND OFFICERS

September 30, 2017 (unaudited) (continued)

 

Officer’s Name,
Address1 and
Year of Birth
  Position(s)
Held with
the Trust
  Term of Office2
and Length of
Time Served
  Principal Occupation(s) During The Past Five Years
Matthew A. Babinsky,
1983
  Assistant Vice President and Assistant Secretary  Since 2016  Assistant Vice President, Assistant General Counsel and Assistant Secretary of the Adviser, VESC and VEARA (since 2016); Associate, Clifford Chance US LLP (October 2011-April 2016); Officer of other investment companies advised by the Adviser.
Russell G. Brennan, 1964  Assistant Vice President and Assistant Treasurer  Since 2008  Assistant Vice President and Assistant Treasurer of the Adviser (since 2008); Manager (Portfolio Administration) of the Adviser, September 2005 to October 2008; Officer of other investment companies advised by the Adviser.
Charles T. Cameron, 1960  Vice President  Since 2006  Director of Trading (since 1995) and Portfolio Manager (since 1997) for the Adviser; Officer of other investment companies advised by the Adviser.
Simon Chen,
1971
  Assistant Vice President  Since 2012  Greater China Director of the Adviser (since January 2012); General Manager, SinoMarkets Ltd. (June 2007-December 2011).
John J. Crimmins, 1957  Vice President, Treasurer, Chief Financial Officer and Principal Accounting Officer  Vice President, Chief Financial Officer and Principal Accounting Officer (Since 2012); Treasurer (Since 2009)  Vice President of Portfolio Administration of the Adviser, June 2009 to present; Vice President of VESC and VEARA, June 2009 to present; Chief Financial, Operating and Compliance Officer, Kern Capital Management LLC, September 1997 to February 2009; Officer of other investment companies advised by the Adviser.
Eduardo Escario, 1975  Vice President  Since 2012  Regional Director, Business Development/Sales for Southern Europe and South America of the Adviser (since July 2008); Regional Director (Spain, Portugal, South America and Africa) of Dow Jones Indexes and STOXX Ltd. (May 2001-July 2008).
Susan C. Lashley, 1955  Vice President  Since 2006  Vice President of the Adviser and VESC; Officer of other investment companies advised by the Adviser.
Laura I. Martínez, 1980  Vice President and Assistant Secretary  Vice President (Since 2016) and Assistant Secretary (Since 2008)  Vice President (since 2016), Associate General Counsel and Assistant Secretary (since 2008) and Assistant Vice President (2008 to 2016) of the Adviser, VESC and VEARA (since 2008); Associate, Davis Polk & Wardwell (October 2005-June 2008); Officer of other investment companies advised by the Adviser.
James Parker,
1969
  Assistant Treasurer  Since June 2014  Manager (Portfolio Administration) of the Adviser (since June 2010); Vice President of JPMorgan Chase & Co. (April 1999-January 2010).
Philipp Schlegel, 1974  Vice President  Since 2016  Senior Director of Van Eck Switzerland AG (since 2010).
Jonathan R. Simon, 1974  Senior Vice President, Secretary and Chief Legal Officer  Senior Vice President (Since 2016) and Secretary and Chief Legal Officer (Since 2014)  Senior Vice President (since 2016), General Counsel and Secretary (since 2014) and Vice President (2006 to 2016) of the Adviser, VESC and VEARA; Officer of other investment companies advised by the Adviser.
Bruce J. Smith,
1955
  Senior Vice President  Since 2006  Senior Vice President, Chief Financial Officer, Treasurer and Controller of the Adviser, VESC and VEARA (since 1997); Director of the Adviser, VESC and VEARA (since October 2010); Officer of other investment companies advised by the Adviser.
Irina Toyberman, 1973  Chief Compliance Officer  Since September 2017  Chief Compliance Officer of the Adviser, VESC and the Adviser (since September 2017); Deputy Chief Compliance Officer and Director of Compliance of the Adviser, VESC and the Adviser (March 2014 to September 2017); Vice President and Compliance Manager of Allianz Global Investors U.S. LLC (July 2006 to March 2014).

 

 

1 The address for each Officer is 666 Third Avenue, 9th Floor, New York, New York 10017.
2 Officers are elected yearly by the Trustees.
50

VANECK VECTORS ETF TRUST

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENTS

September 30, 2017 (unaudited)

 

At a meeting held on June 9, 2017 (the “Renewal Meeting”), the Board of Trustees (the “Board”) of VanEck Vectors® ETF Trust (the “Trust”), including all of the Trustees that are not interested persons of the Trust (the “Independent Trustees”), approved the continuation of the investment management agreements between the Trust and Van Eck Associates Corporation (the “Adviser”) (the “Investment Management Agreements”) with respect to the VanEck Vectors Asia ex Japan Equal Weight ETF, Australia Equal Weight ETF, Australia Hedged Equal Weight ETF, Biotech ETF, Brazil Equal Weight ETF, China Equal Weight ETF, Environmental Services ETF, Europe Equal Weight ETF, Europe Hedged Equal Weight ETF, Gaming ETF, Generic Drugs ETF, Germany Equal Weight ETF, Global Chemicals ETF, Global Spin-Off ETF, Hong Kong Equal Weight ETF, India Equal Weight ETF, Italy Equal Weight ETF, Japan Equal Weight ETF, Japan Hedged Equal Weight ETF, Mexico Equal Weight ETF, Morningstar International Moat ETF, Morningstar Wide Moat ETF, Pharmaceutical ETF, Retail ETF, Russia Equal Weight ETF, Semiconductor ETF, South Africa Equal Weight ETF, South Korea Equal Weight ETF, Spain Equal Weight ETF, Taiwan Equal Weight ETF and United Kingdom Equal Weight ETF (each, a “Fund” and together, the “Funds”).

 

The Board’s approval of the Investment Management Agreements was based on a comprehensive consideration of all of the information available to the Trustees and was not the result of any single factor. Some of the factors that figured particularly in the Trustees’ deliberations and how the Trustees considered those factors are described below, although individual Trustees may have evaluated the information presented differently, giving different weights to various factors.

 

In preparation for the Renewal Meeting, the Trustees held a meeting on May 8, 2017. At that meeting, the Trustees discussed the information the Adviser and Broadridge Financial Solutions, Inc. (“Broadridge”), an independent third party data provider, had provided to them in advance. The information provided to the Trustees included, among other things, information about the performance (for those Funds which had begun operations) and expenses of the Funds and the Funds’ peer funds (other index-based exchange-traded funds (“ETFs”)), information about the advisory services provided to the Funds and the personnel providing those services, and the profitability and other benefits enjoyed by the Adviser and its affiliates as a result of the Adviser’s relationship with the Funds. In reviewing performance information for the Funds against their peer groups, the Trustees considered that each Fund generally invests in a different group of issuers than the funds in its designated peer group. In addition, as noted below, the Trustees reviewed certain performance information for each Fund that was not provided by Broadridge. For these and other reasons, the Trustees noted that the peer group performance information did not necessarily provide meaningful direct comparisons to the Funds.

 

The Independent Trustees’ consideration of the Investment Management Agreements was based, in part, on their review of information obtained through discussions with the Adviser at the Renewal Meeting and with the Adviser at the May 8, 2017 meeting regarding the management of the Funds and information obtained at other meetings of the Trustees and/or based on their review of the materials provided by the Adviser, including the background and experience of the portfolio managers and others involved in the management and administration of the Funds. The Trustees also considered the terms of, and scope of services that the Adviser provides under, the Investment Management Agreements, including, where applicable, the Adviser’s commitment to waive certain fees and/or pay expenses of each of the Funds to the extent necessary to prevent the operating expenses of each of the Funds from exceeding agreed upon limits for a period of time.

 

The Trustees concluded that the Adviser and its personnel have the requisite expertise and skill to manage the Funds’ portfolios. In evaluating the performance over relevant periods of each of the Funds that had commenced operations prior to the date of the Renewal Meeting (the “Operating Funds”), the Trustees reviewed various performance metrics but relied principally on a comparison of the “gross” performance of each Operating Fund (i.e., measured without regard to the impact of fees and expenses) to the performance of its benchmark index, in each case incorporating any systematic fair value adjustments to the underlying securities. Based on the foregoing, the Trustees concluded that the investment performance of the Operating Funds was satisfactory.

 

The Trustees also considered information relating to the financial condition of the Adviser and the current status, as they understood it, of the Adviser’s compliance environment.

 

As noted above, the Trustees were also provided various data from Broadridge comparing the Operating Funds’ expenses and performance to that of other ETFs. The Trustees noted that the information provided showed that each Operating Fund had management fees (after the effect of any applicable fee waiver) below the average and median of its respective peer group of funds, except for VanEck Vectors Morningstar Wide Moat ETF, which had management fees (after the effect of any applicable fee waiver) greater than the average and median of its peer group of funds. The

51

VANECK VECTORS ETF TRUST

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENTS

September 30, 2017 (unaudited) (continued)

 

Trustees also noted that the information provided showed that each Operating Fund had a total expense ratio (after the effect of any applicable expense limitation) below the average and median of its respective peer group of funds, except for each of VanEck Vectors Gaming ETF, Generic Drugs ETF, Morningstar International Moat ETF and Morningstar Wide Moat ETF, which had a total expense ratio (after the effect of any applicable expense limitation) greater than the average and median of its peer group of funds. With respect to these Operating Funds, the Trustees reviewed the amount by which these Operating Funds’ management fees and/or total expense ratios (after the effect of any applicable expense limitation) exceeded the average and median of their respective peer groups and information provided by the Adviser providing context for these comparisons. The Trustees concluded, in light of this information and the other information available to them, that the fees paid by the Operating Funds were reasonable in light of the performance of the Operating Funds and the quality of services received.

 

The Trustees also considered the benefits, other than fees under the Investment Management Agreements, received by the Adviser from serving as adviser to the Funds.

 

The Trustees also considered information provided by the Adviser about the overall profitability of the Adviser and its profitability or loss in respect of each Operating Fund. The Trustees reviewed each Fund’s asset size, expense ratio and expense cap and noted that the Investment Management Agreements do not include breakpoints in the advisory fee rates as asset levels in a Fund increase. The Trustees considered the potential variability in the net assets of these Funds and the sustainability of any potential economies of scale which may exist given where fees are currently set. The Trustees also evaluated the extent to which management fees for the Operating Funds effectively incorporate the benefits of economies of scale. The Trustees noted that the Adviser has capped expenses on each Operating Fund since its inception. Based on the foregoing and the other information available to them, the Trustees determined that the advisory fee rate for each Fund is reasonable and appropriate in relation to the current asset size of each Fund and the other factors discussed above and that the advisory fee rate for each Fund currently reflects an appropriate sharing with shareholders of any economies of scale which may exist. The Trustees also determined that the profits earned by the Adviser in respect of the Funds that were profitable to the Adviser were reasonable in light of the nature and quality of the services received by such Funds.

 

The Trustees did not consider historical information about the cost of the services provided by the Adviser or the profitability to the Adviser of VanEck Vectors Asia ex Japan Equal Weight ETF, Australia Equal Weight ETF, Australia Hedged Equal Weight ETF, Brazil Equal Weight ETF, China Equal Weight ETF, Europe Equal Weight ETF, Europe Hedged Equal Weight ETF, Germany Equal Weight ETF, Global Chemicals ETF, Hong Kong Equal Weight ETF, India Equal Weight ETF, Italy Equal Weight ETF, Japan Equal Weight ETF, Japan Hedged Equal Weight ETF, Mexico Equal Weight ETF, Russia Equal Weight ETF, South Africa Equal Weight ETF, South Korea Equal Weight ETF, Spain Equal Weight ETF, Taiwan Equal Weight ETF and United Kingdom Equal Weight ETF because the Funds had not yet commenced operations at the time of the Renewal Meeting. The Trustees also could not consider the historical performance or the quality of services previously provided to each of these Funds, although they concluded that the nature, quality and extent of the services to be provided by the Adviser were appropriate based on the Trustees’ knowledge of the Adviser and its personnel and the operations of the other series of the Trust.

 

The Independent Trustees were advised by and met in executive session with their independent counsel at the Renewal Meeting and at their May 8, 2017 meeting as part of their consideration of the Investment Management Agreements.

 

In voting to approve the continuation of the Investment Management Agreements, the Trustees, including the Independent Trustees, concluded that the terms of each Investment Management Agreement are reasonable and fair in light of the services to be performed, expenses to be incurred and such other matters as the Trustees considered relevant in the exercise of their reasonable judgment. The Trustees further concluded that each Investment Management Agreement is in the best interest of each Fund and such Fund’s shareholders.

52

 

This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.

 

Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.

 

The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.

 

 

Investment Adviser: Van Eck Associates Corporation  
Distributor: Van Eck Securities Corporation  
  666 Third Avenue, New York, NY 10017  
  vaneck.com  
Account Assistance: 800.826.2333 INDUAR
 
  ANNUAL REPORT
September 30, 2017

 

VANECK VECTORS®

 

Global Spin-Off ETF SPUN®
   
Morningstar International Moat ETF MOTI®
   
Morningstar Wide Moat ETF MOAT®

 

  800.826.2333 vaneck.com

 

 

 

President’s Letter 1
Management Discussion 3
Performance Comparison  
Global Spin-Off ETF 4
Morningstar International Moat ETF 5
Morningstar Wide Moat ETF 6
Explanation of Expenses 8
Schedule of Investments  
Global Spin-Off ETF 9
Morningstar International Moat ETF 12
Morningstar Wide Moat ETF 15
Statements of Assets and Liabilities 18
Statements of Operations 19
Statements of Changes in Net Assets 20
Financial Highlights  
Global Spin-Off ETF 22
Morningstar International Moat ETF 22
Morningstar Wide Moat ETF 23
Notes to Financial Statements 24
Report of Independent Registered Public Accounting Firm 31
Tax Information 32
Board of Trustees and Officers 33
Approval of Investment Management Agreements 35

 

The information contained in the management discussion represents the opinions of VanEck Vectors ETFs and may differ from other persons. This information is not intended to be a forecast of future events, a guarantee of future results or investment advice. The information contained herein regarding each index has been provided by the relevant index provider. Also, unless otherwise specifically noted, any discussion of the Funds’ holdings and the Funds’ performance, and the views of VanEck Vectors ETFs are as of September 30, 2017, and are subject to change.

 

VANECK VECTORS ETFs

September 30, 2017 (unaudited)

 

Dear Shareholder:

 

We are pleased to present this annual report for the three strategic equity exchange-traded funds (ETFs) of the VanEck Vectors® ETF Trust for the 12-month period ended September 30, 2017.

 

Moativated Investing

 

Both VanEck Vectors Morningstar Wide Moat ETF (NYSE Arca: MOAT) and VanEck Vectors Morningstar International Moat ETF (NYSE Arca: MOTI) outperformed broad market indices over the past 12 months by investing in companies identified by Morningstar as having sustainable competitive advantages and trading at attractive valuations. While the S&P 500® Index1 gained 18.61%, MOAT returned 19.96%* and MOTI 26.91%,* both based on net asset value. MOTI also comfortably outperformed the MSCI All Country World Index ex-USA (MSCI ACWI ex-USA)2—up 19.61% over the 12-month period.

 

MOTI—An Impressive Story

 

MOTI’s story has been an impressive one. Building on both the success and popularity of MOAT and its approach to investing in the U.S., we launched MOTI in 2015 in order to expand investor access to Morningstar’s top equity research ideas in the international arena. While MOTI’s performance these last 12 months alone has been notable, its returns since inception have been equally inspiring. Ranked in the 4th percentile (13th of 316 funds) this last year among its Morningstar peer group (US Fund Foreign Large Value), for the period since inception MOTI is ranked in the 6th percentile (22nd of 324 funds).3

 

Growth of $100 Since MOTI’s Inception

 

July 13, 2015 – September 30, 2017

 

 

Source: Morningstar, FactSet. Not intended to be a forecast of future events, a guarantee of future results or investment advice. This graph illustrates a hypothetical $100 investment in MOTI invested at net asset value (NAV). Returns reflect capital appreciation and the reinvestment of dividends and capital gains, if any, as well as all fees and expenses. The category average is calculated using a weighted average of the NAV return of the share classes of the funds within the category and reflects the reinvestment of all dividends and fees and expenses applicable to the funds in the category, but does not reflect the payment of transaction costs that are associated with an investment in the funds. A category average’s performance is not illustrative of an investment in all of the funds in that category. Category averages are not securities in which investments can be made. Results reflect past performance and do not guarantee future results.

 

But MOTI’s story has not just been one of performance, it has also been one of investor popularity. Having started the 12-month period with $12.8 million in assets under management, this figure had risen more than six-fold to $81.6 million by its fiscal year end. We have high hopes for the fund going forward.

1

VANECK VECTORS ETFs

(unaudited)

 

Access investment and market insights from VanEck’s investment professionals by subscribing to our blogs. To subscribe to the Moat Investing updates, please contact us at 800.826.2333 or visit vaneck.com/subscription to register.

 

Thank you for participating in the VanEck Vectors ETF Trust. On the following pages, you will find the performance record of each of the funds for the 12-month period ending September 30, 2017. You will also find their financial statements. We value your continuing confidence in us and look forward to helping you meet your investment goals in the future.

 

 

Jan F. van Eck
Trustee and President
VanEck Vectors ETF Trust

 

October 23, 2017

 

Represents the opinions of the investment adviser. Past performance is no guarantee of future results. Not intended to be a forecast of future events, a guarantee of future results or investment advice. Current market conditions may not continue.

 

All indices are unmanaged and include the reinvestment of all dividends, but do not reflect the payment of transaction costs, advisory fees or expenses that are associated with an investment in a fund. An index’s performance is not illustrative of a fund’s performance. Indices are not securities in which investments can be made. Results reflect past performance and do not guarantee future results.

 

* Returns are based on net asset value. All Fund assets referenced are Total Net Assets as of September 30, 2017.
   
1 S&P 500® Index consists of 500 widely held common stocks covering the leading industries in the U.S. economy.
   
2 The MSCI ACWI ex USA Index (MSCI ACWI ex-USA) captures large- and mid-cap representation across 22 of 23 Developed Markets countries (excluding the U.S.) and 24 Emerging Markets countries. The index covers approximately 85% of the global equity opportunity set outside the U.S.
   
3 As of September 30, 2017. US Fund Foreign Large Value Category: foreign large-value portfolios invest mainly in big international stocks that are less expensive or growing more slowly than other large-cap stocks. Most of these portfolios divide their assets among a dozen or more developed markets, including Japan, Britain, France, and Germany. These portfolios primarily invest in stocks that have market caps in the top 70% of each economically integrated market (such as Europe or Asia ex-Japan). Value is defined based on low valuations (low price ratios and high dividend yields) and slow growth (low growth rates for earnings, sales, book value, and cash flow). These portfolios typically will have less than 20% of assets invested in U.S. stocks.
2

 

 

Management Discussion (unaudited)

 

All three VanEck Vectors Strategic Equity ETFs posted notable positive returns for the 12-month period under review.

 

 

Source: VanEck. Returns based on each fund’s net asset value (NAV). The performance data quoted represent past performance. Past performance is not a guarantee of future results. Performance information for the Funds reflects temporary waivers of expenses and/or fees. Had the Funds incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Funds will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than performance data quoted.

 

Global Spin-Off

 

VanEck Vectors Global Spin-Off ETF (NYSE Arca: SPUN) returned 14.37%. During this 12-month period, U.S. companies were by far the largest contributors to the Fund’s total returns. The three sectors contributing the most to performance were materials, information technology, and consumer discretionary. The energy and telecommunication services sectors were the only negative contributors to the Fund’s performance. New Zealand and the Cayman Islands were the largest detractors from performance.

 

Morningstar International Moat

 

For the 12-month period, VanEck Vectors Morningstar International Moat ETF (NYSE Arca: MOTI) returned 26.91%. The primary driver of the Fund’s performance was the financials sector. Companies in the industrials, healthcare, consumer discretionary, and information technology sectors also contributed solid positive performance. Only one sector detracted from performance: energy.

 

Morningstar Wide Moat

 

VanEck Vectors Morningstar Wide Moat ETF (NYSE Arca: MOAT) returned 19.96% for the 12-month period. The primary drivers of performance were the Fund’s exposures to the consumer discretionary and financials sectors. In addition, stocks in the information technology, industrials, and healthcare sectors contributed solid positive returns. The materials sector contributed the least to the Fund’s performance.

3

VANECK VECTORS GLOBAL SPIN-OFF ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns  Cumulative Total Returns
   Share Price  NAV  GSPIN1  Share Price  NAV  GSPIN1
One Year   15.43%     14.37%     14.86%     15.43%     14.37%     14.86%  
Life*   8.75%   8.60%   9.12%   21.39%   20.98%   22.34%
   
* Commencement of Fund: 6/9/15; First Day of Secondary Market Trading: 6/10/15.
   
1 Horizon Kinetics Global Spin-Off Index (GSPIN) is a rules-based, equal-weighted index intended to track the performance of listed, publicly-held spin-offs that are domiciled and trade in the U.S. or developed markets of Western Europe and Asia.

 

    Hypothetical Growth of $10,000 (Since Inception)

This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.

 

 

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 7 for more information.

4

VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF

PERFORMANCE COMPARISON

September 30, 2017 (unaudited)

 

   Average Annual Total Returns    Cumulative Total Returns
   Share Price  NAV  MGEUMFUN1  Share Price  NAV  MGEUMFUN1
One Year   27.37%     26.91%     27.84%     27.37%     26.91%     27.84%  
Life*   8.90%   8.66%   9.45%   20.80%   20.21%   22.15%
   
* Commencement of Fund: 7/13/15; First Day of Secondary Market Trading: 7/14/15.
   
1 Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN) is a rules-based, equal-weighted index intended to offer exposure to companies that Morningstar, Inc. determines have sustainable competitive advantages based on a proprietary methodology that considers quantitative and qualitative factors (“wide and narrow moat companies”).

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 7 for more information.

5

VANECK VECTORS MORNINGSTAR WIDE MOAT ETF

PERFORMANCE COMPARISON

 September 30, 2017 (unaudited)

 

   Average Annual Total Returns    Cumulative Total Returns
   Share Price  NAV  MWMFTR1  Share Price  NAV  MWMFTR1
One Year   19.82%     19.96%     20.54%     19.82%     19.96%     20.54%  
Five Year   14.69%   14.73%   15.31%   98.45%   98.77%   103.85%
Life*   14.88%   14.87%   15.45%   112.53%   112.48%   118.36%
   
* Commencement of Fund: 4/24/12; First Day of Secondary Market Trading: 4/25/12.
   
1 Morningstar® Wide Moat Focus IndexSM (MWMFTR) is a rules-based, equal-weighted index intended to offer exposure to companies that Morningstar, Inc. determines have sustainable competitive advantages based on a proprietary methodology that considers quantitative and qualitative factors (“wide moat companies”).

 

    Hypothetical Growth of $10,000 (Since Inception)
This chart shows the value of a hypothetical $10,000 investment in the Fund at NAV and at Share Price over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The result is compared with the Fund’s benchmark.  

 

Past performance is no guarantee of future results. Performance results do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption or sale of fund shares.

 

See “About Fund Performance” on page 7 for more information.

6

VANECK VECTORS ETF TRUST

ABOUT FUND PERFORMANCE

(unaudited)

 

The price used to calculate market return (Share Price) is determined by using the closing price listed on its primary listing exchange. Since the shares of each Fund did not trade in the secondary market until after each Fund’s commencement, for the period from commencement to the first day of secondary market trading in shares of each Fund, the NAV of each Fund is used as a proxy for the secondary market trading price to calculate market returns.

 

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Performance information for each Fund reflects temporary waivers of expenses and/or fees. Had each Fund incurred all expenses, investment returns would have been reduced. These returns do not reflect the deduction of taxes that a shareholder would pay on Fund dividends and distributions or the sale of Fund shares.

 

Investment return and value of the shares of each Fund will fluctuate so that an investor’s shares, when sold, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Fund returns reflect reinvestment of dividends and capital gains distributions. Performance current to the most recent month-end is available by calling 800.826.2333 or by visiting vaneck.com.

 

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called “creation units” and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market.

 

The net asset value (NAV) of each VanEck Vectors exchange-traded fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of each fund; it is calculated by taking the total assets of each fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAVs are not necessarily the same as each ETF’s intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell fund shares at NAV.

 

Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Certain indices may take into account withholding taxes. Investors cannot invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

 

The Horizon Kinetics Global Spin-Off Index is published by Horizon Kinetics, LLC (Horizon Kinetics). The Morningstar® Global ex-US Moat Focus IndexSM and Morningstar® Wide Moat Focus IndexSM are published by Morningstar. The Morningstar name and logo are registered trademarks of Morningstar. Morningstar Global ex-US Moat Focus IndexSM and Morningstar Wide Moat Focus IndexSM are service marks of Morningstar.

 

Horizon Kinetics and Morningstar are referred to herein as the “Index Providers”. The Index Providers do not sponsor, endorse, or promote the Funds and bear no liability with respect to the Funds or any security.

 

Premium/discount information regarding how often the closing trading price of the Shares of each Fund were above (i.e., at a premium) or below (i.e., at a discount) the NAV of the Fund for each of the four previous calendar quarters and the immediately preceding five years (if applicable) can be found at www.vaneck.com.

7

VANECK VECTORS ETF TRUST

EXPLANATION OF EXPENSES

(unaudited)

 

Hypothetical $1,000 investment at beginning of period

As a shareholder of a Fund, you incur operating expenses, including management fees and other Fund expenses. This disclosure is intended to help you understand the ongoing costs (in dollars) of investing in your Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

 

The disclosure is based on an investment of $1,000 invested at the beginning of the period and held for the entire period, April 1, 2017 to September 30, 2017.

 

Actual Expenses

The first line in the table below provides information about account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled “Expenses Paid During the Period.”

 

Hypothetical Example for Comparison Purposes

The second line in the table below provides information about hypothetical account values and hypothetical expenses based on your Fund’s actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund’s actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in your Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

 

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as program fees. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

 

   Beginning  Ending  Annualized  Expenses Paid
   Account  Account  Expense  During the Period*
   Value  Value  Ratio  April 1, 2017-
   April 1, 2017  September 30, 2017  During Period  September 30, 2017
Global Spin-Off ETF                    
Actual  $1,000.00   $1,059.70    0.55%     $2.84   
Hypothetical**  $1,000.00   $1,022.31    0.55%  $2.79 
Morningstar International Moat ETF                    
Actual  $1,000.00   $1,145.20    0.57%  $3.07 
Hypothetical**  $1,000.00   $1,022.21    0.57%  $2.89 
Morningstar Wide Moat ETF                    
Actual  $1,000.00   $1,074.30    0.48%  $2.50 
Hypothetical**  $1,000.00   $1,022.66    0.48%  $2.43 

 

* Expenses are equal to the Fund’s annualized expense ratio (for the six months ended September 30, 2017) multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year divided by the number of days in the fiscal year (to reflect the one-half year period).
** Assumes annual return of 5% before expenses.

 

See Notes to Financial Statements

8

VANECK VECTORS GLOBAL SPIN-OFF ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value 
  
COMMON STOCKS: 84.5%
Australia: 2.1%
 24,768   Orora Ltd. #  $60,446 
 24,612   South32 Ltd. #   63,692 
         124,138 
Cayman Islands: 1.1%
 1,846   Theravance Biopharma, Inc. (USD) * †   63,207 
China / Hong Kong: 3.3%
 260,000   China Overseas Property Holdings Ltd. #   62,402 
 7,500   CK Asset Holdings Ltd. #   62,357 
 680,000   Global Brands Group Holding Ltd. * #   65,642 
         190,401 
Finland: 2.1%
 6,644   Caverion Corp. * † #   61,008 
 3,129   Valmet OYJ #   61,535 
         122,543 
France: 1.1%
 657   Fnac Darty SA * #   63,296 
Germany: 2.1%
 2,999   METRO AG *   63,410 
 744   OSRAM Licht AG #   59,438 
         122,848 
Ireland: 2.1%
 741   Allegion Plc (USD)   64,074 
 951   Prothena Corp. Plc (USD) * †   61,596 
         125,670 
Italy: 1.1%
 11,064   Italgas SpA #   62,162 
Norway: 1.1%
 11,771   Aker Solutions ASA * # Reg S   62,558 
Singapore: 1.1%
 40,700   Frasers Centrepoint Ltd. #   62,699 
Sweden: 2.1%
 3,785   Bonava AB #   61,175 
 7,444   Svenska Cellulosa AB #   62,965 
         124,140 
Switzerland: 1.0%
 3,404   Idorsia Ltd. * #   60,880 
United Kingdom: 2.4%
 44,231   Gocompare.Com Group Plc   62,013 
 14,412   Indivior Plc * #   65,726 
 478   Micro Focus International Plc (ADR) *   15,248 
         142,987 
United States: 61.8%
 707   AbbVie, Inc.   62,824 
 752   Adient Plc   63,160 
 1,621   AdvanSix, Inc. *   64,435 
 1,337   Alcoa Corp.   62,331 
 1,792   Associated Capital Group, Inc. †   63,974 
 1,104   Bioverativ, Inc. *   63,005 
 1,072   Brighthouse Financial, Inc. *   65,178 
 87   Cable One, Inc.   62,824 
 2,420   Cars.com Inc. * †   64,396 
 993   CDK Global, Inc.   62,648 
 1,190   Chemours Co.   60,226 
 2,640   CommerceHub, Inc. *   59,585 
Number
of Shares
      Value 
  
United States: (continued)
 3,976   Conduent, Inc. *  $62,304 
 1,927   CSRA, Inc.   62,184 
 1,418   CSW Industrials, Inc. *   62,888 
 3,016   Donnelley Financial Solutions, Inc. *   65,025 
 1,376   Energizer Holdings, Inc.   63,365 
 2,070   Exterran Corp. *   65,433 
 884   Fortive Corp.   62,578 
 7,777   Gannett Co., Inc. †   69,993 
 1,972   GCP Applied Technologies, Inc. *   60,540 
 1,350   Halyard Health, Inc. *   60,791 
 1,330   Herc Holdings, Inc. * †   65,343 
 4,484   Hewlett Packard Enterprise Co.   65,960 
 1,628   Hilton Grand Vacations, Inc. *   62,890 
 847   Hyster-Yale Materials Handling, Inc.   64,745 
 1,001   Ingevity Corp. *   62,532 
 3,209   International Seaways, Inc. *   63,217 
 1,523   Keysight Technologies, Inc. *   63,448 
 2,987   Kimball Electronics, Inc. *   64,669 
 1,190   KLX, Inc. *   62,987 
 4,018   Knowles Corp. *   61,355 
 1,348   Lamb Weston Holdings, Inc.   63,208 
 657   Liberty Broadband Corp. *   61,876 
 3,817   LSC Communications, Inc.   63,019 
 1,123   Lumentum Holdings, Inc. * †   61,035 
 290   Madison Square Garden Co. *   62,089 
 1,774   Mallinckrodt Plc *   66,294 
 917   Murphy USA, Inc. *   63,273 
 4,407   Navient Corp.   66,193 
 4,401   New Media Investment Group, Inc. †   65,091 
 4,727   News Corp.   62,680 
 4,764   NOW, Inc. *   65,791 
 831   ONE Gas, Inc.   61,195 
 957   PayPal Holdings, Inc. *   61,277 
 2,967   Pinnacle Entertainment, Inc. *   63,227 
 1,651   PJT Partners, Inc. †   63,250 
 4,573   Rayonier Advanced Materials, Inc. †   62,650 
 949   Science Applications International Corp.   63,441 
 1,643   SPX FLOW, Inc. *   63,354 
 4,927   Time, Inc.   66,514 
 4,020   TimkenSteel Corp. * †   66,330 
 1,008   TopBuild Corp. *   65,691 
 1,873   Varex Imaging Corp. *   63,382 
 1,651   Versum Materials, Inc.   64,092 
 2,712   Vista Outdoor, Inc. * †   62,213 
 2,748   Welbilt, Inc. *   63,341 
         3,617,339 
Total Common Stocks
(Cost: $4,147,072)
   4,944,868 
REAL ESTATE INVESTMENT TRUSTS: 15.9%
United States: 15.9%
 5,636   Altisource Residential Corp. †   62,616 
 3,249   CareTrust REIT, Inc.   61,861 
 4,793   Colony NorthStar, Inc.   60,200 
 2,442   Four Corners Property Trust, Inc.   60,855 
 1,673   Gaming and Leisure Properties, Inc.   61,717 
 3,685   New Residential Investment Corp.   61,650 
 6,817   New Senior Investment Group, Inc.   62,376 
 4,888   NorthStar Realty Europe Corp.   62,615 


 

See Notes to Financial Statements

9

VANECK VECTORS GLOBAL SPIN-OFF ETF

SCHEDULE OF INVESTMENTS

(continued)

 

Number
of Shares
      Value 
         
United States: (continued)
 2,267   Park Hotels and Resorts, Inc.  $62,479 
 4,206   Quality Care Properties, Inc. *   65,193 
 1,707   Starwood Waypoint Homes   62,084 
 3,862   Uniti Group, Inc. †   56,617 
 2,587   Urban Edge Properties   62,398 
 7,700   Washington Prime Group, Inc.   64,141 
 3,001   Xenia Hotels and Resorts, Inc.   63,171 
Total Real Estate Investment Trusts
(Cost: $878,418)
   929,973 
MONEY MARKET FUND: 0.1%
(Cost: $8,526)
     
 8,526   Dreyfus Government Cash Management Fund - Institutional Shares   8,526 
Total Investments Before Collateral for Securities
Loaned: 100.5%

(Cost: $5,034,016)
   5,883,367 
Principal
Amount
       Value 
          
SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES LOANED: 10.1%
(Cost: $592,883)
    
Repurchase Agreement: 10.1%
$ 592,883    Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $592,936; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $604,741 including accrued interest)  $592,883 
Total Investments: 110.6%
(Cost: $5,626,899)
   6,476,250  
Liabilities in excess of other assets: (10.6)%   (622,447 )
NET ASSETS: 100.0% $ 5,853,803  


 

 

Definitions:

ADR American Depositary Receipt
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $512,167.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $997,981 which represents 17.0% of net assets.
Reg S Security was purchased pursuant to Regulation S under the Securities Act of 1933, which exempts from registration securities offered and sold outside of the United States. Such a security cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value 
Consumer Discretionary   17.4%  $1,021,634 
Consumer Staples   3.2    189,983 
Energy   3.3    191,208 
Financials   6.6    385,270 
Health Care   9.7    567,705 
Industrials   15.0    884,497 
Information Technology   14.1    829,259 
Materials   10.6    626,147 
Real Estate   17.9    1,055,781 
Utilities   2.1    123,357 
Money Market Fund   0.1    8,526 
           100.0%        $5,883,367 

 

See Notes to Financial Statements

10

 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
     Level 3
Significant
Unobservable
Inputs
  Value  
Common Stocks                      
Australia  $   $124,138     $   $124,138 
Cayman Islands   63,207              63,207 
China / Hong Kong       190,401          190,401 
Finland       122,543          122,543 
France       63,296          63,296 
Germany   63,410    59,438          122,848 
Ireland   125,670              125,670 
Italy       62,162          62,162 
Norway       62,558          62,558 
Singapore       62,699          62,699 
Sweden       124,140          124,140 
Switzerland       60,880          60,880 
United Kingdom   77,261    65,726          142,987 
United States   3,617,339              3,617,339 
Real Estate Investment Trusts*   929,973              929,973 
Money Market Fund   8,526              8,526 
Repurchase Agreement       592,883          592,883 
Total  $4,885,386   $1,590,864     $   $6,476,250 

 

* See Schedule of Investments for geographic sector breakouts.

 

During the year ended September 30, 2017, transfers of securities from Level 1 to Level 2 were $38,620. These transfers resulted primarily from changes in certain foreign securities valuation methodologies between the last close of the securities’ primary market (Level 1) and valuation by a pricing service (Level 2), which takes into account market direction or events occurring before the Fund’s pricing time but after the last local close, as described in the Notes to Financial Statements.

 

See Notes to Financial Statements

11

VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number      
of Shares     Value
       
COMMON STOCKS: 96.8%   
Australia: 12.2%
 202,073   AMP Ltd. #  $767,571 
 41,780   Ansell Ltd. #   732,377 
 26,233   Commonwealth Bank of Australia #   1,553,836 
 166,274   Crown Ltd. #   1,478,950 
 7,241   CSL Ltd. #   762,526 
 42,053   Magellan Financial Group Ltd. #   812,762 
 178,142   QBE Insurance Group Ltd. #   1,404,842 
 46,960   Sonic Healthcare Ltd. #   771,932 
 66,207   Westpac Banking Corp. #   1,665,870 
         9,950,666 
Belgium: 2.1%
 20,061   KBC Group NV #   1,702,405 
Brazil: 0.9%
 137,300   Embraer SA   776,535 
Canada: 6.2%
 9,439   Canadian Imperial Bank of Commerce   823,936 
 5,096   Canadian Pacific Railway Ltd.   853,972 
 79,977   Comeco Corp. †   770,578 
 19,714   Enbridge, Inc.   821,568 
 18,776   National Bank of Canada   901,530 
 45,276   Potash Corp. of Saskatchewan, Inc.   869,571 
         5,041,155 
China / Hong Kong: 16.0%
 1,565,000   Bank of China Ltd. #   777,461 
 482,000   China Resources Gas Group Ltd. #   1,682,699 
 1,614,000   China Telecom Corp. Ltd. #   830,480 
 193,500   CK Asset Holdings Ltd. #   1,608,815 
 260,000   ENN Energy Holdings Ltd. #   1,883,821 
 2,268,000   Industrial & Commercial Bank of China Ltd. #   1,695,547 
 387,863   MGM China Holdings Ltd. † #   930,962 
 16,201   SINA Corp. (USD) *   1,857,445 
 51,000   Sun Hung Kai Properties Ltd. #   830,898 
 22,000   Tencent Holdings Ltd. #   961,966 
         13,060,094 
France: 8.1%
 9,432   Airbus SE #   898,108 
 33,459   Bureau Veritas SA #   863,708 
 10,105   Danone SA #   793,886 
 95,463   Orange SA #   1,563,502 
 8,626   Safran SA #   881,707 
 16,235   Sanofi #   1,616,550 
         6,617,461 
Germany: 8.4%
 6,195   Bayer AG #   846,472 
 16,378   Bayerische Motoren Werke AG #   1,662,693 
 16,336   HeidelbergCement AG #   1,681,557 
 10,221   KION Group AG #   979,371 
 5,979   Siemens AG #   843,907 
 10,646   Symrise AG #   809,568 
         6,823,568 
India: 1.9%
 110,428   Tata Motors Ltd. * #   680,557 
 195,259   Wipro Ltd. #   838,382 
         1,518,939 
Number      
of Shares     Value
       
Italy: 2.0%
 14,002   Luxottica Group SpA #  $783,744 
 867,997   Telecom Italia SpA * #   814,419 
         1,598,163 
Japan: 9.0%
 8,800   East Japan Railway Co. #   812,025 
 4,200   FANUC Corp. #   851,263 
 9,200   Hoshizaki Corp. #   807,871 
 13,000   Kao Corp. #   765,082 
 5,400   Murata Manufacturing Co. Ltd. #   794,696 
 14,800   Nidec Corp. #   1,818,731 
 15,600   Nippon Telegraph and Telephone Corp. #   714,549 
 10,100   SoftBank Group Corp. #   818,782 
         7,382,999 
Luxembourg: 1.0%
 12,534   Millicom International Cellular SA (SEK) #   826,217 
Mexico: 4.9%
 1,854,200   America Movil, SAB de CV   1,650,061 
 1,718,444   Cemex SAB de CV *   1,566,158 
 136,700   Grupo Aeroportuario del Centro Norte SAB de CV   759,484 
         3,975,703 
Netherlands: 2.1%
 42,279   Koninklijke Philips NV #   1,744,872 
Russia: 1.1%
 181,552   Mobile TeleSystems PJSC #   889,517 
Singapore: 5.0%
 303,100   CapitaLand Ltd. #   801,081 
 105,900   DBS Group Holdings Ltd. #   1,628,431 
 200,701   Oversea-Chinese Banking Corp. Ltd. #   1,653,205 
         4,082,717 
Spain: 3.9%
 33,165   Gas Natural SDG SA † #   734,875 
 21,588   Industria de Diseno Textil SA #   814,079 
 147,869   Telefonica SA #   1,607,309 
         3,156,263 
Sweden: 3.0%
 158,198   Elekta AB † #   1,634,131 
 61,003   Nordea Bank AB #   826,481 
         2,460,612 
Switzerland: 4.0%
 14,413   Julius Baer Group Ltd. * #   855,932 
 9,606   Novartis AG #   824,593 
 6,110   Roche Holding AG #   1,563,050 
         3,243,575 
United Kingdom: 4.0%
 35,883   GlaxoSmithKline PCL #   718,207 
 975,775   Lloyds Banking Group Plc #   887,834 
 242,125   Meggitt Plc #   1,693,257 
         3,299,298 
United States: 1.0%
 198,300   Samsonite International SA (HKD) #   852,945 
Total Common Stocks
(Cost: $72,827,815)
   79,003,704 


 

See Notes to Financial Statements

12

 

 

Number
of Shares
     Value
       
PREFERRED STOCKS: 1.1%
Brazil: 1.1%
(Cost: $777,719)
 55,350   Telefonica Brasil SA, 4.59%  $883,143 
REAL ESTATE INVESTMENT TRUSTS: 1.9%
Singapore: 1.9%
 567,700   CapitaLand Commercial Trust Ltd. #   693,432 
 557,700   CapitaLand Mall Trust #   822,163 
Total Real Estate Investment Trusts
(Cost: $1,412,102)
 1,515,595 
RIGHTS: 0.0%
(Cost: $0)
Singapore: 0.0%
 94,238   CapitaLand Commercial Trust Ltd. Rights (SGD 1.36, expiring 10/19/17) * #   20,264 
MONEY MARKET FUND: 0.0%
(Cost: $4,531)
     
 4,531   Dreyfus Government Cash Management Fund - Institutional Shares   4,531 
Total Investments Before Collateral for Securities
Loaned: 99.8%

(Cost: $75,022,167)
   81,427,237 
Principal      
Amount     Value
       
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 3.0%        
Repurchase Agreements: 3.0%
$1,000,000   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc. , 1.08%, due 10/2/17, proceeds $1,000,090; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $1,020,000 including accrued interest)  $1,000,000 
 1,000,000   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $1,000,089; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $1,020,000 including accrued interest)   1,000,000 
 487,929   Repurchase agreement dated 9/29/17 with HSBC Securities USA, Inc., 1.05%, due 10/2/17, proceeds $487,972; (collateralized by various U.S. government and agency obligations, 2.50% to 6.50%, due 5/1/22 to 8/1/47, valued at $497,690 including accrued interest)   487,929 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $2,487,929)
   2,487,929 
Total Investments: 102.8%
(Cost: $77,510,096)
   83,915,166 
Liabilities in excess of other assets: (2.8)%    (2,284,155)
NET ASSETS: 100.0%  $81,631,011 


 

 

Definitions:

HKD Hong Kong Dollar
SEK Swedish Krona
SGD Singapore Dollar
USD United States Dollar

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $2,351,868.
# Indicates a fair valued security which has been valued in good faith pursuant to guidelines established by the Board of Trustees. The aggregate value of fair valued securities is $68,888,725 which represents 84.4% of net assets.

 

See Notes to Financial Statements

13

VANECK VECTORS MORNINGSTAR INTERNATIONAL MOAT ETF

SCHEDULE OF INVESTMENTS

(continued)

 

       
Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value  
Consumer Discretionary   8.8%  $7,203,930 
Consumer Staples   1.9    1,558,968 
Energy   2.0    1,592,146 
Financials   22.0    17,957,643 
Health Care   13.8    11,214,710 
Industrials   15.8    12,839,939 
Information Technology   5.5    4,452,489 
Materials   6.0    4,926,854 
Real Estate   5.9    4,776,653 
Telecommunication Services   13.0    10,597,979 
Utilities   5.3    4,301,395 
Money Market Fund   0.0    4,531 
           100.0%        $81,427,237 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
    Level 2
Significant
Observable
Inputs
    Level 3
Significant
Unobservable
Inputs
  Value  
Common Stocks                      
Australia  $   $9,950,666     $   $9,950,666 
Belgium       1,702,405          1,702,405 
Brazil   776,535              776,535 
Canada   5,041,155              5,041,155 
China / Hong Kong   1,857,445    11,202,649          13,060,094 
France       6,617,461          6,617,461 
Germany       6,823,568          6,823,568 
India       1,518,939          1,518,939 
Italy       1,598,163          1,598,163 
Japan       7,382,999          7,382,999 
Luxembourg       826,217          826,217 
Mexico   3,975,703              3,975,703 
Netherlands       1,744,872          1,744,872 
Russia       889,517          889,517 
Singapore       4,082,717          4,082,717 
Spain       3,156,263          3,156,263 
Sweden       2,460,612          2,460,612 
Switzerland       3,243,575          3,243,575 
United Kingdom       3,299,298          3,299,298 
United States       852,945          852,945 
Preferred Stocks *   883,143              883,143 
Real Estate Investment Trusts *       1,515,595          1,515,595 
Rights *       20,264          20,264 
Money Market Fund   4,531              4,531 
Repurchase Agreements       2,487,929          2,487,929 
Total  $12,538,512   $71,376,654     $   $83,915,166 

 

* See Schedule of Investments for geographic sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

14

VANECK VECTORS MORNINGSTAR WIDE MOAT ETF

SCHEDULE OF INVESTMENTS

September 30, 2017

 

Number
of Shares
      Value  
          
COMMON STOCKS: 100.1%
Banks: 2.6%
 611,931   Wells Fargo & Co.    $33,747,995 
Capital Goods: 9.7%
 519,109   Emerson Electric Co.     32,620,810  
 1,177,617   General Electric Co.     28,474,779  
 122,528   TransDigm Group, Inc. †     31,324,283  
 277,557   United Technologies Corp.     32,218,817  
           124,638,689  
Commercial & Professional Services: 2.4%
 425,664   Stericycle, Inc. *     30,486,056  
Consumer Durables & Apparel: 5.4%
 335,064   Polaris Industries, Inc. †     35,057,746  
 532,485   VF Corp.     33,850,071  
           68,907,817  
Consumer Services: 2.3%
 558,242   Starbucks Corp.     29,983,178  
Diversified Financials: 8.2%
 192,990   American Express Co.     17,457,875  
 310,483   Bank of New York Mellon Corp.     16,461,809  
 92,217   Berkshire Hathaway, Inc. *     16,905,220  
 37,478   BlackRock, Inc.     16,756,039  
 409,561   Charles Schwab Corp.     17,914,198  
 214,100   T Rowe Price Group Inc.     19,408,165  
           104,903,306  
Food & Staples Retailing: 2.5%
 400,055   CVS Caremark Corp.     32,532,473  
Food, Beverage & Tobacco: 2.3%
 741,556   Mondelez International, Inc.     30,151,667  
Health Care Equipment & Services: 16.5%
 364,802   AmerisourceBergen Corp.     30,187,366  
 232,389   Cardinal Health, Inc.     15,551,472  
 499,442   Express Scripts Holding Co. *     31,624,667  
 200,165   McKesson Corp.     30,747,346  
 377,809   Medtronic Plc     29,382,206  
 734,704   Patterson Cos, Inc.     28,396,310  
 273,767   Veeva Systems, Inc. *     15,443,196  
 260,904   Zimmer Biomet Holdings, Inc.     30,549,249  
           211,881,812  
Materials: 4.9%
 474,328   Compass Minerals International, Inc. †      30,783,887  
 268,068   Monsanto Co.     32,119,908  
           62,903,795  
Media: 6.0%
 297,123   John Wiley & Sons, Inc.     15,896,081  
 1,177,847   Twenty-First Century Fox, Inc.     31,071,604  
 305,862   Walt Disney Co.     30,148,817  
           77,116,502  
Pharmaceuticals, Biotechnology: 18.3%
 137,938   Allergan Plc     28,270,393  
 185,041   Amgen, Inc.     34,500,894  
 112,236   Biogen Idec, Inc. *     35,143,336  
 553,955   Bristol-Myers Squibb Co.     35,309,092  
 387,895   Eli Lilly & Co.     33,180,538  
 243,418   Gilead Sciences, Inc.     19,721,726  
 249,127   Merck and Co., Inc.     15,951,602  
 942,730   Pfizer, Inc.     33,655,461  
           235,733,042  
Number
of Shares
       Value  
           
Real Estate: 1.3%    
 446,193   CBRE Group, Inc. *    $16,901,791 
Retailing: 7.2%
 32,304   Amazon.com, Inc. *     31,055,450 
 724,561   L Brands, Inc. †     30,148,983 
 397,755   Lowe’s Cos, Inc.     31,796,535 
           93,000,968 
Software & Services: 9.2%    
 239,695   Guidewire Software, Inc. *     18,662,653 
 216,846   Microsoft Corp.     16,152,859 
 349,422   Salesforce.com, Inc. *     32,643,003 
 861,382   The Western Union Co.     16,538,534 
 320,759   Visa, Inc.     33,756,677 
           117,753,726 
Transportation: 1.3%    
 221,187   CH Robinson Worldwide, Inc. †     16,832,331 
Total Common Stocks
(Cost: $1,219,701,658)
     1,287,475,148 
              
Principal           
Amount           
            
SHORT-TERM INVESTMENTS HELD AS COLLATERAL FOR SECURITIES LOANED: 8.4%          
Repurchase Agreements: 8.4%
$25,730,494   Repurchase agreement dated 9/29/17 with Citigroup Global Markets, Inc., 1.08%, due 10/2/17, proceeds $25,732,810; (collateralized by various U.S. government and agency obligations, 1.90% to 9.00%, due 12/1/17 to 6/1/51, valued at $26,245,103 including accrued interest)     25,730,494 
 5,414,237   Repurchase agreement dated 9/29/17 with Credit Agricole CIB, 1.04%, due 10/2/17, proceeds $5,414,706; (collateralized by U.S. government obligations, 2.13%, due 2/29/24, valued at $5,522,522 including accrued interest)     5,414,237 
 25,730,494   Repurchase agreement dated 9/29/17 with Daiwa Capital Markets America, Inc., 1.07%, due 10/2/17, proceeds $25,732,788; (collateralized by various U.S. government and agency obligations, 0.00% to 6.50%, due 10/12/17 to 12/1/51, valued at $26,245,104 including accrued interest)     25,730,494 
 25,730,494   Repurchase agreement dated 9/29/17 with Merrill Lynch, Pierce, Fenner & Smith, Inc., 1.07%, due 10/2/17, proceeds $25,732,788; (collateralized by various U.S. government and agency obligations, 1.83% to 4.50%, due 1/1/26 to 7/15/52, valued at $26,245,104 including accrued interest)     25,730,494 


 

See Notes to Financial Statements

15

VANECK VECTORS MORNINGSTAR WIDE MOAT ETF

SCHEDULE OF INVESTMENTS

(continued)

 

Principal       
Amount      Value  
 
Repurchase Agreements: (continued)     
$ 25,730,494     Repurchase agreement dated 9/29/17 with Nomura Securities International, Inc., 1.08%, due 10/2/17, proceeds $25,732,810; (collateralized by various U.S. government and agency obligations, 0.00% to 9.00%, due 11/15/17 to 8/20/67, valued at $26,245,105 including accrued interest)    $25,730,494 
Total Short-Term Investments Held as Collateral for Securities Loaned
(Cost: $108,336,213)
     108,336,213 
Total Investments: 108.5%
(Cost: $1,328,037,871)
     1,395,811,361 
Liabilities in excess of other assets: (8.5)%     (109,360,441)
NET ASSETS: 100.0%    $1,286,450,920 


 

 

Footnotes:

* Non-income producing
Security fully or partially on loan. Total market value of securities on loan is $105,886,209.

 

Summary of Investments by Sector Excluding
Collateral for Securities Loaned                        
  % of Investments  Value  
Consumer Discretionary   20.9%  $269,008,465 
Consumer Staples   4.9    62,684,140 
Financials   10.8    138,651,301 
Health Care   34.8    447,614,854 
Industrials   13.3    171,957,076 
Information Technology   9.1    117,753,726 
Materials   4.9    62,903,795 
Real Estate   1.3    16,901,791 
           100.0%        $1,287,475,148 

 

The summary of inputs used to value the Fund’s investments as of September 30, 2017 is as follows:

 

   Level 1
Quoted
Prices
   Level 2
Significant
Observable
Inputs
   Level 3
Significant
Unobservable
Inputs
  Value 
Common Stocks*  $1,287,475,148   $     $   $1,287,475,148 
Repurchase Agreements       108,336,213          108,336,213 
Total  $1,287,475,148   $108,336,213     $   $1,395,811,361 

 

* See Schedule of Investments for industry sector breakouts.

 

There were no transfers between levels during the year ended September 30, 2017.

 

See Notes to Financial Statements

16

[This Page Intentionally Left Blank.]

 

VANECK VECTORS ETF TRUST

STATEMENTS OF ASSETS AND LIABILITIES

September 30, 2017

 

   Global
Spin-Off ETF
  Morningstar
International
Moat ETF
  Morningstar
Wide Moat ETF
Assets:                     
Investments, at value (1) (2)    $5,883,367     $81,427,237     $1,287,475,148 
Short-term investments held as collateral for securities loaned (3)     592,883      2,487,929      108,336,213 
Cash                 855 
Cash denominated in foreign currency, at value (4)           144,612       
Receivables:                     
Investment securities sold     703,568      139,848       
Due from Adviser     5,616             
Dividends and interest     14,284      201,119      966,562 
Prepaid expenses     62      479      10,760 
Total assets     7,199,780      84,401,224      1,396,789,538 
                      
Liabilities:                     
Payables:                     
Investment securities purchased     719,193      144,527       
Collateral for securities loaned     592,883      2,487,929      108,336,213 
Line of credit           82,542      1,388,146 
Due to Adviser           18,427      483,291 
Due to custodian     8             
Deferred Trustee fees     22      110      32,431 
Accrued expenses     33,871      36,678      98,537 
Total liabilities     1,345,977      2,770,213      110,338,618 
NET ASSETS    $5,853,803     $81,631,011     $1,286,450,920 
Shares outstanding     250,000      2,300,000      31,900,000 
Net asset value, redemption and offering price per share    $23.42     $35.49     $40.33 
                      
Net assets consist of:                     
Aggregate paid in capital    $5,029,018     $71,803,976     $1,341,165,022 
Net unrealized appreciation     849,374      6,405,871      67,773,490 
Undistributed net investment income     40,434      1,245,849      12,305,911 
Accumulated net realized gain (loss)     (65,023)     2,175,315      (134,793,503)
     $5,853,803     $81,631,011     $1,286,450,920 
(1) Value of securities on loan    $512,167     $2,351,868     $105,886,209 
(2) Cost of investments    $5,034,016     $75,022,167     $1,219,701,658 
(3) Cost of short-term investments held as collateral for securities loaned    $592,883     $2,487,929     $108,336,213 
(4) Cost of cash denominated in foreign currency    $     $144,597     $ 

 

See Notes to Financial Statements

18

VANECK VECTORS ETF TRUST

STATEMENTS OF OPERATIONS

For the Year Ended September 30, 2017

 

   Global
Spin-Off ETF
  Morningstar
International
Moat ETF
  Morningstar
Wide Moat ETF
Income:                     
Dividends    $63,548     $1,549,458     $19,247,809 
Securities lending income     7,873      16,478      435,941 
Foreign taxes withheld     (1,349)     (94,383)      
Total income     70,072      1,471,553      19,683,750 
                      
Expenses:                     
Management fees     22,868      210,372      4,652,297 
Professional fees     60,852      51,764      100,280 
Insurance     41      253      9,682 
Trustees’ fees and expenses     126      953      26,857 
Reports to shareholders     13,998      40,227      70,466 
Indicative optimized portfolio value fee     5,000      4,999      1,513 
Custodian fees     8,614      22,861      28,924 
Registration fees     5,064      5,064      5,064 
Transfer agent fees     2,400      2,400      1,983 
Fund accounting fees     1,641      9,297      51,211 
Interest     38      3,151      19,180 
Other     1,005      2,474      25,602 
Total expenses     121,647      353,815      4,993,059 
Waiver of management fees     (22,868)     (115,046)      
Expenses assumed by the Adviser     (73,587)            
Net expenses     25,192      238,769      4,993,059 
Net investment income     44,880      1,232,784      14,690,691 
                      
Net realized gain (loss) on:                     
Investments     (35,714)     3,734,812      41,000,868 
In-kind redemptions                 82,089,759 
Foreign currency transactions and foreign denominated assets and liabilities     (240)     (2,502)      
Net realized gain (loss)     (35,954)     3,732,310      123,090,627 
                      
Net change in unrealized appreciation (depreciation) on:                     
Investments     572,324      5,936,516      40,676,068 
Foreign currency transactions and foreign denominated assets and liabilities     114      558       
Net change in unrealized appreciation (depreciation)     572,438      5,937,074      40,676,068 
Net Increase in Net Assets Resulting from Operations    $581,364     $10,902,168     $178,457,386 

 

See Notes to Financial Statements

19

VANECK VECTORS ETF TRUST

STATEMENTS OF CHANGES IN NET ASSETS

 

   Global Spin-Off ETF  Morningstar
International Moat ETF
   For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
Operations:                            
Net investment income    $44,880     $57,911     $1,232,784     $339,352 
Net realized gain (loss)     (35,954)     6,075      3,732,310      (1,083,259)
Net change in unrealized appreciation (depreciation)     572,438      524,789      5,937,074      1,665,276 
Net increase in net assets resulting from operations     581,364      588,775      10,902,168      921,369 
                             
Dividends to shareholders:                            
Dividends from net investment income     (48,600)     (16,650)     (407,000)     (90,000)
                             
Share transactions:**                            
Proceeds from sale of shares     2,202,041            58,380,932      1,332,150 
Cost of shares redeemed                        
Increase (Decrease) in net assets resulting from share transactions     2,202,041            58,380,932      1,332,150 
Total increase in net assets     2,734,805      572,125      68,876,100      2,163,519 
Net Assets, beginning of period     3,118,998      2,546,873      12,754,911      10,591,392 
Net Assets, end of period†    $5,853,803     $3,118,998     $81,631,011     $12,754,911 
† Including undistributed net investment income    $40,434     $45,047     $1,245,849     $333,495 
                             
** Shares of Common Stock Issued (no par value)                            
Shares sold     100,000            1,850,000      50,000 
Shares redeemed                        
Net increase (decrease)     100,000            1,850,000      50,000 

 

See Notes to Financial Statements

20

 

 

Morningstar Wide Moat ETF
For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
    
  $14,690,691     $10,263,758 
   123,090,627      42,525,390 
   40,676,068      87,339,736 
   178,457,386      140,128,884 
            
   (9,710,400)     (15,301,600)
            
   698,870,832      518,341,447 
   (334,524,711)     (632,174,449)
   364,346,121      (113,833,002)
   533,093,107      10,994,282 
   753,357,813      742,363,531 
  $1,286,450,920     $753,357,813 
  $12,305,911     $7,325,620 
            
   18,300,000      16,550,000 
   (8,550,000)     (20,950,000)
   9,750,000      (4,400,000)

 

See Notes to Financial Statements

21

VANECK VECTORS ETF TRUST

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period:

 

   Global Spin-Off ETF  
   For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Period
June 9, 2015(a)
through
September 30,
2015
 
Net asset value, beginning of period    $20.79     $16.98     $19.78   
Income from investment operations:                       
Net investment income     0.22(b)     0.39      0.05   
Net realized and unrealized gain (loss) on investments     2.73      3.53      (2.85)  
Total from investment operations     2.95      3.92      (2.80)  
Less:                       
Dividends from net investment income     (0.32)     (0.11)        
Net asset value, end of period    $23.42     $20.79     $16.98   
Total return (c)     14.37%     23.22%     (14.16)%(d)  
Ratios/Supplemental Data                       
Net assets, end of period (000’s)  $5,854   $3,119   $2,547   
Ratio of gross expenses to average net assets     2.66%     5.07%     6.24%(e)  
Ratio of net expenses to average net assets     0.55%     0.55%     0.55%(e)  
Ratio of net expenses to average net assets excluding interest expense     0.55%     0.55%     0.55%(e)  
Ratio of net investment income to average net assets     0.98%     2.13%     1.24%(e)  
Portfolio turnover rate (f)     53%     58%     30%(d)  
                        
   Morningstar International Moat ETF  
   For the Year
Ended
September 30,
2017
  For the Year
Ended
September 30,
2016
  For the Period
July 13, 2015(a)
through
September 30,
2015
 
Net asset value, beginning of period    $28.34     $26.48     $30.17   
Income from investment operations:                       
Net investment income     0.93(b)     0.76      0.18   
Net realized and unrealized gain (loss) on investments     6.59      1.33      (3.87)  
Total from investment operations     7.52      2.09      (3.69)  
Less:                       
Dividends from net investment income     (0.37)     (0.23)        
Net asset value, end of period    $35.49     $28.34     $26.48   
Total return (c)     26.91%     7.91%     (12.23)%(d)  
Ratios/Supplemental Data                       
Net assets, end of period (000’s)  $81,631   $12,755   $10,591   
Ratio of gross expenses to average net assets     0.84%     1.62%     2.49%(e)  
Ratio of net expenses to average net assets     0.56%     0.56%     0.56%(e)  
Ratio of net expenses to average net assets excluding interest expense     0.56%     0.56%     0.56%(e)  
Ratio of net investment income to average net assets     2.92%     2.99%     3.27%(e)  
Portfolio turnover rate (f)     129%     168%     54%(d)  

 

 
(a) Commencement of operations
(b) Calculated based upon average shares outstanding
(c) Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(d) Not Annualized
(e) Annualized
(f) Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.

 

See Notes to Financial Statements

22

 

 

   Morningstar Wide Moat ETF  
   For the Year Ended September 30,  
   2017  2016  2015  2014  2013  
Net asset value, beginning of year          $34.01            $27.96            $31.27           $27.09          $21.54     
Income from investment operations:                                     
Net investment income     0.53(a)     0.48      0.57      0.37      0.23   
Net realized and unrealized gain (loss) on investments     6.20      6.19      (3.46)     4.04      5.46   
Total from investment operations     6.73      6.67      (2.89)     4.41      5.69   
Less:                                     
Dividends from net investment income     (0.41)     (0.62)     (0.42)     (0.23)     (0.14)  
Net asset value, end of year    $40.33     $34.01     $27.96     $31.27     $27.09   
Total return (b)     19.96%     24.23%     (9.41)%     16.35%     26.54%  
Ratios/Supplemental Data                                     
Net assets, end of year (000’s)  $1,286,451   $753,358   $742,364   $853,616   $364,395   
Ratio of gross expenses to average net assets     0.48%     0.50%     0.50%     0.50%     0.51%  
Ratio of net expenses to average net assets     0.48%     0.49%     0.49%     0.49%     0.49%  
Ratio of net expenses to average net assets excluding interest expense     0.48%     0.49%     0.49%     0.49%     0.49%  
Ratio of net investment income to average net assets     1.42%     1.44%     1.88%     1.63%     1.48%  
Portfolio turnover rate (c)     53%     178%     14%     15%     1%  

 

 
(a)Calculated based upon average shares outstanding
(b)Total return is calculated assuming an initial investment made at the net asset value at the beginning of period, reinvestment of any dividends and distributions at net asset value on the dividend/distributions payment date and a redemption at the net asset value on the last day of the period. The return does not reflect the deduction of taxes that a shareholder would pay on Fund dividends/distributions or the redemption of Fund shares.
(c)Portfolio turnover rates exclude securities received or delivered as a result of processing in-kind capital share transactions.

 

See Notes to Financial Statements

23

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

 

Note 1—Fund Organization—VanEck Vectors ETF Trust (the “Trust”) is registered under the Investment Company Act of 1940, as amended, as an open-end management investment company. The Trust was incorporated in Delaware as a statutory trust on March 15, 2001. The Trust operates as a series fund, and as of September 30, 2017, offers fifty-nine investment portfolios, each of which represents a separate series of the Trust.

 

These financial statements relate only to the following investment portfolios: Global Spin-Off ETF, Morningstar International Moat ETF and Morningstar Wide Moat ETF (each a “Fund” and, together, the “Funds”). Each Fund was created to provide investors with the opportunity to purchase a security representing a proportionate undivided interest in a portfolio of securities consisting of substantially all of the common stocks in substantially the same weighting, in an index sponsored, licensed or managed by Morningstar, Inc. or Horizon Kinetics, LLC.

 

The Funds’ commencement of operations dates and their respective indices are presented below:

 

Fund   Commencement
of Operations      
  Index
Global Spin-Off ETF   June 9, 2015   Horizon Kinetics Global Spin-Off Index(1)
Morningstar International Moat ETF   July 13, 2015   Morningstar® Global ex-US Moat Focus IndexSM(2)
Morningstar Wide Moat ETF   April 24, 2012   Morningstar® Wide Moat Focus IndexSM(2)

 

(1) Published by Horizon Kinetics, LLC
(2) Published by Morningstar, Inc.

 

Note 2—Significant Accounting Policies—The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates.

 

The Funds are investment companies and are following accounting and reporting requirements of Accounting Standards Codification (“ASC”) 946 Financial Services—Investment Companies.

 

The following is a summary of significant accounting policies followed by the Funds.

 

A. Security Valuation—The Funds value their investments in securities and other assets and liabilities at fair value daily. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Securities traded on national exchanges or traded on the NASDAQ National Market System are valued at the last sales price as reported at the close of each business day. Securities traded on the NASDAQ Stock Market are valued at the NASDAQ official closing price. Over-the-counter securities not included in the NASDAQ National Market System and listed securities for which no sale was reported are valued at the mean of the bid and ask prices. To the extent these securities are actively traded they are categorized as Level 1 in the fair value hierarchy (described below). Certain foreign securities, whose values may be affected by market direction or events occurring before the Funds’ pricing time (4:00 p.m. Eastern Standard Time) but after the last close of the securities’ primary market, are fair valued using a pricing service and are categorized as Level 2 in the fair value hierarchy. The pricing service, using methods approved by the Board of Trustees, considers the correlation of the trading patterns of the foreign security to intraday trading in the U.S. markets, based on indices of domestic securities and other appropriate indicators such as prices of relevant ADR’s and futures contracts. The Funds may also fair value securities in other situations, such as, when a particular foreign market is closed but the Fund is open. Short-term obligations with sixty days or less to maturity are valued at amortized cost, which with accrued interest approximates fair value. Money market fund investments are valued at net asset value and are considered to be Level 1 in the fair value hierarchy. The Pricing Committee of the Adviser provides oversight of the Funds’ valuation policies and procedures, which are approved by the Funds’ Board of Trustees. Among other things, these procedures allow the Funds to utilize independent pricing services, quotations from securities dealers, and other market sources to determine fair value. The Pricing Committee convenes regularly to review the fair value of financial instruments or other assets. If market quotations for a security or other asset are not readily available, or if the Adviser believes it does not otherwise reflect the fair value of a security or asset, the security or asset will be fair valued by the Pricing Committee in accordance with the Funds’ valuation policies and procedures. The Pricing Committee employs various methods for calibrating the valuation approaches utilized to determine fair value, including a regular review of key inputs and assumptions, periodic comparisons to valuations provided by other independent pricing services, transactional back-testing and disposition analysis.
24

 

 

  Certain factors such as economic conditions, political events, market trends, the nature of and duration of any restrictions on disposition, trading in similar securities of the issuer or comparable issuers and other security specific information are used to determine the fair value of these securities. Depending on the relative significance of valuation inputs, these securities may be classified either as Level 2 or Level 3 in the fair value hierarchy. The price which the Funds may realize upon sale of an investment may differ materially from the value presented in the Schedules of Investments.
   
  The Funds utilize various methods to measure the fair value of their investments on a recurring basis, which includes a hierarchy that prioritizes inputs to valuation methods used to measure fair value. The fair value hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The transfers between levels of the fair value hierarchy assume the financial instruments where transferred at the beginning of the reporting period. The three levels of the fair value hierarchy are described below:
   
  Level 1 — Quoted prices in active markets for identical securities.
   
  Level 2 — Significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
   
  Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
   
  A summary of the inputs, the levels used to value the Funds’ investments, and transfers between levels are located in the Schedules of Investments. Additionally, tables that reconcile the valuation of the Funds’ Level 3 investments and that present additional information about valuation methodologies and unobservable inputs, if applicable, are located in the Schedules of Investments.

 

B. Federal Income Taxes—It is each Fund’s policy to comply with the provisions of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Therefore, no federal income tax provision is required.
   
C. Dividends and Distributions to Shareholders—Dividends to shareholders from net investment income and distributions from net realized capital gains, if any, are declared and paid annually by each Fund. Income dividends and capital gain distributions are determined in accordance with U.S. income tax regulations, which may differ from such amounts determined in accordance with GAAP.
   
D. Currency Translation—Assets and liabilities denominated in foreign currencies and commitments under foreign currency contracts are translated into U.S. dollars at the closing prices of such currencies each business day as quoted by one or more sources. Purchases and sales of investments are translated at the exchange rates prevailing when such investments are acquired or sold. Foreign denominated income and expenses are translated at the exchange rates prevailing when accrued. The portion of realized and unrealized gains and losses on investments that result from fluctuations in foreign currency exchange rates is not separately disclosed in the financial statements. Recognized gains or losses attributable to foreign currency fluctuations on foreign currency denominated assets, other than investments, and liabilities are recorded as net realized gain (loss) on foreign currency transactions and foreign denominated assets and liabilities in the Statements of Operations.
   
E. Restricted Securities—The Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities, if any, is included at the end of each Fund’s Schedule of Investments.
   
F. Use of Derivative Instruments—The Funds may invest in derivative instruments, including, but not limited to, options, futures, swaps and other derivatives relating to foreign currency transactions. A derivative is an instrument whose value is derived from underlying assets, indices, reference rates or a combination of these factors. Derivative instruments may be privately negotiated contracts (often referred to as over-the-counter (“OTC”) derivatives) or they may be listed and traded on an exchange. Derivative contracts may involve future commitments to purchase or sell
25

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

  financial instruments at specified terms on a specified date, or to exchange interest payment streams or currencies based on a notional or contractual amount. Derivative instruments may involve a high degree of financial risk. The use of derivative instruments also involves the risk of loss if the Adviser is incorrect in its expectation of the timing or level of fluctuations in securities prices, interest rates or currency prices. Investments in derivative instruments also include the risk of default by the counterparty, the risk that the investment may not be liquid and the risk that a small movement in the price of the underlying security or benchmark may result in a disproportionately large movement, unfavorable or favorable, in the price of the derivative instruments. The Funds held no derivative instruments during the year ended September 30, 2017.
   
G. Repurchase Agreements—The Funds may enter into repurchase agreements with financial institutions, deemed to be creditworthy by the Adviser, to generate income from their excess cash balances and to invest securities lending cash collateral. A repurchase agreement is an agreement under which a Fund acquires securities from a seller, subject to resale to the seller at an agreed upon price and date. A Fund, through its custodian/securities lending agent, takes possession of securities collateralizing the repurchase agreement. Pursuant to the terms of the repurchase agreement, such securities must have an aggregate market value greater than or equal to the terms of the repurchase price plus accrued interest at all times. If the value of the underlying securities falls below the value of the repurchase price plus accrued interest, the Funds will require the seller to deposit additional collateral by the next business day. If the request for additional collateral is not met, or the seller defaults on its repurchase obligation, the Funds maintain their right to sell the underlying securities at market value and may claim any resulting loss against the seller. Repurchase agreements held as of September 30, 2017 are reflected in the Schedules of Investments.
   
H. Offsetting Assets and Liabilities—In the ordinary course of business, the Funds enter into transactions subject to enforceable master netting or other similar agreements. Generally, the right of setoff in those agreements allows the Funds to set off any exposure to a specific counterparty with any collateral received or delivered to that counterparty based on the terms of the agreements. The Funds may pledge or receive cash and/or securities as collateral for derivative instruments, securities lending and repurchase agreements. For financial reporting purposes, the Funds present securities lending and repurchase agreement assets and liabilities on a gross basis in the Statements of Assets and Liabilities. Collateral held at September 30, 2017 is presented in the Schedules of Investments. Refer to related disclosures in Note 2G (Repurchase Agreements) and Note 9 (Securities Lending).
   
I. Other—Security transactions are accounted for on trade date. Transactions in certain securities may take longer than the customary settlement cycle to be completed. Realized gains and losses are calculated on the identified cost basis. Dividend income is recorded on the ex-dividend date except that certain dividends from foreign securities are recognized upon notification of the ex-dividend date/rate. The Funds may record distributions received in excess of income from certain underlying investments as a reduction of cost of investments and/or as an increase in capital gains. Such amounts are based on estimates if actual amounts are not available, and actual amounts of income, realized gains and return of capital may differ from estimated amounts.
   
  In the normal course of business, the Funds enter into contracts that contain a variety of general indemnifications. The Funds’ maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Funds that have not yet occurred. However, the Adviser believes the risk of loss under these arrangements to be remote.

 

Note 3—Investment Management and Other Agreements—The Adviser is the investment adviser to the Funds. The Adviser receives a management fee, calculated daily and payable monthly based on an annual rate of each Fund’s average daily net assets. The Adviser has agreed, until at least February 1, 2018, to waive management fees and assume expenses to prevent each Fund’s total annual operating expenses (excluding acquired fund fees and expenses, interest expense, trading expenses, taxes and extraordinary expenses) from exceeding expense limitations listed in the table below.

26

 

 

The current management fee rate, expense limitations and the amounts waived/assumed by the Adviser for the year ended September 30, 2017, are as follows:

 

Fund  Management
Fee Rates
  Expense
Limitations
  Waiver of
Management
Fees
  Expenses
Assumed by
the Adviser
Global Spin-Off ETF   0.50%   0.55%   $22,868    $73,587 
Morningstar International Moat ETF   0.50    0.56    115,046     
Morningstar Wide Moat ETF   0.45    0.49         

 

In addition, Van Eck Securities Corporation, an affiliate of the Adviser, acts as the Funds’ distributor (“the Distributor”). Certain officers and a Trustee of the Trust are officers, directors or stockholders of the Adviser and Distributor.

 

Note 4—Investments—For the year ended September 30, 2017, the cost of purchases and proceeds from sales of investments other than U.S. government obligations and short-term obligations (excluding in-kind transactions described in Note 6) were as follows:

 

Fund  Cost of Investments
Purchased
  Proceeds from
Investments Sold
Global Spin-Off ETF  $2,418,834   $2,369,382 
Morningstar International Moat ETF   58,916,526    55,049,759 
Morningstar Wide Moat ETF   548,470,147    543,769,567 

 

Note 5—Income Taxes—As of September 30, 2017, for Federal income tax purposes, the identified cost of investments owned, net unrealized appreciation (depreciation), gross unrealized appreciation, and gross unrealized depreciation of investments were as follows:

 

Fund  Cost of Investments  Gross Unrealized
Appreciation
  Gross Unrealized
Depreciation
  Net Unrealized
Appreciation
(Depreciation)
Global Spin-Off ETF  $5,633,590   $1,043,548   $(200,888)  $842,660 
Morningstar International Moat ETF   78,265,944    6,420,239    (771,017)   5,649,222 
Morningstar Wide Moat ETF   1,328,124,931    98,986,280    (31,299,850)   67,686,430 

 

At September 30, 2017, the components of accumulated earnings (deficit) on a tax basis, for each Fund, were as follows:

 

Fund  Undistributed
Ordinary
Income
  Undistributed
Long-Term
Capital Gains
  Accumulated
Capital
Losses
  Qualified Late Year
Losses
  Other
Temporary
Difference
  Unrealized
Appreciation
(Depreciation)
  Total
Global Spin-Off ETF  $40,456   $   $(58,333)  $   $(22)  $842,684   $824,785 
Morningstar International Moat ETF   3,891,670*   285,452            (110)   5,650,023    9,827,035 
Morningstar Wide Moat ETF   12,338,342        (134,706,443)       (32,431)   67,686,430    (54,714,102)

 

* Includes short-term capital gains

 

The tax character of dividends paid to shareholders during the years ended September 30, 2017 and September 30, 2016 was as follows:

 

Fund  2017 Dividends
Ordinary Income
  2016 Dividends
Ordinary Income
Global Spin-Off ETF  $48,600   $16,650 
Morningstar International Moat ETF   407,000    90,000 
Morningstar Wide Moat ETF   9,710,400    15,301,600 

 

At September 30, 2017, the Funds had capital loss carryforwards available to offset future capital gains, as follow:

 

Fund  No Expiration
Short-Term
Capital Losses
  No Expiration
Long-Term
Capital Losses
  Total
Global Spin-Off ETF  $(58,333)  $   $(58,333)
Morningstar International Moat ETF            
Morningstar Wide Moat ETF   (102,440,499)   (32,265,944)   (134,706,443)
27

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

During the year ended September 30, 2017 Morningstar International Moat ETF and Morningstar Wide Moat ETF utilized $1,466,714 and $41,068,939 of each of their respective accumulated capital loss carryforwards available from previous years.

 

During the year ended September 30, 2017, as a result of permanent book to tax differences, primarily due to investments in Passive Foreign Investment Companies, foreign currency gains and losses, and tax treatment of in-kind redemptions, the Funds’ incurred differences that affected undistributed net investment income (loss), accumulated net realized gain (loss) on investments and aggregate paid in capital by the amounts in the table below. Net assets were not affected by these reclassifications.

 

Fund  Increase (Decrease)
in Accumulated
Net Investment
Income (Loss)
  Increase (Decrease)
Accumulated in
Net Realized
Gain (Loss)
  Increase (Decrease)
in Aggregate
Paid in Capital
Global Spin-Off ETF        $(893)      $893   $ 
Morningstar International Moat ETF   86,570    (86,570)    
Morningstar Wide Moat ETF       (82,089,759)   82,089,759 

 

The Funds recognize the tax benefits of uncertain tax positions only where the position is “more-likely-than-not” to be sustained assuming examination by applicable tax authorities. Management has analyzed the Funds’ tax positions, and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on return filings for all open tax years. The Funds do not have exposure for additional years that might still be open in certain foreign jurisdictions. Therefore, no provision for income tax is required in the Funds’ financial statements. However, the Funds are subject to foreign taxes on the appreciation in value of certain investments. The Funds provide for such taxes on both realized and unrealized appreciation.

 

The Funds recognize interest and penalties, if any, related to uncertain tax positions as income tax expense in the Statements of Operations. During the year ended September 30, 2017, the Funds did not incur any interest or penalties.

 

Note 6—Capital Share Transactions—As of September 30, 2017, there were an unlimited number of capital shares of beneficial interest authorized by the Trust with no par value. Fund shares are not individually redeemable and are issued and redeemed at their net asset value per share only through certain authorized broker-dealers (“Authorized Participants”) in blocks of shares (“Creation Units”), consisting of 50,000 shares, or multiples thereof.

 

The consideration for the purchase or redemption of Creation Units of the Funds generally consists of the in-kind contribution or distribution of securities constituting the Funds’ underlying index (“Deposit Securities”) plus a balancing cash component to equate the transaction to the net asset value per share of the Fund on the transaction date. Cash may also be substituted in an amount equivalent to the value of certain Deposit Securities, generally as a result of market circumstances, or when the securities are not available in sufficient quantity for delivery, or are not eligible for trading by the Authorized Participant. The Funds may issue Creation Units in advance of receipt of Deposit Securities subject to various conditions, including a requirement to maintain on deposit at the Custodian for the benefit of the Funds, collateral consisting of cash in the form of U.S. dollars at least equal to 115% of the daily marked to market value of the missing Deposit Securities.

 

Authorized Participants purchasing and redeeming Creation Units may pay transaction fees directly to The Bank of New York Mellon. In addition, the Funds may impose certain variable fees for creations and redemptions with respect to transactions in Creation Units for cash, or on transactions effected outside the clearing process, which are treated as increases in capital. These variable fees, if any, are reflected in share transactions in the Statements of Changes in Net Assets.

 

For the year ended September 30, 2017, the Funds had in-kind contributions and redemptions as follows:

 

Fund  In-Kind Contributions  In-Kind Redemptions
Global Spin-Off ETF  $2,205,402   $ 
Morningstar International Moat ETF   55,118,904     
Morningstar Wide Moat ETF   698,852,853    333,302,871 
28

 

 

The in-kind contributions and in-kind redemptions in this table represent the accumulation of each Fund’s daily net shareholder transactions including rebalancing activity, while the Statements of Changes in Net Assets reflect shareholder transactions including any cash component of the transactions.

 

Note 7—Concentration of Risk—The investment objective of each Fund is to seek investment results that correspond generally to the price and yield performance, before fees and expenses, of its underlying index, as indicated in the name of each Fund. The Adviser uses a “passive” or index approach to achieve each Fund’s investment objective by investing in a portfolio of securities that generally replicates the Funds’ index. Each of the Funds is classified as a non-diversified fund under the 1940 Act. Non-diversified funds generally hold securities of fewer issuers than diversified funds and may be more susceptible to the risks associated with these particular issuers, or to a single economic, political or regulatory occurrence affecting these issuers. The Funds may purchase securities on foreign exchanges. Securities of foreign issuers involve special risks and considerations not typically associated with investing in U.S. issuers. These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.

 

These risks include devaluation of currencies, currency controls, less reliable information about issuers, different securities transaction clearance and settlement practices, future adverse political and economic developments and local/regional conflicts. These risks are heightened for investments in emerging market countries. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than those of comparable U.S. issuers.

 

Global Spin-Off ETF may invest in companies that have been spun-off from a parent company for a number of reasons, including but not limited to low growth prospects, high capital requirements or an unfavorable capitalization structure. Investments in spun-off companies are subject to the risk that any of these characteristics will adversely affect the value of investments in the spun-off companies. There can be no assurance that a spun-off company will be financially independent or profitable, especially where the company represented a non-core or non-competitive business line of the parent company at the time of the spin-off.

 

Global Spin-Off ETF may invest directly in real estate investment trusts (“REITs”) and is exposed to the risk of owning real estate directly, as well as to risks that relate specifically to the way in which REITs are organized and operated. REITs generally invest directly in real estate, in mortgages or in some combination of the two. The Fund indirectly bears management expenses along with the direct expenses of the Fund. Individual REITs may own a limited number of properties and may concentrate in a particular region or property type. REITs may also be subject to heavy cash flow dependency, default by borrowers and self-liquidation.

 

In March 2017, the United Kingdom triggered Article 50, and is now scheduled to leave the EU by the end of March 2019. Significant uncertainty exists on how the withdrawal will take place, the terms of the withdrawal and the effects such withdrawal will have on the European Union and the United Kingdom. This may further impact the value of the Euro and the British pound sterling, and has caused volatility and uncertainty in European and global markets.

 

As a result of events involving Ukraine and the Russian Federation, the United States and the European Union have imposed sanctions on certain Russian individuals and companies. These sanctions do not currently impact the Funds. Additional economic sanctions may be imposed or other actions may be taken that may adversely affect the value and liquidity of the Russian-related issuers held by the Funds.

 

A more complete description of risks is included in each Fund’s prospectus and Statement of Additional Information.

 

Note 8—Trustee Deferred Compensation Plan—The Trust has a Deferred Compensation Plan (the “Plan”) for Trustees under which the Trustees can elect to defer receipt of their trustee fees until retirement, disability or termination from the Board of Trustees. The fees otherwise payable to the participating Trustees are deemed invested in shares of the Funds as directed by the Trustees.

 

The expense for the Plan is included in “Trustees’ fees and expenses” in the Statements of Operations. The liability for the Plan is shown as “Deferred Trustee fees” in the Statements of Assets and Liabilities.

29

VANECK VECTORS ETF TRUST

NOTES TO FINANCIAL STATEMENTS

(continued)

 

Note 9—Securities Lending—To generate additional income, each of the Funds may lend its securities pursuant to a securities lending agreement with The Bank of New York Mellon, the securities lending agent and also the Funds’ custodian. Each Fund may lend up to 33% of its investments requiring that the loan be continuously collateralized by cash, U.S. government or U.S. government agency securities, shares of an investment trust or mutual fund, or any combination of cash and such securities at all times equal to at least 102% (105% for foreign securities) of the market value plus accrued interest on the securities loaned. Daily market fluctuations could cause the value of loaned securities to be more or less than the value of the collateral received. When this occurs, the collateral is adjusted and settled on the next business day. During the term of the loan, the Funds will continue to receive any dividends, interest or amounts equivalent thereto, on the securities loaned while receiving a fee from the borrower and/or earning interest on the investment of the cash collateral. Such fees and interest are shared with the securities lending agent under the terms of the securities lending agreement. The Funds may pay reasonable finders’, administrative and custodial fees in connection with a loan of its securities. Securities lending income is disclosed as such in the Statements of Operations. The collateral for securities loaned is recognized in the Schedules of Investments and the Statements of Assets and Liabilities. The cash collateral is maintained on the Funds’ behalf by the lending agent and is invested in repurchase agreements collateralized by obligations of the U.S. Treasury and/or Government Agencies. Loans are subject to termination at the option of the borrower or the Funds. Upon termination of the loan, the borrower will return to the lender securities identical to the securities loaned. The Funds bear the risk of delay in recovery of, or even loss of rights in, the securities loaned should the borrower of the securities fail financially. The value of loaned securities and related collateral outstanding at September 30, 2017 are presented on a gross basis in the Schedules of Investments and Statements of Assets and Liabilities.

 

The following table presents the amount of repurchase agreements held as collateral by type of security on loan pledged as of September 30, 2017:

 

   Gross Amount of Recognized
Liabilities for Securities Loaned
in the Statements of Assets
and Liabilities*
Fund  Equity Securities
Global Spin-Off ETF   $       592,883 
Morningstar International Moat ETF   2,487,929 
Morningstar Wide Moat ETF   108,336,213 

 

* Remaining contractual maturity of the agreements: overnight and continuous

 

Note 10—Bank Line of Credit—The Funds may participate in a $200 million committed credit facility (the “Facility”) to be utilized for temporary financing until the settlement of sales or purchases of portfolio securities, the repurchase or redemption of shares of the Funds at the request of the shareholders and other temporary or emergency purposes. The Funds have agreed to pay commitment fees, pro rata, based on the unused but available balance. Interest is charged to the Funds at rates based on prevailing market rates in effect at the time of borrowings. During the year ended September 30, 2017, the following Funds borrowed under this Facility:

 

Fund  Days
Outstanding
  Average Daily
Loan Balance
  Average
Interest Rate
  Outstanding Loan
Balance as of
September 30, 2017
Global Spin-Off ETF   3   $178,869    2.56%  $ 
Morningstar International Moat ETF   161    194,287    2.43    82,542 
Morningstar Wide Moat ETF   231    1,226,994    2.20    1,388,146 

 

Note 11—Custodian Fees—The Funds have entered into an expense offset agreement with the custodian wherein they receive a credit toward the reduction of custodian fees whenever there are uninvested cash balances. The Funds could have invested their cash balances elsewhere if they had not agreed to a reduction in fees under the expense offset agreement with the custodian. For the year ended September 30, 2017, there were no offsets to custodian fees.

 

Note 12—Subsequent Event Review—The Funds have evaluated subsequent events and transactions for potential recognition or disclosure through the date the financial statements were issued.

30

VANECK VECTORS ETF TRUST

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Board of Trustees and Shareholders of VanEck Vectors ETF Trust

 

We have audited the accompanying statements of assets and liabilities, including the schedules of investments, of VanEck Vectors Global Spin-Off ETF, VanEck Vectors Morningstar International Moat ETF and VanEck Vectors Morningstar Wide Moat ETF (three of the series constituting VanEck Vectors ETF Trust) (the “Funds”) as of September 30, 2017, and the related statements of operations, the statements of changes in net assets and the financial highlights for the periods indicated therein. These financial statements and financial highlights are the responsibility of the Funds’ management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement. We were not engaged to perform an audit of the Funds’ internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements and financial highlights, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our procedures included confirmation of securities owned as of September 30, 2017, by correspondence with the custodian and brokers or by other appropriate auditing procedures where replies from brokers were not received. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements and financial highlights referred to above present fairly, in all material respects, the financial position of VanEck Vectors Global Spin-Off ETF, VanEck Vectors Morningstar International Moat ETF and VanEck Vectors Morningstar Wide Moat ETF (three of the series constituting VanEck Vectors ETF Trust) at September 30, 2017, and the results of their operations, the changes in their net assets and the financial highlights for the periods indicated therein, in conformity with U.S. generally accepted accounting principles.

 

 

New York, New York

November 27, 2017

31

VANECK VECTORS ETF TRUST

TAX INFORMATION

(unaudited)

 

The information set forth below relates to distributions paid during each Fund’s current fiscal year as required by federal laws. Shareholders, however, must report dividends on a calendar year basis for income tax purposes, which may include dividends for portions of two fiscal years of a Fund.

 

Accordingly, the information needed by shareholders for calendar year 2017 income tax purposes will be sent to them in early 2018. Please consult your tax advisor for proper treatment of this information.

 

The following information is provided with respect to the distributions paid during the taxable year ended September 30, 2017:

 

   Global
Spin-Off
ETF
  Morningstar
International
Moat ETF
  Morningstar
Wide
Moat ETF
Record Date   12/21/2016    12/21/2016    12/21/2016 
Ex Date   12/19/2016    12/19/2016    12/19/2016 
Payable Date   12/23/2016    12/23/2016    12/23/2016 
                
Amount Paid Per Share   $0.324000    $0.370000    $0.408000 
                
Ordinary Income:               
Qualified Dividend Income for Individuals   83.45%   69.79%*   100.00%
Dividends Qualifying for the Dividends Received Deduction for Corporations   34.72%       100.00%
Foreign Source Income       99.88%*    
Foreign Taxes Paid Per Share       $0.020084**    

 

* Expressed as a percentage of the cash distribution grossed up for foreign taxes.
** The foreign taxes paid represent taxes incurred by the Fund on income received by the Fund from foreign sources. Foreign taxes paid may be included in taxable income with an offsetting deduction from gross income or may be taken as a credit for taxes paid to foreign governments. You should consult your tax adviser regarding the appropriate treatment of foreign taxes paid.

 

Please retain this information for your records.

32

VANECK VECTORS ETF TRUST

BOARD OF TRUSTEES AND OFFICERS

September 30, 2017 (unaudited)

 

Name, Address1
and Year of Birth
  Position(s)
Held with
the Trust
  Term of
Office2 and
Length of
Time Served
  Principal Occupation(s)
During Past Five Years
  Portfolios
in Fund
Complex3
Overseen
  Other Directorships Held
By Trustee During Past Five Years
Independent Trustees:                
David H. Chow,
1957*†
  Chairman Trustee   Since 2008 Since 2006   Founder and CEO, DanCourt Management LLC (financial/strategy consulting firm and Registered Investment Adviser), March 1999 to present.   59   Director, Forward Management LLC and Audit Committee Chairman, May 2008 to June 2015; Trustee, Berea College of Kentucky and Vice-Chairman of the Investment Committee, May 2009 to present; Member of the Governing Council of the Independent Directors Council, October 2012 to present; President, July 2013 to June 2015, and Board Member of the CFA Society of Stamford, July 2009 to present; Advisory Board member, MainStay Fund Complex4, June 2015 to December 2015; Trustee, MainStay Fund Complex4, January 2016 to present.
R. Alastair Short,
1953*†
  Trustee   Since 2006   President, Apex Capital Corporation (personal investment vehicle), January 1988 to present; Vice Chairman, W.P. Stewart & Co., Inc. (asset management firm), September 2007 to September 2008; and Managing Director, The GlenRock Group, LLC (private equity investment firm), May 2004 to September 2007.   71   Chairman and Independent Director, EULAV Asset Management, January 2011 to present; Independent Director, Tremont offshore funds, June 2009 to present; Director, Kenyon Review.
Peter J. Sidebottom,
1962*†
  Trustee   Since 2012   Lead Partner, North America Banking and Capital Markets Strategy, Accenture, May 2017 to present; Partner, PWC/Strategy & Financial Services Advisory, February 2015 to March 2017; Founder and Board Member, AspenWoods Risk Solutions, September 2013 to February 2016; Independent consultant, June 2013 to February 2015; Partner, Bain & Company (management consulting firm), April 2012 to December 2013; Executive Vice President and Senior Operating Committee Member, TD Ameritrade (on-line brokerage firm), February 2009 to January 2012.   59   Board Member, Special Olympics, New Jersey, November 2011 to September 2013; Director, The Charlotte Research Institute, December 2000 to 2009; Board Member, Social Capital Institute, University of North Carolina Charlotte, November 2004 to January 2012; Board Member, NJ-CAN, July 2014 to 2016.
Richard D. Stamberger,
1959*†
  Trustee   Since 2006   Director, President and CEO, SmartBrief, Inc. (media company).   71   Director, Food and Friends, Inc., 2013 to present.
Interested Trustee:                
Jan F. van Eck,
19635
  Trustee, President and Chief Executive Officer   Trustee (Since 2006); President and Chief Executive Officer (Since 2009)   Director, President, Chief Executive Officer and Owner of the Adviser, Van Eck Associates Corporation; Director, President and Chief Executive Officer, VESC; Director, President and Chief Executive Officer, VEARA.   59   Director, National Committee on US-China Relations.

 

 

 

1 The address for each Trustee and Officer is 666 Third Avenue, 9th Floor, New York, New York 10017.
2 Each Trustee serves until resignation, death, retirement or removal. Officers are elected yearly by the Trustees.
3 The Fund Complex consists of the VanEck Funds, VanEck VIP Trust, and the Trust.
4 The MainStay Fund Complex consists of MainStay Funds Trust, MainStay Funds, MainStay VP Funds Trust, Private Advisors Alternative Strategies Master Fund, Private Advisors Alternative Strategies Fund and MainStay DefinedTerm Municipal Opportunities Fund.
5 “Interested person” of the Trust within the meaning of the 1940 Act. Mr. van Eck is an officer of the Adviser.
* Member of the Audit Committee.
Member of the Nominating and Corporate Governance Committee.
33

VANECK VECTORS ETF TRUST

BOARD OF TRUSTEES AND OFFICERS

September 30, 2017 (unaudited) (continued)

 

Officer’s Name,
Address1 and
Year of Birth
  Position(s)
Held with
the Trust
  Term of Office2
and Length of
Time Served
  Principal Occupation(s) During The Past Five Years
Matthew A. Babinsky,
1983
  Assistant Vice President and Assistant Secretary   Since 2016   Assistant Vice President, Assistant General Counsel and Assistant Secretary of the Adviser, VESC and VEARA (since 2016); Associate, Clifford Chance US LLP (October 2011-April 2016); Officer of other investment companies advised by the Adviser.
Russell G. Brennan,
1964
  Assistant Vice President and Assistant Treasurer   Since 2008   Assistant Vice President and Assistant Treasurer of the Adviser (since 2008); Manager (Portfolio Administration) of the Adviser, September 2005 to October 2008; Officer of other investment companies advised by the Adviser.
Charles T. Cameron,
1960
  Vice President   Since 2006   Director of Trading (since 1995) and Portfolio Manager (since 1997) for the Adviser; Officer of other investment companies advised by the Adviser.
Simon Chen,
1971
  Assistant Vice President   Since 2012   Greater China Director of the Adviser (since January 2012); General Manager, SinoMarkets Ltd. (June 2007-December 2011).
John J. Crimmins,
1957
  Vice President, Treasurer, Chief Financial Officer and Principal Accounting Officer   Vice President, Chief Financial Officer and Principal Accounting Officer (Since 2012); Treasurer (Since 2009)   Vice President of Portfolio Administration of the Adviser, June 2009 to present; Vice President of VESC and VEARA, June 2009 to present; Chief Financial, Operating and Compliance Officer, Kern Capital Management LLC, September 1997 to February 2009; Officer of other investment companies advised by the Adviser.
Eduardo Escario,
1975
  Vice President   Since 2012   Regional Director, Business Development/Sales for Southern Europe and South America of the Adviser (since July 2008); Regional Director (Spain, Portugal, South America and Africa) of Dow Jones Indexes and STOXX Ltd. (May 2001-July 2008).
Susan C. Lashley,
1955
  Vice President   Since 2006   Vice President of the Adviser and VESC; Officer of other investment companies advised by the Adviser.
Laura I. Martínez,
1980
  Vice President and Assistant Secretary   Vice President (Since 2016) and Assistant Secretary (Since 2008)   Vice President (since 2016), Associate General Counsel and Assistant Secretary (since 2008) and Assistant Vice President (2008 to 2016) of the Adviser, VESC and VEARA (since 2008); Associate, Davis Polk & Wardwell (October 2005-June 2008); Officer of other investment companies advised by the Adviser.
James Parker,
1969
  Assistant Treasurer   Since June 2014   Manager (Portfolio Administration) of the Adviser (since June 2010); Vice President of JPMorgan Chase & Co. (April 1999-January 2010).
Philipp Schlegel,
1974
  Vice President   Since 2016   Senior Director of Van Eck Switzerland AG (since 2010).
Jonathan R. Simon,
1974
  Senior Vice President, Secretary and Chief Legal Officer   Senior Vice President (Since 2016) and Secretary and Chief Legal Officer (Since 2014)   Senior Vice President (since 2016), General Counsel and Secretary (since 2014) and Vice President (2006 to 2016) of the Adviser, VESC and VEARA; Officer of other investment companies advised by the Adviser.
Bruce J. Smith,
1955
  Senior Vice President   Since 2006   Senior Vice President, Chief Financial Officer, Treasurer and Controller of the Adviser, VESC and VEARA (since 1997); Director of the Adviser, VESC and VEARA (since October 2010); Officer of other investment companies advised by the Adviser.
Irina Toyberman,
1973
  Chief Compliance Officer   Since September 2017   Chief Compliance Officer of the Adviser, VESC and the Adviser (since September 2017); Deputy Chief Compliance Officer and Director of Compliance of the Adviser, VESC and the Adviser (March 2014 to September 2017); Vice President and Compliance Manager of Allianz Global Investors U.S. LLC (July 2006 to March 2014).

 

 

 

1 The address for each Officer is 666 Third Avenue, 9th Floor, New York, New York 10017.
2 Officers are elected yearly by the Trustees.
34

VANECK VECTORS ETF TRUST

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENTS

September 30, 2017 (unaudited)

 

At a meeting held on June 9, 2017 (the “Renewal Meeting”), the Board of Trustees (the “Board”) of VanEck Vectors® ETF Trust (the “Trust”), including all of the Trustees that are not interested persons of the Trust (the “Independent Trustees”), approved the continuation of the investment management agreements between the Trust and Van Eck Associates Corporation (the “Adviser”) (the “Investment Management Agreements”) with respect to the VanEck Vectors Asia ex Japan Equal Weight ETF, Australia Equal Weight ETF, Australia Hedged Equal Weight ETF, Biotech ETF, Brazil Equal Weight ETF, China Equal Weight ETF, Environmental Services ETF, Europe Equal Weight ETF, Europe Hedged Equal Weight ETF, Gaming ETF, Generic Drugs ETF, Germany Equal Weight ETF, Global Chemicals ETF, Global Spin-Off ETF, Hong Kong Equal Weight ETF, India Equal Weight ETF, Italy Equal Weight ETF, Japan Equal Weight ETF, Japan Hedged Equal Weight ETF, Mexico Equal Weight ETF, Morningstar International Moat ETF, Morningstar Wide Moat ETF, Pharmaceutical ETF, Retail ETF, Russia Equal Weight ETF, Semiconductor ETF, South Africa Equal Weight ETF, South Korea Equal Weight ETF, Spain Equal Weight ETF, Taiwan Equal Weight ETF and United Kingdom Equal Weight ETF (each, a “Fund” and together, the “Funds”).

 

The Board’s approval of the Investment Management Agreements was based on a comprehensive consideration of all of the information available to the Trustees and was not the result of any single factor. Some of the factors that figured particularly in the Trustees’ deliberations and how the Trustees considered those factors are described below, although individual Trustees may have evaluated the information presented differently, giving different weights to various factors.

 

In preparation for the Renewal Meeting, the Trustees held a meeting on May 8, 2017. At that meeting, the Trustees discussed the information the Adviser and Broadridge Financial Solutions, Inc. (“Broadridge”), an independent third party data provider, had provided to them in advance. The information provided to the Trustees included, among other things, information about the performance (for those Funds which had begun operations) and expenses of the Funds and the Funds’ peer funds (other index-based exchange-traded funds (“ETFs”)), information about the advisory services provided to the Funds and the personnel providing those services, and the profitability and other benefits enjoyed by the Adviser and its affiliates as a result of the Adviser’s relationship with the Funds. In reviewing performance information for the Funds against their peer groups, the Trustees considered that each Fund generally invests in a different group of issuers than the funds in its designated peer group. In addition, as noted below, the Trustees reviewed certain performance information for each Fund that was not provided by Broadridge. For these and other reasons, the Trustees noted that the peer group performance information did not necessarily provide meaningful direct comparisons to the Funds.

 

The Independent Trustees’ consideration of the Investment Management Agreements was based, in part, on their review of information obtained through discussions with the Adviser at the Renewal Meeting and with the Adviser at the May 8, 2017 meeting regarding the management of the Funds and information obtained at other meetings of the Trustees and/or based on their review of the materials provided by the Adviser, including the background and experience of the portfolio managers and others involved in the management and administration of the Funds. The Trustees also considered the terms of, and scope of services that the Adviser provides under, the Investment Management Agreements, including, where applicable, the Adviser’s commitment to waive certain fees and/or pay expenses of each of the Funds to the extent necessary to prevent the operating expenses of each of the Funds from exceeding agreed upon limits for a period of time.

 

The Trustees concluded that the Adviser and its personnel have the requisite expertise and skill to manage the Funds’ portfolios. In evaluating the performance over relevant periods of each of the Funds that had commenced operations prior to the date of the Renewal Meeting (the “Operating Funds”), the Trustees reviewed various performance metrics but relied principally on a comparison of the “gross” performance of each Operating Fund (i.e., measured without regard to the impact of fees and expenses) to the performance of its benchmark index, in each case incorporating any systematic fair value adjustments to the underlying securities. Based on the foregoing, the Trustees concluded that the investment performance of the Operating Funds was satisfactory.

 

The Trustees also considered information relating to the financial condition of the Adviser and the current status, as they understood it, of the Adviser’s compliance environment.

 

As noted above, the Trustees were also provided various data from Broadridge comparing the Operating Funds’ expenses and performance to that of other ETFs. The Trustees noted that the information provided showed that each Operating Fund had management fees (after the effect of any applicable fee waiver) below the average and median of its respective peer group of funds, except for VanEck Vectors Morningstar Wide Moat ETF, which had management fees (after the effect of any applicable fee waiver) greater than the average and median of its peer group of funds. The

35

VANECK VECTORS ETF TRUST

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENTS

September 30, 2017 (unaudited) (continued)

 

Trustees also noted that the information provided showed that each Operating Fund had a total expense ratio (after the effect of any applicable expense limitation) below the average and median of its respective peer group of funds, except for each of VanEck Vectors Gaming ETF, Generic Drugs ETF, Morningstar International Moat ETF and Morningstar Wide Moat ETF, which had a total expense ratio (after the effect of any applicable expense limitation) greater than the average and median of its peer group of funds. With respect to these Operating Funds, the Trustees reviewed the amount by which these Operating Funds’ management fees and/or total expense ratios (after the effect of any applicable expense limitation) exceeded the average and median of their respective peer groups and information provided by the Adviser providing context for these comparisons. The Trustees concluded, in light of this information and the other information available to them, that the fees paid by the Operating Funds were reasonable in light of the performance of the Operating Funds and the quality of services received.

 

The Trustees also considered the benefits, other than fees under the Investment Management Agreements, received by the Adviser from serving as adviser to the Funds.

 

The Trustees also considered information provided by the Adviser about the overall profitability of the Adviser and its profitability or loss in respect of each Operating Fund. The Trustees reviewed each Fund’s asset size, expense ratio and expense cap and noted that the Investment Management Agreements do not include breakpoints in the advisory fee rates as asset levels in a Fund increase. The Trustees considered the potential variability in the net assets of these Funds and the sustainability of any potential economies of scale which may exist given where fees are currently set. The Trustees also evaluated the extent to which management fees for the Operating Funds effectively incorporate the benefits of economies of scale. The Trustees noted that the Adviser has capped expenses on each Operating Fund since its inception. Based on the foregoing and the other information available to them, the Trustees determined that the advisory fee rate for each Fund is reasonable and appropriate in relation to the current asset size of each Fund and the other factors discussed above and that the advisory fee rate for each Fund currently reflects an appropriate sharing with shareholders of any economies of scale which may exist. The Trustees also determined that the profits earned by the Adviser in respect of the Funds that were profitable to the Adviser were reasonable in light of the nature and quality of the services received by such Funds.

 

The Trustees did not consider historical information about the cost of the services provided by the Adviser or the profitability to the Adviser of VanEck Vectors Asia ex Japan Equal Weight ETF, Australia Equal Weight ETF, Australia Hedged Equal Weight ETF, Brazil Equal Weight ETF, China Equal Weight ETF, Europe Equal Weight ETF, Europe Hedged Equal Weight ETF, Germany Equal Weight ETF, Global Chemicals ETF, Hong Kong Equal Weight ETF, India Equal Weight ETF, Italy Equal Weight ETF, Japan Equal Weight ETF, Japan Hedged Equal Weight ETF, Mexico Equal Weight ETF, Russia Equal Weight ETF, South Africa Equal Weight ETF, South Korea Equal Weight ETF, Spain Equal Weight ETF, Taiwan Equal Weight ETF and United Kingdom Equal Weight ETF because the Funds had not yet commenced operations at the time of the Renewal Meeting. The Trustees also could not consider the historical performance or the quality of services previously provided to each of these Funds, although they concluded that the nature, quality and extent of the services to be provided by the Adviser were appropriate based on the Trustees’ knowledge of the Adviser and its personnel and the operations of the other series of the Trust.

 

The Independent Trustees were advised by and met in executive session with their independent counsel at the Renewal Meeting and at their May 8, 2017 meeting as part of their consideration of the Investment Management Agreements.

 

In voting to approve the continuation of the Investment Management Agreements, the Trustees, including the Independent Trustees, concluded that the terms of each Investment Management Agreement are reasonable and fair in light of the services to be performed, expenses to be incurred and such other matters as the Trustees considered relevant in the exercise of their reasonable judgment. The Trustees further concluded that each Investment Management Agreement is in the best interest of each Fund and such Fund’s shareholders.

36

 

This report is intended for the Funds’ shareholders. It may not be distributed to prospective investors unless it is preceded or accompanied by a VanEck Vectors ETF Trust (the “Trust”) Prospectus, which includes more complete information. An investor should consider the investment objective, risks, and charges and expenses of the Funds carefully before investing. The prospectus contains this and other information about the investment company. Please read the prospectus carefully before investing.

 

Additional information about the Trust’s Board of Trustees/Officers and a description of the policies and procedures the Trust uses to determine how to vote proxies relating to portfolio securities are provided in the Statement of Additional Information. The Statement of Additional Information and information regarding how the Trust voted proxies relating to portfolio securities during the most recent twelve month period ending June 30 is available, without charge, by calling 800.826.2333, or by visiting vaneck.com, or on the Securities and Exchange Commission’s website at http://www.sec.gov.

 

The Trust files its complete schedule of portfolio holdings with the Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-Q. The Trust’s Form N-Qs are available on the Commission’s website at http://www.sec.gov and may be reviewed and copied at the Commission’s Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 202.942.8090. The Funds’ complete schedules of portfolio holdings are also available by calling 800.826.2333 or by visiting vaneck.com.

 

 

Investment Adviser: Van Eck Associates Corporation  
Distributor: Van Eck Securities Corporation
666 Third Avenue, New York, NY 10017
vaneck.com
 
Account Assistance: 800.826.2333 STRATAR
 

Item 2. CODE OF ETHICS.

(a)  The Registrant has adopted a code of ethics (the "Code of Ethics") that
     applies to the principal executive officer, principal financial officer,
     principal accounting officer or controller, or persons performing
     similar functions.

(b)  The Registrant's code of ethics is reasonably described in this Form N-CSR.

(c)  The Registrant has not amended its Code of Ethics during the period
     covered by the shareholder report presented in Item 1 hereto.

(d)  The Registrant has not granted a waiver or an implicit waiver from a
     provision of its Code of Ethics during the period covered by the
     shareholder report presented in Item 1 hereto.

(e)  Not applicable.

(f)  The Registrant's Code of Ethics is attached as an Exhibit hereto.

Item 3. AUDIT COMMITTEE FINANCIAL EXPERT.

     The Registrant's Board of Trustees has determined that David Chow, R.
     Alastair Short and Richard Stamberger, members of the Audit and
     Governance Committees, are "audit committee financial experts" and
     "independent" as such terms are defined in the instructions to Form N-CSR
     Item 3(a)(2).

Item 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

     The principal accountant fees disclosed in Item 4(a), 4(b), 4(c), 4(d) and
     4(g) are for the Funds of the Registrant for which the fiscal year end is
     September 30.

(a)  Audit Fees. The aggregate Audit Fees of Ernst & Young for professional
     services billed for the audits of the financial statements, or services
     that are normally provided in connection with statutory and regulatory
     filings or engagements for the fiscal years ended September 30, 2017 and
     September 30, 2016, were $253,930 and $249,930 respectively.

(b)  Audit-Related Fees. Not applicable.

(c)  Tax Fees. The aggregate Tax Fees of Ernst & Young for professional
     services billed for the review of Federal, state and excise tax returns
     and other tax compliance consultations for the fiscal years ended
     September 30, 2017 and September 30, 2016, were $282,757 and $211,876
     respectively.

(d)  All Other Fees

     None.

(e)  The Audit Committee will pre-approve all audit and non-audit services,
     to be provided to the Fund, by the independent accountants as required by
     Section 10A of the Securities Exchange Act of 1934. The Audit Committee
     has authorized the Chairman of the Audit Committee to approve, between
     meeting dates, appropriate non-audit services.

     The Audit Committee after considering all factors, including a review of
     independence issues, will recommend to the Board of Trustees the
     independent auditors to be selected to audit the financial statements of
     the Funds.

(f) Not applicable. (g) Not applicable. (h) Not applicable. Item 5. AUDIT COMMITTEE OF LISTED REGISTRANTS. The Registrant's Board has an Audit Committee established in accordance with Section 3(a)(58)(A) of the Exchange Act (15 U.S.C. 78c(a)(58)(A)) consisting of four Independent Trustees. Messrs. Chow, Short, Sidebottom and Stamberger currently serve as members of the Audit Committee. Mr. Short is the Chairman of the Audit Committee. Item 6. SCHEDULE OF INVESTMENTS. Information included in Item 1. Item 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES. Not applicable. Item 8. PORTFOLIO MANAGER OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES. Not applicable. Item 9. PURCHASE OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS. Not applicable. Item 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. None. Item 11. CONTROLS AND PROCEDURES. (a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR 270.30a-3 (c)) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15 (b)). (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a(d)) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. Item 12. DISCLOSURE OF SECURITIES LENDING ACTIVITIES FOR CLOSED-END MANAGEMENT COMPANIES. Not applicable. Item 13. EXHIBITS. (a)(1) The code of ethics is attached as EX-99.CODE ETH (a)(2) A separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2 under the Act (17 CFR 270.30a-2) is attached as Exhibit 99.CERT. (b) Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 is furnished as Exhibit 99.906CERT.

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. (Registrant) VANECK VECTORS ETF TRUST By (Signature and Title) /s/ John J. Crimmins, Treasurer and CFO --------------------------------------- Date December 8, 2017 ---------------- Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. By (Signature and Title) /s/ Jan F. van Eck, CEO -------------------------- Date December 8, 2017 ---------------- By (Signature and Title) /s/ John J. Crimmins, Treasurer and CFO ------------------------------------------ Date December 8, 2017 ----------------